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Abstract 
Platinum complexes, e.g. cisplatin, oxaliplatin, carboplatin, have been used for near 40 years 
in clinic as potent anticancer drugs. However, these drugs can cause severe side effects, and 
hence there is an urgent need to develop other metal based antiproliferative agents. For 
example, organometallic RuII/IIIcomplexes possess potent anticancer activity but low 
cytotoxicity towards normal cells, which makes them promising alternatives to currently used 
anticancer drugs. 
In this thesis, a series of neutral pseudo-octahedral RuII-sulfonamidoethylenediamine 
complexes [(η6-arene)Ru(N,N’)X] where η6-arene is p-cym, biph and benzene, N,N’ is 
ethylenediamine chelating ligands with sulfonyl substituents (e.g. Ts or Nb) on one terminal N 
and various functional groups (e.g. Me, Me2, Et, benzyl, 4-fluorobenzyl or naphthalen-2-
ylmethyl) on the other terminal N were synthesized and fully characterized, including X-ray 
crystal structures. These complexes catalyse the reduction of NAD+ regioselectively to 1, 4-
NADH using sodium formate as hydride source under biologically relevant conditions. The 
catalytic efficiency depends markedly on the steric and electronic effects of the N-substituent, 
with turnover frequencies (TOFs) increasing with the enhancement of bulkiness and electron 
withdrawing of the substituents, achieving a highest TOF of 12.9 h-1 for complex 10 [(η6-
biph)Os(TsEnBz)Cl]. These complexes exhibited antiproliferative activity against A2780 
human ovarian cancer cells. Co-administration with sodium formate (2 mM) increased their 
potency significantly towards A2780 cells. Substituted RuII sulfonylethylenediamine 
complexes can also interact rapidly with glutathione (GSH) and N-acetyl-L-cysteine (NAC) to 
form S-bridged [(η6-arene)2Ru2(GS)3]2+ or [(η6-arene)2Ru2(NAC)3]+ dimers, and the presence 
of GSH can effectively hamper the catalytic reduction of NAD+ to NADH. 
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Next, a series of neutral organometallic tethered [Ru(η6-benzene-N-R-ethylenediamine)Cl] 
complexes was synthesized and characterized, where R = methylsulfonyl (Ms), toluenesulfonyl 
(Ts), trifluorobenzenesulfonyl (Tf) and 4-nitrobenzenesulfonyl (Nb), including their X-ray 
crystal structures. In general, these complexes also exhibited potent catalytic activity in the 
transfer hydrogenation of NAD+ to NADH with formate as hydride donor (310 K, pH 7), but 
with moderate antiproliferative activity towards human ovarian, lung, liver and breast cancer 
cell lines. Tethered RuII complexes showed preferential binding to 9-ethylguanine (9-EG) over 
adenosine 5’-monophosphate (5’-AMP). However, DNA appears not to be the target, as little 
binding of complex 17 [Ru(η6-benzene-N-Ts-ethylenediamine)Cl] to ct-DNA or bacterial 
plasmid DNA was observed. Also, the tethered complexes bind rapidly to GSH, which might 
again hamper the transfer hydrogenation reactions in cells. Interestingly, these tethered RuII 
complexes can induce a dose-dependent G1 cell cycle arrest and high level of reactive oxygen 
species (ROS) generation, which is likely to contribute to their antiproliferative activity. 
Diseases caused by bacterial infections, especially by multidrug-resistance bacteria, are the 
major cause of deaths worldwide. Traditional clinical drugs cannot cope with the rapid rise of 
drug resistance. 
In this thesis, a new class of organometallic antimicrobial complexes of the type 
[(arene/Cpx)Ir(Big)Z]Z (where arene is para-cymene or biphenyl, Cpx = Cp* 
(tetramethylcyclopentadienyl), Cp*ph or Cp*biph, Big = biguanide ligands and functional 
sulfonyl substituted biguanide ligands,  Z = Cl, Br and I) were synthesized and characterized 
by NMR, ESI-MS, elemental analysis and X-ray crystallography. These complexes not only 
have promising antibacterial activity against Gram-negative bacteria and excellent potency 
against Gram-positive bacteria, but also exhibit high antifungal potency towards C. albicans 
and C. neoformans. Most of the complexes have low cytotoxicity towards mammalian cells 
(HEK-293 human red blood cells and HaCaT keratinocyte cells), indicating a high selectivity. 
vi 
 
These IrIII complexes have a high stability in both medium even at high temperature (315 K). 
A mutant generation study suggests that S. aureus exhibits a low tendency to generate mutants 
in response to these complexes. Ir biguanide complexes 27 [(η5-CpXbiph)Ir(PhBig)]Cl, 30 [(η5-
CpXbiph)Ir(TolBig)Cl]Cl and 33 [(η5-CpXbiph)Ir(TsTolBig)Cl] exhibited synergy with clinical 
drug vancomycin when co-administered in vancomycin-resistant Enterococci (VRE), with the 
MIC 256× lower at sub-MIC complex concentration. These complexes also exhibited potent 
anti-biofilm activity against biofilms generated by S. aureus. Potent antimicrobial activity 
against various microbes might provide an alternative pathway to treat drug resistant 
nosocomial pathogens. 
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1.1 Cancer Chemotherapy  
What is cancer? Cancer is a collection of diseases with common features of uncontrolled cell 
proliferation.1 Cancer now has been one of the worldwide leading fatal diseases and estimated 
to cause approximately 13.1 million deaths in 2030.2 Until now, over 100 types of cancers in 
the human body have been diagnosed. Treatment of cancers is generally divided into three 
ways: initially, the benign tumours can be removed by physical surgery; however, when 
tumours are becoming malignant and metastasised, radio-therapy or chemotherapy must be 
introduced.1 Undoubtedly, treatment of cancer with chemotherapy (chemodrugs are taken 
orally or intravenously) is one of the biggest challenges for biochemical science. 
Over the last few decades, metallodrugs are routinely used in chemotherapy for the treatment 
of cancers. The frontline anticancer drug, cisplatin (CDDP) was synthesized over a century 
ago, however, its potent antiproliferative activity was not observed until the 1960s by 
Rosenberg and co-workers in their course of investigation of the effect of electric current on 
Escherichia coli (Figure 1.1).3 CDDP was approved soon by FDA (Food and Drug 
Administration of U.S.A) as anticancer drug in 1978. Since then, a series of platinum based 
anticancer drugs were developed and approved by FDA, e.g. Carboplatin (1986), Oxaliplatin 
(1996) and Nedaplatin (1994), etc (Figure 1.1). Encouragingly, over 95% cure rate for the 
treatment of testicular cancers has made CDDP the most prevailing chemodrug.4 The 
mechanism of cancer killing for CDDP is complex, numerous related reports have been 
revealed over the last few decades, briefly, the most widely accepted routes are the following. 
CDDP enters cancer cells by passive diffusion,5 and undergoes one chloride hydrolysis prior 
to DNA nucleobase binding, then the aqua CDDP species enter the nucleus and bind to N7 of 
DNA nucleobase guanine,6 until then after a second Cl hydrolysis, to guanine or adenine 
nucleobase, to form an intrastrand DNA cross-linked adduct, which subsequently induces 
cancer cell apoptosis.7 However, the severe side effects of CDDP, e.g. nephrotoxicity, 
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neurotoxicity and vomiting, and have limited its use. Also, with the emergence of cisplatin 
resistant cancers, for instance cisplatin resistant A2780 human ovarian cancer, which now has 
made platinum based anticancer drugs much less effective.   
 
Figure 1.1 Examples of current clinical platinum anticancer drugs. 
The success of platinum based antiproliferative agents has greatly stimulated the development 
of new generations of anticancer drugs. Metallocene compounds being considered as promising 
CDDP alternatives. The study of metallocenes began with the discovery of ferrocene in 1952, 
and the ferrocene structure was identified as having C5-symmetrical sandwich geometry with 
iron covered with two π–bonded Cp rings.8 The Nobel Prize in chemistry was awarded to 
Wilkinson, Woodward and Fisher for their contribution to the elucidation of the sandwich 
complex of ferrocene in 1973. Ferrocene itself is relatively non toxic to human beings; but by 
modification of the ferrocene structure, Jaouen et al. have developed a series of ferrocifens 
based on the anticancer drug tamoxifen (Figure 1.2).9,10 Tamoxifen is one of the frontline 
chemotherapy agents for treating hormone-dependent breast cancer (breast cancers are mainly 
divided into two types: estrogen receptor presence (ER+) or absence (ER-), tamoxifen acts as 
a (ER+) modulator which is an active drug for (ER+) patients).11 Ferrocifen was believed to 
show similar antiproliferative behaviour to tamoxifen. Unexpectedly, ferrocifen when n = 4 
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(Figure 1.2) was found to be active against (ER-) type tumour cells (MDA-MB231) and 
hormone-dependent MRC-7 breast cancer cell lines, probably indicating a different mode of 
action. Another ferrocene-related complex, ferroquine exhibits strong antimalarial activity 
(Figure 1.2), and now has entered phase III clinical trials and may become a next generation 
antimalarial drug in the near future.12 
   
Figure 1.2 Examples of anticancer and antimalarial metallocene agents. 
Titanocene is, structurally similar to ferrocene, but a ‘non-classical’ metallocene complex with 
two ‘bent’ Cp rings (Figure 1.2). As a representative ‘bent’ metallocene, titanocene dichloride 
has poor in vitro but good in vivo anticancer activity.13,14 However, the poor physiochemical 
behaviour of titanocene dichloride prevented it from proceeding further than phase II clinical 
trials. It has very poor aqueous solubility but can hydrolyse readily. This hydrolysis leads to 
deprotonation of bound water to form hydroxido-oligomers, which generate the biologically 
nontoxic and insoluble TiO2.
15-17  
In recent years, organometallic half-sandwich complexes have become of particular interest as 
next generation anticancer agents.18,19 η5-Cyclopentadienyls and η6-arenes can stabilize the 
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metal centre occupying three binding sites, with three unoccupied coordination sites. The 
biological activity of organometallic complexes can be tuned by subtle chemical 
modification.20 The azopyrididine OsII complexes of the type [(η6-p-cym)Os(Impy-NMe2)X] 
where Impy is p-dimethyl aminophenylazopyridine and X is halide (Cl or I), were synthesized 
by Fu and coworkers.20, 21 Complexes FY25 (X = Cl) and FY26 (X = I) are water soluble 
(Figure 1.3), and have shown high antiproliferative potency towards A2780 human ovarian 
cancer cells (IC50 as low as 140 nM), but low cytotoxicity against normal MRC 5 human 
fibroblasts. Active azopyridine complex FY26 can induce a dramatic increase in the levels of 
reactive oxygen species (ROS) in A549 lung cancer cells. Liu et al. have reported a series of Ir 
complexes of the type [(Cp*X)Ir(phpy)(py)]PF6, X = phenyl or biphenyl (Figure 1.3).
22, 23  
These novel complexes showed potent antiproliferative activity towards A2780 human ovarian 
cancer cells (IC50 = 120 nm), about 10 times more effective than CDDP. Furthermore, this 
complex exhibited relatively low cytotoxicity against MRC 5 normal cell lines, with a similar 
selectivity to that of CDDP (approximately 13 times less toxic). [(CpXbiph)Ir(phpy)(py)]PF6 can 
oxidise cellular coenzyme NADH (reduced form of nicotinamide adenine dinucleotide 
(NAD+); discussed in following section) to generate hydrogen peroxide (H2O2), and induce 
high levels of reactive oxidative species (ROS) in A2780 cancer cells (92.5%) but low ROS 
and superoxide levels in the MRC 5 normal cell (only 3.6%), such complexes can also change 
the cell mitochondrial membrane potential, which leads to apoptosis.23 
 
Figure 1.3 Azopyridine OsII complexes and phenyl-pyridine IrIII anticancer complexes. 
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1.2 Organo-Ruthenium Anticancer Agents 
Two sets of rutheniumIII complexes have exhibited significant antitumor activity and have 
attracted wide attention since the 1990s.24 Two of these have reached phase II clinical trials: 
NAMI-A ((imidazoleH)[trans-RuCl4-(imidazole)(DMSO)], Figure 1.4),
25 the first 
rutheniumIII anticancer agent developed by Alessio et al.; and KP1019 ((indazoleH)[trans-
RuCl4-(indazole)2], Figure 1.4), studied by Keppler and co-workers from the end of 1980s. 
The latter is effective against resistant CDDP resistant tumours, especially active against 
autochthonous colorectal tumors.26 NAMI-A and KP-1019 exhibit structural resemblance. 
Unlike CDDP, NAMI-A has very low cytotoxicity against the NCI 60 panel of cell lines in 
vitro (on average over 1000 times less cytotoxic than CDDP).27 However, NAMI-A manifested 
excellent in vivo activity and selectivity against lung metastases of a variety of solid 
metastasizing tumours in nude mice.28 To date, the mechanism of action of NAMI-A and KP-
1019 is not yet very clear, with activation of reduction of RuIII to RuII as a plausible pathway 
which is responsible for the in vivo potency.26a  
 
Figure 1.4 RuIII anticancer agents, NAMI-A and KP-1019. 
The success of NAMI-A and KP-1019 has inspired intensive antiproliferative studies on 
various organo-ruthenium complexes. RAPTA ([RuII-(η6-p-cym)(PTA)Cl2], PTA is 1,3,5-
triaza-7-phosphatricyclo [3.3.1.1]-decane) and its derivatives, developed by Dyson et al. 
(Figure 1.5),29 have also added extra value in the family of Ru based anticancer agents. 
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Structurally, RAPTA-RuII complexes have a ‘piano-stool’ geometry, with aromatic arene on 
the top and three monodentate ligands (two chlorides and one PTA) on the bottom. Similarly 
to NAMI-A and KP-1019, RAPTA series complexes also show good aqueous solubility. In 
vitro anticancer studies with these complexes revealed that such complexes are much less toxic 
than the clinical drug cisplatin towards various cancer cell lines (IC50 > 200 μM),29 however, 
RAPTA-C RuII complexes can effectively reduce the mice lung cancer cells metastasis without 
affecting the primary tumour size,30,31 and have shown promising antiangiogenic activity 
against chicken chorioallantoic membrane.32 According to a molecular docking experiment, 
the Ru-PTA complex is initially hydrolysed with one Cl- replaced by a H2O molecule; next, 
other than binding to DNA, aqueous species coordinate to the important cell enzymes, e.g. 
cathepsin B. Cathepsin B is a lysosomal cysteine protease important for cellular metabolism 
processes, tumour progression and metastasis, is a prognostic marker for several types of 
cancer.33 Thioredoxin reductase (TrXR, a selenoenzyme that can regulate intracellular 
oxidative stress and is overexpressed in many human cancer cells) is also a potential target that 
can induce cell apoptosis.34 
 
Figure 1.5 RAPTA-C and its derivatives and OsII and RhIII analogues. 
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Combinations of biologically active organic molecules with organometallic complexes may 
have synergistic effects to improve the cytotoxicity against cancer cells via different 
mechanism of actions.35 Inspired by Jaouen’s work, Dyson et al. decorated the RAPTA 
complex by introducing naphthalimide (a strong DNA intercalator, Figure 1.6) to the aromatic 
arene. The new complex is known to show moderate anticancer activity towards A2780 human 
ovarian cancer cells, with IC50 value as low as 6.1 μM when compared to RAPTA RuII 
complexes (IC50 over 100 μM). Interestingly, the new napthalimide-tagged RuII complex 
prefers to bind to proteins rather than targeting DNA.36 
 
Figure 1.6 Modified RAPTA with functional groups: naphthalimide and curcumin. 
Curcumin is a low molecular weight polyphenol with multiple biological activity, e.g. anti-
inflammatory and anti-tumor activity.37 The curcumin based RAPTA RuII complex, RAPTA-
curc (Figure 1.16) exhibited potent antiproliferative activity against A2780 human ovarian 
cancer cells (IC50 values as low as 0.14 μM) and cisplatin-resistant A2780 cells (A2780 cisR 
IC50 as low as 0.27 μM), but low cytotoxicity towards human embryonic kidney cells (HEK-
293, IC50, 30 μM).38  
Ang and Gaiddon et al. have reported a library of water-soluble RuII-arene Schiff-base (RAS) 
complexes synthesized via a water-stimulated multicomponent reaction (RAS-1H and RAS-
1T in Figure 1.7).39  RAS complexes are stable in aqueous medium and unlikely to target 
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DNA, some of these complexes exhibit potent cell killing efficacy towards A2780 human 
ovarian cancer cells, making them comparable to cisplatin; and importantly the complexes did 
not show any cross-resistance against A2780cisR (Resistant Factors (RFs) ca. 1, approximately 
10 times lower than that of cisplatin) and colorectal cancer cell lines (RFs are 4.5 and 2.8, 
respectively).39,40 A suitable modification may cause a drastic change in the mode of action. 
The subsequent mechanism of actions study revealed that RuII complexes RAS-1H and RAS-
1T did not change the p53 level in cancer cells, but could induce endoplasmic reticulum (ER) 
stress through ROS-independent and ROS-mediated pathways, to induce a non-apoptotic 
programmed cell death. p53 is an important tumour suppressor gene, mutations of p53 in cancer 
cells are associated with DNA repair, and cell apoptosis.41 
 
Figure 1.7 Ruthenium−arene Schiff-base complexes. 
Very recently, Ang and Gaiddon et al. developed a phenotypic screening protocol against 
colorectal cancer cell lines to identify the apoptosis-independent RAS RuII complexes. By 
screening anticancer activity of over 100 RAS RuII complexes, two RAS complexes 532m and 
532p with RFs of 0.9 and 0.8, respectively, were selected (Figure 1.7).42  Anticancer activity 
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for both the RAS RuII complexes is through a non-apoptotic pathway without activating p53 
tumour suppressor genes.   
Sadler and co-workers have reported a series of RuII complexes of the type [(η6-
arene)Ru(en)X]PF6 where arene is benzene, η6-p-cymene, η6-biphenyl, dihydroanthracene or 
tetrahydroanthracene, en is ethylenediamine and X is halide (Cl, Br and I), pyridine ligands 
and thiol-containing molecules,43 and have also built up the relationship between hydrolysis 
and functional substitutions, which are associated with the antiproliferative activity against 
various cancer cells (Figure 1.8).43  RuII-en complexes exhibited antiproliferative activity in 
the range of 0.5-100 μM, such potency has made some complexes comparable to clinical drug 
cisplatin (0.6 μM) against A2780 human ovarian cancer cells without any cross resistance 
against cisplatin resistant ovarian cancer cells A2780 cisR.44 The complexes, RM-175 and 
HC27 of this series have been studied intensively (Figure 1.8).45 RuII-arene(en) complexes are 
believed to target DNA in cancer cells to induce apoptosis, e.g. RuII-en complex RM-175, 
proved to be highly selective in binding to the N7 of DNA nucleobase guanine to form the 
[Ru(en)-(9EtG-N7)]PF6 adduct.
45, 46, 47 
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Figure 1.8 Structures of RuII-arene ethylenediamine complexes, guanine and Ru-9-EtG adduct. 
1.3 Reactive Oxygen Species (ROS) 
Reactive oxygen species describe a series of oxygen-contained molecules and free radicals, 
including peroxide (O2
2-), superoxide (O2
•-), hydroxyl radical (OH•-) and singlet oxygen (1O2).
48 
The process of conversion of O2 to water and carbon dioxide during aerobic respiration starts 
from the reduction of oxygen; by accepting one electron, O2 can be reduced to generate 
superoxide anions (O2
•-), followed by the dismutation of superoxide by superoxide dismutase 
(SOD) produces hydrogen peroxide (H2O2), and further reduction of H2O2 generates H2O (fully 
reduced) and hydroxyl radicals (partially reduced through Fenton Reaction, OH• is one of the 
highly reactive oxygen species, can directly react with DNA, e.g. guanine can react with 
hydroxyl to form 8-oxoguanine to induce the degradation or mutation,49 Figure 1.9).48  
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Figure 1.9 ROS generation and damaging level of ROS in mammalian cells and bacteria. 
ROS can be produced enzymatically and non-enzymatically, mitochondria are the main 
organelle of ROS generation,50 basal levels of ROS are important for cell progression and 
signaling.51 However, excessive ROS can damage cell membrane lipid, nucleic acid and 
proteins.52 Most importantly, enhanced ROS levels can potentially induce tumor progression 
and cancer cells metastasis.53 Cancer cells and microorganisms are exposed to high oxidative 
stress due to the continuous cell proliferation and metabolism. To cope with such severe 
situation, cancer cells are normally equipped with over-expressed thiol-containing tripeptide, 
glutathione or amino acid cysteine, to attenuate ROS levels and maintain the cellular redox 
homeostasis;54 while bacteria such as Bacillus subtilis (B. subtilis, Gram-positive bacteria) and 
Staphylococcus aureus (S. aureus, Gram-positive bacteria) contain unique small thiol-
containing molecules, e.g. Mycothiol and Bacillithiol (Figure 1.10), to deal with the 
metabolized byproduct.55  
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Figure 1.10 Thiol-containing peptides of mammalian cells and bacteria. 
Taking the advantage of the upregulated ROS levels in cancer cells, development of ROS 
induced antiproliferative or antibacterial agents may provide an effective and alternative 
chemotherapy for treating malignant cancers and severe antibiotic resistance.56  
1.4 Transfer Hydrogenation 
Transfer hydrogenation (TH) of unsaturated substrates catalysed by organometallic complexes 
has been studied for decades. In the 1950s, the first TH reduction report of hydrogen transferred 
from cyclohexene to organic acceptors catalysed by palladium black was revealed.57  
As one of the most powerful catalytic tools for the asymmetric synthesis of amines and 
alcohols, with an aim of constructing important natural product scaffolds and satisfying the 
higher demand of industry, chemists have been in pursuit of developing novel and effective 
catalysts.58 A variety of half-sandwich transition-metal complexes have been developed and 
studied as transfer hydrogenation catalysts towards the asymmetric transfer hydrogenation of 
ketones and amines.59  
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Noyori and co-workers have reported the chiral half-sandwich ruthenium complexes of the 
type [(η6-arene)Ru(TsDPEN)Cl] (arene: η6-p-cym or biph; TsDPEN: N-((1S,2S)-2-amino-1,2-
diphenylethyl)-4-methylbenzenesulfon amide, Figure 1.11).60 Up to 97% ee and 95% yield 
was achieved when the Noyori-type RuII complexes were used in asymmetric transfer 
hydrogenation of aromatic ketones. 
 
Figure 1.11 Noyori-type organometallic transition metal complexes for asymmetric transfer 
hydrogenation (ATH) reactions. 
A wider series of Noyori-type complexes have now been reported for the same application. 
Xiao and co-workers have utilized a series of Noyori-type organometallic transition metal (i.e. 
RhIII, IrIII and RuII, TSCYDN complexes in Figure 1.11) complexes in the asymmetric transfer 
hydrogenation of aromatic ketones, e.g. acetophenone and methyl beta-naphthyl ketone and 
imines in aqueous solution with good yield and excellent ee values (up to 99%, Figure 1.11).61 
To further improve the stability and catalytic activity of Noyori-type complexes, Wills et al. 
have reported a series of Ru η6-arene tethered RuII complexes by introducing a “tethering” 
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chain between the η6-arene and the diamine.62 Such modification allowed lower catalysts 
loading, and up to 99% yield and ee values were obtained for the asymmetric transfer 
hydrogenation of acetophenone, and some other reduction challenging ketones, such as α-
chloroketones and alkynyl ketones (Figure 1.11).63  
1.5 Important Roles of NAD+ and NADH 
Nicotinamide adenine dinucleotide (NAD+) and its reduced form (NADH) play an essential 
role in biological metabolic systems. As an important coenzyme, NAD+  exists ubiquitously in 
both prokaryotic and eukaryotic cells.64 NAD+ can bind to approximately 500 human cell 
proteins,65 for example, nucleophilic amino acid residues (e.g. Arg, Asn, Glu, Asp and Cys) 
can react with NAD+ to yield ADP-ribosylated proteins,66 poly(ADP-ribose) polymerases 
(PARPs) and Sirtuins (SIRTs) require NAD+ for covalent modifications during group transfer 
reactions.67 In cell metabolism, over 400 enzymatic redox reactions rely on the action of 
nicotinamide enzymes, in which transformation of NAD(P)+ to NAD(P)H is involved.68  
 
Figure 1.12 Transformation between coenzyme pair NAD+ and NADH. 
Originally, according a popular synthesis route: the Preiss-Handler pathway,69 NAD+ was 
synthesized by consecutive addition of ribose-P (ribosephosphate), AMP (from ATP) and an 
amino group (from ammonium or glutamine) to nicotinic acid.70 NAD+ and NADH are 
structurally similar to each other, NAD+ is the oxidized form of the NAD+/NADH pair.71 By 
accepting hydride on the C18 active site, NAD+ is reduced to NADH (Figure 1.12).  
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Cancer cells rely more on lactate than normal tissues to survive; this feature has led cancer cells 
toward more glucose uptake. Lactate is generated through an aerobic glycolysis catalysed by 
lactate dehydrogenase A (LDH-A), an important NADH dependent enzyme, which can 
regenerate and build-up large amount of NAD+ in cancer cells.72 Nicotinamide phosphoribosyl 
transferase mediated biosynthesis of NAD+ in cancer cells can play a significant role, as it is 
involved in many physiological processes, e.g. cell metabolism, survival, apoptosis, DNA 
repair and inflammation, etc.73 Cancer cells are constantly exposed to high levels of oxidative 
stress, partially due to the built-up of NAD+; a suitable ratio change to the NAD+/NADH can 
modify the oxidative homeostasis and potentially cause apoptosis of cancer cells.74 Research 
on the interconversion between NAD+ and NADH is likely to have great significance in terms 
of strategy for the next generation anticancer therapy.  
1.6 Transformation between NAD+ and NADH 
The catalytic transformation between NAD+ and NADH usually involves two pathways: 
enzymatic and non-enzymatic. The non-enzymatic catalytic pathway often possesses 
significant advantages: cheaper, reaction conditions are less complicated and the catalysts used 
are more stable than enzymes.75 The first TH reduction of NAD+ model compounds was 
introduced by Steckhan et al. by utilizing RhIII complex [(Cp*)Rh(bpy)Cl]PF6 as catalyst either 
using formate as hydride donor, or electrochemically, to achieve a regioselective product 1, 4-
NADH (Figure 1.13).76,77 In 1999, Fish and co-workers used RhIII complex 
[(Cp*)Rh(bpy)Cl]PF6 as catalyst in the TH reaction of NAD
+ type substrate BNAD+ to its 
reduced form with sodium formate as hydride source.78 Later, Fish et al. used horse liver 
alcohol dehydrogenase (HLADH) to fulfil the catalytic reduction cycle of ketones 
enantioselectively (Figure 1.13), giving asymmetric alcohols with ee values up to 99%.79  
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Figure 1.13 Organometallic RhIII catalysts for transfer hydrogenation of NAD+ to NADH. 
HLADH is horse liver alcohol dehydrogenase. 
Betanzos-Lara et al. have demonstrated the conversion of NADH to NAD+ using organo- 
ruthenium and organoiridium as double action catalysts (Figure 1.14).80 Interestingly, these 
complexes can reduce NAD+ to NADH using formate as hydride source, once the hydride is 
fully transferred to NADH, a reverse hydride transfer between NADH and organo-ruthenium 
or iridium catalysts is reported to occur, with a sharp 1H NMR singlet for Ru-H observed at -
7.44 ppm. They also utilized the reversible reaction to reduce pyruvate to lactate to mimic the 
action of enzyme lactate dehydrogenase in vitro (Figure 1.1). Liu et al. in the Sadler group 
suggested a straightforward catalytic reduction of quinones using organoiridium complex 
[(Cp*)Ir(phen)Cl]PF6 (Ir complex in Figure 1.14) as catalyst and NADH as hydride source.
81 
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however such reductions can provide only semiquinones rather than dihydroquinones, which 
may involve a novel mechanism of action.       
 
Figure 1.14 Reversible hydride transfer between NAD+ and NADH catalysed by 
organoruthenium and iridium complexes.   
1.7 Mechanistic Study 
In recent years, much effort has been devoted to the development of transition metal complexes 
capable of reducing unsaturated compounds via transfer hydrogenation.82  
In 2000, Noyori et al. reported the reversible hydrogen transfer between alcohols and carbonyl 
compounds by using [(benzene)RuCl2]2, N-tosylethylenediamine or ethanolamine (Noyori-
type) as catalysts and KOH as base.83 The results from his work reveal that the carbonyl oxygen 
atom interacts with the terminal N-H on the RuII complexes and the hydroxyl moiety with the 
amido nitrogen via hydrogen bonding; the protons of NH or NH2 in the ethylenediamine are 
19 
 
crucial for TH reaction between alcohols and ketones. A simple and different mechanism in 
which a 16-e intermediate is involved was proposed by Noyori (Figure 1.15). 
 
Figure 1.15 A mechanism for asymmetric transfer hydrogenation of aromatic ketones to 
alcohol involving the 16-e intermediate proposed by Noyori et al.83 
In 2011, Wills et al. demonstrated the important role of the N-H proton in the asymmetric 
reduction of ketones and amines through hydrogen transfer reactions by using Noyori type RuII 
TsDPEN complexes as catalysts.84 In Wills’ work, it was observed that RuII complexes with 
two alkyl groups on the terminal nitrogen atom are poor catalysts for transfer hydrogenation of 
ketones and imines. The TH reaction of ketones and amines probably underwent a six-
membered ring transition state, and involvement of N-H indicates that proton on terminal 
nitrogen atom of the TsDPEN ligand is a necessity for the TH reaction of ketones and imines 
to occur (Figure 1.16).  
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Figure 1.16 Involvement of N–H in the transition state for reduction. 
The proton of the terminal N-H on the chelating ligand appears to play an essential role in the 
transfer hydrogenation of ketones and amines. The modified Noyori type complexes such as 
[(η6-p-cym)Ru(TsEn)Cl] have also been shown to perform the TH reaction of NAD+ in cells 
successfully.74 The mechanism of action of such compounds have been proposed recently by 
Sadler el al. (Figure 1.17). In this proposal, the aqua RuII species can bind to formate ions to 
form arene-Ru formate transition states, then the formate twists to form the Ru-H species, 
followed by the terminal N H-interaction with NAD+ to effect hydride transfer.  
 
Figure 1.17 Proposed mechanism of TH reduction from NAD+ to NADH. 
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In 1999, Fish et al. reported a mechanistic study of transfer hydrogenation of BNA+ (NAD+ 
type compound a in Figure 1.18) to BNAH using [(Cp*)Rh(bpy)H]+ as catalyst and sodium 
formate as hydride source,78 in which a Cp* ring slipped intermediate containing Rh 
coordinated to the amide of the pyridine ring is involved. Fish and coworkers used different 
substituents to the C3 position of pyridine ring as substrates to assess the electronic and steric 
effects of the TH reaction as well, in which a Cp* ring-slipped intermediate with Rh 
coordinated to the amide of the pyridine ring was proposed (Figure 1.18).  
 
Figure 1.18 Proposed mechanism for catalytic reduction of NAD+ type substrate. 
In 2000, Ishitani et al. reported a mechanistic study of the regio-specific transfer hydrogenation 
of a NAD+ model to its reduced form using cis-[Ru(bpy)2(CO)(CHO)]
+ as catalyst and hydride 
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source.85 To mimic the enzymatic reactions catalysed by aldehyde dehydrogenases in cells, 
Ishitani and coworkers applied the ruthenium formyl complex to transfer hydrogenation of 
NAD+ model compounds without using any auxiliary hydride source. It is worth mentioning 
that among all the substrates, the strong electron-withdrawing group CF3 at 3-position of the 
pyridine which is totally different from the amide group of the NAD+ was used, and exceptional 
conversion was obtained in TH reactions (Figure 1.19).  
 
Figure 1.19 Reduction of NAD+ models catalysed by RuII formyl complexes. 
1.8 Current Antibacterial Study 
Infectious diseases are currently the second main cause of death worldwide and the third 
leading cause of death in developed countries.86 According to the latest survey, over 20000 
deaths were caused by bacterial and bacterial resistant infections per year in America alone.87 
And 1.4 million people are affected in other developed countries, this number is increased by 
200-2000% in developing countries.88 
Bacteria normally have a rigid cell wall as outer cell membrane, to guard the cell from changes 
in osmotic pressure, chemical or enzymatic lysis and mechanical damage. Bacteria are mainly 
classified into two groups: Gram-positive and Gram-negative.89 The cell wall of Gram-positive 
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bacteria (which stains with purple Crystal Violet) is composed of a thick layer of peptidoglycan 
with a group of inlaid molecules called teichoic acids. While the Gram-negative cell wall 
consists of a thin layer of peptidoglycan but it is covered by an outer membrane. Compared to 
eukaryotic cells (without cell wall), bacteria usually can survive in very extreme conditions 
(Scheme 1.1).89  
 
Scheme 1.1 The biological composition of Gram-positive and Gram-negative bacteria. 
Multidrug resistant bacteria, including the notorious Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, Acetinobacter baumanii, Pseudomonas aeruginosa, and 
Enterobacteriaceae species, abbreviated as ‘ESKAPE’ (underlined letters of each bacteria 
name), are now a huge threat to human health and a major cause of bacterial infectious 
diseases.90  
The antibacterial chemotherapy was developed in late 19th century, when microbiologists 
observed the antagonistic activity between microbial populations.91 In the mid-20th century, the 
sulfonamides were introduced as therapies and β-lactams was used as natural product therapies, 
and antibiotics have been used widely since then.91,92 Currently, the approved antimicrobial 
drugs are mainly organic molecules. However, only 1% of these are natural products and over 
95% are artificially synthesized.93 
The abuse of clinically approved drugs make the growth of pathogens resistant to the existing 
agents surprisingly fast, and in many cases, the current antibiotics are not effective enough to 
kill them. For example, methicillin-resistant Staphylococcus aureus (MRSA) is resistant to β-
lactam antibiotics,90b and about 59.5% of hospital-acquired infections caused by S. aureus have 
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shown resistance to methicillin. Options for chemotherapic drugs for certain microorganisms 
have become increasingly scarce. Thus, novel, effective, and safe antibiotics are urgently 
needed.92  
Over the last few decades, the antibacterial activity of organo-transition-metals have attracted 
particular attention. Noble metals like gold and silver as potent antibacterial agents have been 
well studied.94 The application of silver by mankind dates back about 7000 years, and people 
used silver as containers to conserve food and water in ancient times thereby preventing 
bacterial infections.95 
Some other transition metal complexes have also been reported to exhibit antibacterial 
properties.96 Among those, the platinum group metals have aroused significant interest, as the 
intensive studies based on these metals are related to their anticancer activities.97 Reports of 
antimicrobial activity of the platinum group complexes has been relatively rare in the literature. 
1.9 Antibacterial Study with Organometallic Complexes 
A series of inert polypyridyl rutheniumII 98 and iridiumIII 99 complexes with bridging alkene 
chain has been synthesized by Collins and Keene and coworkers (Figure 1.20), the MICs of 
these complexes against both Gram positive (MRSA and S. aureus) and negative (E. coli and 
P. aeruginosa) bacteria were determined. The dinuclear RuII complexes of the type [(Ru 
(phen)2)2(m-bbn)]
4+ (where phen = 1,10-phenanthroline; bb = bis[4(4’-methyl-2, 2’-bipyridyl)]-
1) showed very potent activity towards both S. aureus and MRSA with MICs value of 1 
µg/mL.98 The HC50 (obtained by incubation of dinuclear Ru
II complexes with red blood cells) 
and IC50 (dinuclear Ru
II drugs against THP-1 cells lines) values were over 100-fold higher than 
the MIC values from antibacterial activity. The high selectivity between mammalian cells and 
bacteria make RuII complexes potential antibiotics for clinical trial.  
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The inert IrIII complexes of the type [(Ir(phen)2)2(μ-bb12)]6+ also showed significant activity 
against bacteria with MIC value as low as 2 µg/mL. The MBC/MIC ratios of dinuclear IrIII 
complexes are over 2, which indicate that the inhibition of bacteria is bacteriostatic rather than 
bactericidal. Interestingly, the determination of pKa values of the Ir
III complexes suggested that 
the dinuclear complexes deprotonate rapidly and enter bacteria as 4+ charged species. 
 
Figure 1.20 Structures of RuII and IrIII antibiotic agents. 
Aggregation-induced phosphorescence (AIP) of active IrIII complexes attracts significant 
research interest.100 Panwar et al. reported a series of phosphorescent IrIII complexes (Figure 
1.21a), and the antibacterial activity of these complexes was determined.101 These complexes 
can penetrate the bacteria cell wall, and a DNA cleavage study suggested that DNA was the 
direct target of IrIII complexes for their bactericidal activity (MBC as low as 4 µg/mL). 
 
Figure 1.21 Structures of IrIII complexes as antibiotics. 
26 
 
Another series of iridium–NHC complexes bearing anionic and cationic substituents were 
synthesised and the antibacterial, antiparasitic and anticancer activities were evaluated by 
Schatzschneider and coworkers.102 IrIII complexes bearing a NHC-phosphonium ligand 
(Figure 1.21b) showed better antibacterial activity (both Gram positive and negative) than IrIII 
complexes bearing NHC-sulfonate ligand (Figure 1.21c) in terms of MIC and MBC; Also, 
IrIII-NHC-phosphonium complexes exhibited a better activity against Gram positive bacteria 
(2.5-20 µg/mL) than Gram negative bacteria (> 20 µg/mL).  
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1.10 Aims 
The general aim of this thesis is to design and synthesize a library of organoruthenium 
ethylenediamine complexes containing various arene and functional substituents on the 
terminal N of ethylenediamine ligands, which can effectively reduce the cell coenzyme NAD+ 
to NADH via transfer hydrogenation using sodium formate as hydride source; and a series of 
organoiridium, ruthenium and osmium biguanide complexes as novel antibacterial agents. The 
details are summarized as follows: 
 Study the catalytic efficacy of RuII ethylenediamine monosulfonyl complexes 
containing different substituents and tethered RuII monosulfonyl ethylenediamine 
complexes towards the TH reduction of NAD+ to NADH using sodium formate as 
hydride source.  
 Investigate the antiproliferative activity of RuII ethylenediamine monosulfonyl and 
tethered RuII complexes. 
 Investigate the potential targets for RuII ethylenediamine monosulfonyl complexes 
(including non-tethered and tethered), e.g. DNA or GSH/cysteine. 
 Synthesize and study the antimicrobial activity of novel IrIII biguanide complexes 
against Gram-positive and Gram-negative bacteria, and fungi; and compare with RuII 
and OsII analogue complexes. 
 Explore the antimicrobial mechanism of action of novel biguanide complexes (IrIII, 
RuII or OsII).  
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2.1 Materials 
2.1.1 Chemicals 
Ruthenium(III) trichloride, iridium(III) trichloride and osmium(III) trichloride were purchased 
from Precious Metals Online (PMO Pty Ltd.) and used as received. 4-nitrobenzenesulfonyl 
chloride, 4-fluorobenzenesulfonyl chloride, 2,3,4,5-tetramethyl-2-cyclopentanone, 1,2,3,4,5-
pentamethylcyclopentadiene, ethylenediamine, 1-(bromomethyl) naphthalene, N-benzyl-
ethylenediamine, 4-bromo-biphenyl, bromobenzene, n-butyllithium in hexane 1.6 M, 
benzenesulfonyl chloride, sodium formate and β-nicotinamide adenine dinucleotide hydrate 
(NAD+) were obtained from Sigma-Aldrich. Metformin was purchased from Cayman chemical 
company, and all other biguanide chelating ligands (ligands without any sulfonyl substitution) 
used in Chapter 4 were also obtained from Sigma-Aldrich. Methanesulfonyl chloride and 
toluenesulfonyl chloride were purchased from Fluka. Magnesium sulphate, potassium 
hydroxide, sodium chloride, sodium iodide, potassium bromide and hydrochloric acid were 
obtained from Fisher Scientific. α-Phellandrene was purchased from SAFC. The solvents used 
for NMR spectroscopy were purchased from Sigma-Aldrich and Cambridge Isotope 
Laboratories Inc. Non-dried solvents used in syntheses were obtained from Fisher Scientific 
and Prolabo. Solvents (including HPLC solvents, e.g. H2O and Acetonitrile) were used as 
obtained, except in the case of ethanol and 2-propanol, which were refluxed and degassed with 
nitrogen, respectively, prior to use. 
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2.1.2 Bio-materials 
2.1.2.1 Cell Culture  
A2780 human ovarian carcinoma cells were obtained from the European Collection of Cell 
Cultures. The cell line was grown in Roswell Park Memorial Institute medium (RPMI-1640) 
supplemented with 10% of fetal calf serum, 1% of 2 mM glutamine and 1% penicillin 
/streptomycin (1000 units). All cells were grown as adherent monolayers at 310 K in a 5% 
CO2-humidified atmosphere and passaged at ca. 70–80% confluency. All bio-materials were 
purchased and handled by Dr. Isolda Romero-Canelon and Ji-Inn Song. 
2.1.2.2 Antimicrobial Study Related Materials 
Staphylococcus aureus (S. aureus, strain type: R 34), Bacillus subtilis (B. subtilis, strain type: 
DSM 10) and Streptococcus pyogenes (S. pyogenes, strain type: 151112), Staphylococcus 
epidermidis (S. epidermidis, strain type: 12228), Enterococcus faecalis (E. faecalis, strain type: 
29212) were obtained from the culture collection of Professor Christopher G. Dowson and Mr 
John Moat (School of Life Sciences, University of Warwick). Antimicrobial activity against 
methillicin-resistant S. aureus (MRSA, strain type: ATCC 43300), FDA control Escherichia 
coli (E. coli, strain type: ATCC 25922), multi-drug resistant Klebsiella pneumoniae (MDR K. 
pneumoniae, strain type: ATCC 700603), Pseudomonas aeruginosa (P. aeruginosa, strain 
type: ATCC 27853), Acinetobacter baumannii (A. baumannii, strain type: ATCC 19606), and 
antifungal activity against Candida albicans (A. albicans, strain type: ATCC 90028) and 
Cryptococcus neoformans (C. neoformans, strain type: ATCC 208821), as well as cytotoxicity 
towards human embryonic kidney cells (HEK-293, strain type: ATCC CRL-1573) and RBC 
(human red blood cells) were screened by Community for Open Antimicrobial Drug Discovery 
(CO-ADD) at the University of Queensland, Australia.  
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2.2 Preparation of Precursors 
2.2.1 Synthesis of Arene Ligands1 
3-Phenyl-1,2,4,5-tetramethyl-1,3-cyclopentandiene (CpXPh)1a,b  
To a solution of phenyllithium (50 mL, 1.9 M in dibutyl ether) was added 2,3,4,5-tetramethyl-
2-cyclopentenone (12 mL) at 273 K under N2. The reaction was allowed to warm slowly to 298 
K with stirring overnight. The yellow solution was cooled down by addition of ice and then 
acidified with HCl (36% in water, v/v). The aqueous solution was extracted with diethyl ether 
(3 × 50 mL). The combined organic portions were dried over anhydrous magnesium sulphate 
and filtered, and the solvent was removed on a rotary evaporator to obtain a yellow oil. The 
product was purified by distillation under vacuum (fraction at 410 K, 0.5 mbar). Yield = 12.87 
g (82%). The ligand purity was confirmed by comparison of 1H NMR spectrum with reported 
literature.1b  
3-Biphenyl-1, 2, 4, 5-tetramethyl-1, 3-cyclopentandiene (CpXbiph)1b,c  
A solution of 4-bromobiphenyl (16 g, 68.6 mmol) in dried tetrahydrofuran (400 mL) was 
treated with a solution of n-BuLi in hexane (50 mL, 1.6 M) at 195 K under nitrogen. After 3 h 
reaction, 2,3,4,5-tetramethyl-2-cyclopentenone (12 mL) was added. The solution was allowed 
to warm slowly to 298 K with stirring overnight. The orange solution was acidified with HCl 
(36% in water, v/v) and the organic phase was removed. The aqueous layer was extracted with 
diethyl ether (3 × 50 mL). The combined organic portions were dried over anhydrous MgSO4 
and filtered, and the solvent was removed on a rotary evaporator to obtain a dark yellow 
powder. The product was washed in methanol (3 × 20 mL) to give a light yellow powder. Yield 
= 21 g (94.4%). 1H NMR (400 MHz, CDCl3): δH 7.64 (m, 4H), 7.44 (m, 2H), 7.33 (m, 3H), 
3.25 (m, 1H), 2.08 (s, 3H), 1.95 (s, 3H), 1.88 (s, 3H), 1.00 (d, J = 7.5 Hz, 3H). 
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2.2.2 Preparation of Dimers 
2.2.2.1 Synthesis of Ru(II) Dimers2 
[(η6-p-cym)RuCl2]2 - Method 12a,b  
RuCl3·3H2O (1.02 g, 4.01 mol) and α-phellandrene (6.15 mL, 5.06 mol) were dissolved in 
freshly distilled ethanol (75 mL) and the reaction mixture heated to reflux (353 K) under a 
nitrogen atmosphere for 18 h. The red precipitate formed was filtered and washed with ice cold 
ethanol (3 × 20 mL) and diethyl ether (3 × 20 mL) and dried under vacuum. Yield = 1.1 g (88 
%). 1H NMR (400 MHz, DMSO-d6): δH 5.82 (d, J = 6.4 Hz, 2H), 5.76 (d, J = 6.4 Hz, 2H), 2.84 
(m, 1H), 2.09 (s, 3H), 1.20 (d, J = 6.9 Hz, 6H). 
Method 22c  
RuCl3·3H2O (1.00 g, 4.00 mol) and α-phellandrene (6.15 mL, 5.06 mol) were dissolved in 
anhydrous MeOH (10 mL) in a microwave vial. The solution was sonicated in water bath at 
313 K for 10 min. Then the mixture was irradiated with microwave irradiation at 413 K for 5 
min. Next, the solution was placed in a freezer at 255 K for 2 h and the resulting precipitate 
was washed with ice-cold MeOH (3 × 20 mL) and diethyl ether (3 × 20 mL), to give a red solid. 
The product was dried overnight in air. Yield = 1 g (77%). 
[(η6-biph)RuCl2]22a,b  
3-Phenyl-1,4-cyclohexadiene (1.77 g, 11.36 mmol) was added to a solution of RuCl3·3H2O 
(1.00 g, 3.79 mmol) in anhydrous MeOH (10 mL) in microwave vial. The solution was 
sonicated in water bath at 313 K for 10 min. Then the mixture was irradiated with microwave 
irradiation at 413 K for 5 min. Next, the solution was placed in a freezer at 255 K for 2 h and 
the resulting precipitate was washed with ice-cold MeOH (3 × 20 mL) and diethyl ether (3 × 
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20 mL), to give a brown solid. The product was dried under vacuum overnight. Yield = 1 g 
(81%). 1H NMR (400 MHz, DMSO-d6): δH 6.07 (m, 3H), 6.42 (d, J = 6.1 Hz, 2H), 7.50 (m, 
3H), 7.82 (m, 2H). 
[(η6-HO(CH2)2OPh)RuCl2]22b  
2-(Cyclohexa-1,4-dien-1-yloxy)ethan-1-ol (1.60 g, 11.40 mmol) was added to a solution of 
RuCl3·3H2O (1.00 g, 3.79 mmol) in freshly distilled ethanol (100 mL). The reaction mixture 
was heated to reflux (363 K) under nitrogen atmosphere for 18 h. The red precipitate formed 
was filtered and washed with ice-cold ethanol (3 × 20 mL) and ether (3 × 20 mL) dried under 
vacuum overnight. Yield = 892 mg (76%). 1H NMR (400 MHz, DMSO-d6): δH 3.72 (t, J = 4.5 
Hz, 2H), 4.21 (t, J = 4.5 Hz, 2H), 4.94 (s, broad, 1H), 5.37 (t, J = 5.3 Hz, 1H), 5.54 (d, J = 6.3 
Hz, 2H), 6.15 (t, J = 5.8 Hz, 2H). 
2.2.2.2 Synthesis of Os(II) Dimers3 
[(η6-biph)OsCl2]2 
OsCl3·3H2O (1.00 g, 2.85 mmol) and 3-phenyl-1,4-cyclohexa diene (1.58 g, 10.12 mmol) were 
dissolved in anhydrous MeOH (10 mL) in a microwave reaction vial, the solution was sonicated 
in water bath at 313 K for 10 min. Then the mixture was irradiated with microwave irradiation 
at 393 K for 10 min. After cooling down to ambient temperature, an orange precipitate was 
collected through filtration, and the solid was washed with ice-cold EtOH (3 × 20 mL) and 
diethyl ether (3 × 20 mL). The product was dried overnight in vacuo. Yield = 1.06 g (80%). 1H 
NMR (400 MHz, DMSO-d6): δH 6.31-6.38 (m, 6H), 6.68 (d, J = 5.6 Hz, 4H), 7.44-7.49 (m, 
6H), 7.71 (dd, J = 1.4 Hz, 8.1 Hz, 4H). 
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2.2.2.3 Synthesis of Ir(III) Dimers1b, 4 
[(η5-Cp*)IrCl2]21b  
IrCl3·3H2O (1.00 g, 2.84 mmol) and 1,2,3,4,5-pentamethylcyclo pentadiene (1.34 mL, 8.56 
mmol) were placed in a microwave vial, to which anhydrous MeOH (10 mL) was added, and 
the solution was sonicated in a water bath for 10 min. Then the solution was irradiated with 
microwave irradiation at 413 K for 5 min. After cooling to room temperature, the vial was 
placed in the freezer for 2 h, and the reddish orange precipitate was collected by filtration. The 
solid was washed with pentane (3 × 20 mL) and diethyl ether (3 × 20 mL), and the product was 
dried in air overnight. Yield = 900 mg (80%). 1H NMR (400 MHz, CDCl3): δH 1.59 (s, 15H). 
[(η5-CpXph)IrCl2]21b, 4  
[(η5-CpXph)IrCl2]2 was synthesized following the procedure described for [(η5-Cp*)IrCl2]2 
using IrCl3·3H2O (1.00 g, 2.84 mmol) and 3-phenyl-1,2,4,5-tetramethyl-1,3-cyclopentadiene 
(1.00 g, 5.00 mmol). An orange solid was obtained. Yield = 600 mg (46%). 1H NMR (400 
MHz, CDCl3): δH 1.63 (s, 6H), 1.72 (s, 6H), 7.35-7.36 (m, 3H), 7.56-7.57 (m, 2H). 
[(η5-CpXbiph)IrCl2]21b, 4  
[(η5-CpXbiph)IrCl2]2 was synthesized following the procedure depicted for [(η5-Cp*)IrCl2]2 
using IrCl3·3H2O (814 mg, 2.31 mmol) and 3-biphenyl-1,2,4,5-tetramethyl-1,3-
cyclopentadiene (1.5 g, 5.47 mmol). An orange solid was obtained. Yield = 796 mg (64%). 1H 
NMR (400 MHz, CDCl3): δH 1.69 (s, 6H), 1.75 (s, 6H), 7.32-7.37 (m, 1H), 7.41-7.45 (m, 2H), 
7.56-7.60 (m, 4H), 7.64-7.67 (m, 2H). 
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2.2.3 Preparation of Bidentate Chelating Ligands5-7 
2.2.3.1 Synthesis of Ethylenediamine Ligands in Chapters 3 and 4 
The ethylenediamine chelating ligands were synthesized according to the literature with the 
guidance of Dr. Joan Joseph Soldevila Barreda at the University of Warwick.  
N-(2-Aminoethyl)-4-toluensulfonamide (TsEn)  
This ligand was obtained following the method described in the literature.5 A solution of 
ethylenediamine (17 mL, 0.26 mol) in dichloromethane (150 mL) was placed in a round bottom 
flask. A solution of toluenesulfonyl chloride (5.0 g, 26 mmol) in dichloromethane (50 mL) was 
added slowly via a dropping funnel, and the mixture stirred vigorously for 1 h. The solution 
was then washed with water (3 × 25 mL), and dried over MgSO4. Solvent was removed on a 
rotary evaporator to give a white solid which was purified by column chromatography (MeOH: 
DCM, 1: 9 (v/v)). Yield = 3 g (54%). 1H NMR (400 MHz, CDCl3): δH 2.43 (s, 3H), 2.78 (t, J 
= 5.6 Hz, 2H), 2.95 (t, J = 5.6 Hz, 2H), 7.30 (d, J = 8.1 Hz, 2H), 7.75 (d, J = 8.1 Hz, 2H). ESI-
MS: Calcd for [C9H14N2O2S + H]
+ 215.0 m/z, found: 215.1 m/z. 
Methyl-(2-((4-methylphenyl)sulfonamido)ethyl)carbamate 
This ligand was synthesized as precursor of 4-methyl-N-(2-(methylamino)ethyl)benzene 
sulfonamide (TsEnMe) and obtained following the method described in the literature.6 TsEn 
(428 mg, 2.0 mmol) was dissolved in dichloromethane (20 mL) and then methyl chloroformate 
(0.185 mL, 2.4 mmol) and triethylamine (0.306 mL, 2.2 mmol) were added and the reaction 
mixture left stirring at ambient temperature overnight. The mixture was washed with water (20 
mL), extracted with chloroform (3 × 30 mL) and then dried over anhydrous MgSO4. The 
solvent was removed under rotary evaporator to give white solid. Yield = 494 mg (89%). 1H 
44 
 
NMR (400 MHz, CDCl3): δH 2.43 (s, 3H), 3.06-3.10 (m, 2H), 3.26-3.29 (m, 2H), 3.65 (s, 3H), 
4.97 (d, J = 23.4 Hz, 2H), 7.31 (d, J = 8.1 Hz, 2H), 7.74 (d, J = 8.2 Hz, 2H).  
4-Methyl-N-(2-(methylamino)ethyl)benzenesulfonamide (TsEnMe)6  
To a stirred solution of amide precursor (408 mg, 1.5 mmol, methyl-(2-((4-methylphenyl) 
sulfonamido)ethyl)carbamate above) in dry THF (20 mL), a 2 M solution of LiAlH4 in THF 
(3.2 mL, 6 mmol) was added dropwise under nitrogen. The reaction was heated under reflux 
for 4 h and then 1 mL water was added and left the reaction mixture stirred for another 2 h. 
The product was extracted with chloroform (3 × 30 mL) and the combined organic fractions 
were washed with brine (2 × 30 mL) and dried over MgSO4, concentrated by rotary evaporation 
to give a crude product which was further purified on a silica gel column to give white solid. 
Yield = 226 mg (66%). 1H NMR (400 MHz, CDCl3): δH 2.29 (s, 3H), 2.42 (s, 3H), 2.66 (t, J = 
5.6 Hz, 2H), 2.99 (t, J = 5.4 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 7.75 (d, J = 8.1 Hz, 2H). ESI-
MS: Calcd for [C10H16N2O2S + H]
+ 229.0 m/z, found: 229.1 m/z. 
N-(2-(Dimethylamino)ethyl)-4-methylbenzenesulfonamide (TsEnMe2)  
This was obtained following the protocol described in the literature.5c A solution of N, N-
dimethylethane-1,2-diamine (0.42 mL, 4.5 mmol) in dichloromethane (80 mL) was placed in 
a round-bottom flask. A solution of toluenesulfonyl chloride (572 mg, 4.5 mmol) in DCM (50 
mL) was added slowly via a dropping funnel, and the mixture was stirred vigorously for another 
4 h in the ice bath. The solution was then washed with water (3 × 25 mL), and dried over 
MgSO4. The solvent was removed on a rotary evaporator to give a white solid. Yield = 490 mg 
(45%). 1H NMR (400 MHz, CDCl3): δH 2.56 (s, 6H), 2.44 (s, 3H), 2.48 (t, J = 6.9 Hz, 2H), 
2.97 (t, J = 6.8 Hz, 2H), 7.40 (d, J = 8.0 Hz, 2H), 7.75 (d, J = 8.2 Hz, 2H). ESI-MS: Calcd for 
[C11H18N2O2S + H]
+ 243.1 m/z, found: 243.1 m/z. 
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N-(2-(Ethylamino)ethyl)-4-methylbenzenesulfonamide (TsEnEt)  
This was obtained following the method described in the literature.5c A solution of N-
ethylethylenediamine (0.737 mL, 7 mmol) in dichloromethane (100 mL) was placed in a round-
bottom flask. A solution of toluenesulfonyl chloride (1 g, 5.2 mmol) in DCM (50 mL) was 
added slowly via a dropping funnel, and the mixture was stirred vigorously for 12 h. The 
product was washed with brine (2 × 30 mL) and dried over MgSO4, and concentrated by rotary 
evaporation to give a crude product which was further purified on a silica gel column (MeOH: 
DCM, 1: 9 (v/v)) to give white solid. Yield = 667 mg (53%). 1H NMR (300 MHz, MeOD-d4): 
δH 1.29 (t, J = 7.2 Hz, 3H), 2.43 (s, 3H), 3.02 (q, J = 7.4 Hz, 14.6 Hz, 2H), 3.08–3.12 (m, 4H), 
7.41 (d, J = 7.6 Hz, 2H), 7.77 (d, J = 7.7 Hz, 2H). ESI-MS: Calcd for [C11H18N2O2S + H]
+ 
243.1 m/z, found: 243.1 m/z. 
N-(2-(Benzylamino)ethyl)-4-methylbenzenesulfonamide (TsEnBz)  
This was obtained following the method described in the literature.5c A solution of N-
benzylethylenediamine (0.94 mL, 6.24 mmol) in dichloromethane (100 mL) was placed in a 
round-bottom flask. A solution of toluenesulfonyl chloride (1 g, 5.2 mmol) in DCM (50 mL) 
was added slowly via a dropping funnel, and the mixture was stirred vigorously for 12 h. The 
product was washed with brine (2 × 30 mL) and dried over MgSO4, and concentrated by rotary 
evaporation to give a crude product which was further purified on a silica gel column (MeOH: 
DCM, 1: 9 (v/v)) to give white solid. Yield = 696 mg (44%). 1H NMR (300 MHz, MeOD-d4): 
δH 2.44 (s, 3H), 3.07 (t, J = 5.3 Hz, 2H), 3.14 (t, J = 5.2 Hz, 2H), 4.15 (s, 2H), 7.40–7.47 (m, 
7H), 7.77 (d, J = 7.6 Hz, 2H). ESI-MS: Calcd for [C16H20N2O2S + H]
+ 305.1 m/z, found: 
305.1m/z. 
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N-(2-((4-Fluorobenzyl)amino)ethyl)-4-methylbenzenesulfonamide (4-F-BzEnTs)  
This was obtained following the method described in the literature.7 A solution of N-(2-
aminoethyl)-4-methylbenzenesulfonamide (TsEn) (500 mg, 2.33 mmol) and triethylamine 
(1.63 mL, 11 mmol) in dichloromethane (100 mL) was placed in a round-bottom flask. A 
solution of 1-(bromomethyl)-4-fluorobenzene (0.29 mL, 2.3 mmol) in DCM (50 mL) was 
added slowly via a dropping funnel, and the mixture was stirred vigorously for 12 h. The 
product was washed with brine (2 × 30 mL) and dried over MgSO4, and concentrated by rotary 
evaporation to give a crude product which was further purified by silica gel column (MeOH: 
DCM, 1: 9 (v/v)) to give white solid. Yield = 400 mg (54%). 1H NMR (300 MHz, MeOD-d4): 
δH 2.41 (s, 3H), 2.63 (t, J = 6.2 Hz, 2H), 2.97 (t, J = 6.2 Hz, 2H), 3.67 (s, 2H), 7.03 (t, J = 8.1 
Hz, 2H), 7.29 (t, J = 6.7 Hz, 2H), 7.35 (d, J = 7.7 Hz, 2H), 7.71 (d, J = 7.4 Hz, 2H). ESI-MS: 
Calcd for [C16H19FN2O2S + H]
+ 323.1 m/z, found: 323.1 m/z. 
4-Methyl-N-(2-((naphthalen-2-ylmethyl)amino)ethyl)benzenesulfonamide (TsEnNaph)  
This was obtained following the method described in the literature.7 A solution of TsEn (500 
mg, 2.33 mmol) and triethylamine (1.63 mL, 11 mmol) in dichloromethane (100 mL) was 
placed in a round-bottom flask. A solution of 2-(bromomethyl)naphthalene (500 mg, 2.33 
mmol) in DCM (50 mL) was added slowly via a dropping funnel, and the mixture was stirred 
vigorously for 12 h. The product was washed with brine (2 × 30 mL) and dried over MgSO4, 
and concentrated by rotary evaporation to get crude product and further purified on a silica gel 
column (MeOH: DCM, 1: 9 (v/v)) to give white solid. Yield = 355 mg (54%). 1H NMR (300 
MHz, MeOD-d4): δH 2.34 (s, 3H), 2.65 (t, J = 6.2 Hz, 2H), 3.00 (t, J = 6.2 Hz, 2H), 3.83 (s, 
2H), 7.26 (d, J = 7.7 Hz, 2H), 7.40-7.47 (m, 3H), 7.67-7.71 (m, 3H), 7.79-7.84 (m, 3H). ESI-
MS: Calcd for [C20H22N2O2S + H]
+ 355.1 m/z, found: 355.1 m/z. 
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N-(t-Boc)-ethylenediamine5c 
A solution of t-Boc-anhydride (6.1 g, 28 mmol) in dichloromethane (250 mL) was added drop-
wise over 2 h to a solution of ethylenediamine (11.2 mL, 166.7 mmol) in dichloromethane (50 
mL) during which the mixture slowly turned cloudy. The mixture was stirred overnight at 
ambient temperature. The solvent was removed on a rotary evaporator to obtain a yellow oil 
which was redissolved in aqueous sodium carbonate (500 mL) and extracted with 
dichloromethane. The organic layer was dried over Na2SO4, filtered and concentrated in 
vacuum to afford a yellow oil. Yield = 3.63 g (81%). 1H NMR (300 MHz, CDCl3): δH 1.44 (s, 
9H), 2.80 (t, J = 5.9 Hz, 2H), 3.17 (m, 2H), 4.85 (s, 1H). 
N-(t-Boc)-N’-(2-aminoethyl)methylensulfonamid5c  
A solution of methane sulfonyl chloride (1.85 mL, 25.8 mmol) in dichloromethane (25 mL) 
was added drop-wise over 45 min to a solution of t-Boc-protected ethylenediamine prepared 
above (3.6 g, 22.7 mmol) and triethylamine (5 mL). The reaction mixture was stirred overnight 
at ambient temperature. The solution was washed with water, dried over MgSO4 and filtered. 
After removal of the solvent on a rotary evaporator, a yellow oil was obtained. A white powder 
precipitated after washing with diethyl ether. Yield = 2.83 mg (52.3%). 1H NMR (300 MHz, 
CDCl3): δH 1.44 (s, 9H), 2.97 (s, 3H), 3.29-3.31 (m, 4H), 4.89 (s, 1H). 
N-(2-Aminoethyl)methylensulfonamide (MsEn)5c  
To a cooled solution (273 K) of t-Boc protected N-(2-aminoethyl)methylenesulfonamide (2.83 
g, 11.87 mmol) in dry dichloromethane (50 mL) was added 3.11 mL of triflic acid (5 mol equiv) 
under a N2 atmosphere. The reaction mixture was stirred for 5 h at room temperature during 
which a white precipitate gradually formed. The solvent was removed on a rotary evaporator 
to give an orange oil which was washed with diethyl ether to precipitate an orange powder. 
48 
 
After filtration, the orange product was washed with ether to remove the triflic acid and a white 
powder was collected by filtration. Yield = 1.56 g (95%). 1H NMR (400 MHz, D2O): δH 3.10 
(s, 3H), 3.16 (t, J = 5.7 Hz, 2H), 3.42 (t, J = 5.7 Hz, 2H). 
N-(2-(Benzylamino)ethyl)-4-nitrobenzenesulfonamide (4-NO2-PhEnBz)5c  
A solution of N-benzylethylenediamine (0.214 mL, 1.43 mmol) in dichloromethane (100 mL) 
was placed in a round-bottom flask. A solution of 4-nitrobenzenesulfonyl chloride (0.3 g, 1.36 
mmol) in DCM (50 mL) was added slowly via a dropping funnel, and the mixture was stirred 
vigorously for 12 h. The solvent was removed on a rotary evaporator and further purified by 
silica gel column (MeOH: DCM, 1: 9 (v/v)) to give white solid. Yield = 246 mg (54%). 1H 
NMR (400 MHz, CDCl3): δH 2.73 (t, J = 5.8 Hz, 2H), 3.05 (t, J = 5.8 Hz, 2H), 3.67 (s, 2H), 
7.21 (d, J = 6.8 Hz, 2H), 7.28-7.33 (m, 3H), 7.99 (d, J = 8.9 Hz, 2H), 8.30 (d, J = 8.6 Hz, 2H); 
ESI-MS: Calcd for [C15H17N3O4S + H]
+  336.1 m/z, found: 335.9 m/z. 
N-(2-(Benzylamino)ethyl)-4-fluorobenzenesulfonamide(4-F-PhSulEnBz)5c  
A solution of N-benzylethylenediamine (0.278 mL, 1.85 mmol) in dichloromethane (100 mL) 
was placed in a round-bottom flask. A solution of 4-fluorobenzenesulfonyl chloride (0.3 g, 1.54 
mmol) in DCM (50 mL) was added slowly via a dropping funnel, and the mixture was stirred 
vigorously for 12 h. The solvent was removed on a rotary evaporator and further purified by 
silica gel column (MeOH: DCM, 1: 9 (v/v)) to get white solid. Yield = 270 mg (57%). 1H NMR 
(400 MHz, CDCl3): δH 2.71 (t, J = 5.8 Hz, 2H), 3.00 (t, J = 5.8 Hz, 2H), 3.66 (s, 2H), 7.15 (t, 
J = 8.6 Hz, 2H), 7.22 (d, J = 6.9 Hz, 2H), 7.28-7.33 (m, 3H), 7.83-7.86 (m, 2H); ESI-MS: Calcd 
for [C15H17FN2O2S + H]
+ 309.1 m/z, found: 308.8 m/z. 
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N-(2-(Benzylamino)ethyl)benzenesulfonamide (PhSulEnBz)5c  
A solution of N-benzylethylenediamine (0.50 mL, 3.33 mmol) in dichloromethane (100 mL) 
was placed in a round-bottom flask. A solution of 4-fluorobenzenesulfonyl chloride (0.212 mL, 
1.664 mmol) in DCM (50 mL) was added slowly via a dropping funnel, and the mixture was 
stirred vigorously for 12 h. The solvent was removed on a rotary evaporator and further purified 
by silica gel column (MeOH: DCM, 1: 9 (v/v)) to give a white solid. Yield = 323 mg (67%). 
1H NMR (400 MHz, CDCl3): δH 2.67 (t, J = 5.8 Hz, 2H), 3.00 (t, J = 5.8 Hz, 2H), 3.62 (s, 2H), 
7.19-7.21 (m, 2H), 7.22-7.24 (m, 1H), 7.28-7.31 (m, 2H), 7.45-7.48 (m, 2H), 7.52-7.56 (m, 
1H), 7.82-7.85 (m, 2H); ESI-MS: Calcd for [C15H18N2O2S + H]
+ 291.1 m/z, found: 290.8 m/z. 
N-(2-(Benzylamino)ethyl)-5-(dimethylamino)naphthalene-1-sulfonamide (DanEnBz).5c  
A solution of N-benzylethylenediamine (0.267 mL, 1.78 mmol) in dichloromethane (100 mL) 
was placed in a round-bottom flask. A solution of dansyl chloride (400 mg, 1.483 mmol) in 
DCM (50 mL) was added slowly via a dropping funnel, and the mixture was stirred vigorously 
for 12 h. The solvent was removed on a rotary evaporator and further purified by silica gel 
column (MeOH: DCM, 4: 96 (v/v)) to get white solid. Yield = 324 mg (57%). 1H NMR (400 
MHz, MeOD-d4): δH 2.51 (t, J = 6.2 Hz, 2H), 2.87 (s, 6H), 2.99 (t, J = 6.2 Hz, 2H), 3.46 (s, 
2H), 7.09 (d, J = 6.6 Hz, 2H), 7.20-7.28 (m, 4H), 7.55-7.60 (m, 2H), 8.21 (dd, J = 0.9 Hz, 7.2 
Hz, 1H), 8.33 (d, J = 8.6 Hz, 1H), 8.56 (d, J = 8.5 Hz, 1H); ESI-MS: Calcd for [C21H26N3O2S 
+ H]+ 384.1 m/z, found: 384.2 m/z. 
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2.2.3.2 Synthesis of Biguanide Related Ligands in Chapter 65c 
4-Methyl-N-(N-(N-(o-tolyl)carbamimidoyl)carbamimidoyl)benzenesulfonamide 
(TsTolBig)  
A solution of 1-(o-tolyl)biguanide  (360 mg, 1.88 mmol)  in dichloromethane (150 mL) was 
placed in a round bottom flask. A solution of toluenesulfonyl chloride (300 g, 1.58 mmol) in 
dichloromethane (50 mL) was added slowly via a dropping funnel, and the mixture stirred 
vigorously for 12 h. Solvent was removed on a rotary evaporator to give a white solid which 
was purified by chromatography column (MeOH: DCM, 7: 93 (v/v)). Yield = 294 mg (54 %). 
1H NMR (400 MHz, MeOD-d4): δH 2.23 (s, 3H), 2.40 (s, 3H), 7.19-7.23 (m, 3H), 7.28 (d, J = 
6.8 Hz, 1H), 7.32 (d, J = 8.0 Hz, 2H), 7.76 (d, J = 8.2 Hz, 2H). ESI-MS: Calcd for 
[C16H19N5O2S + Na]
+ 368.1 m/z, found: 368.1 m/z. 
4-(Bromomethyl)-N-(N-(N-(o-tolyl)carbamimidoyl)carbamimidoyl) 
benzenesulphonamide (4-BrCH2-PhSulTolBig)  
This ligand was obtained following the method described above using 400 mg of 1-(o-
tolyl)biguanide and 470 mg of 4-(bromomethyl)benzene sulfonyl chloride. Yield = 252 mg 
(34%). 1H NMR (400 MHz, DMSO-d6): δH 2.15 (s, 3H), 4.73 (s, 2H), 7.17 (d, J = 7.3 Hz, 2H), 
7.24 (d, J = 7.0 Hz, 2H), 7.59 (d, J = 8.2 Hz, 2H), 7.80 (d, J = 8.4 Hz, 2H). ESI-MS: Calcd for 
[C16H18BrN5O2S + H]
+ 446.0 m/z, found: 446.2 m/z. 
4-Fluoro-N-(N-(N-(o-tolyl)carbamimidoyl)carbamimidoyl)benzenesulfonamide (4-F-
PhSulTolBig)  
This ligand was obtained following the method described above using 400 mg of 1-(o-
tolyl)biguanide and 340 mg of 4-fluoro-benzenesulfonyl chloride. Yield = 390 mg (64%). 1H 
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NMR (400 MHz, MeOD-d4): δH 2.24 (s, 3H), 7.19-7.26 (m, 5H), 7.28 (d, J = 6.6 Hz, 1H), 7.91-
7.94 (m, 2H). ESI-MS: Calcd for [C15H16FN5O2S + Na]
+ 372.0 m/z, found: 371.9 m/z. 
4-Nitro-N-(N-(N-(o-tolyl)carbamimidoyl)carbamimidoyl)benzenesulfonamide (4-NO2-
PhSulTolBig)  
This ligand was obtained following the method described above using 360 mg of 1-(o-
tolyl)biguanide and 300 mg of 4-nitro-benzenesulfonyl chloride. Yield = 240 mg (47%). 1H 
NMR (400 MHz, DMSO-d6): δH 2.17 (s, 3H), 7.01 (t, J = 6.8 Hz, 1H), 7.26 (dd, J = 7.6 Hz, 22 
Hz, 3H), 8.05 (d, J = 8.4 Hz, 2H), 8.34 (d, J = 3.4 Hz, 2H). ESI-MS: Calc for [C15H16N6O4S + 
H]+ 377.1 m/z, found: 376.9 m/z. 
5-(Dimethylamino)-N-(N-(N-(o-tolyl)carbamimidoyl)carbamimidoyl) naphthalene-1-
sulfonamide (DanTolB)  
This ligand was obtained following the method described above using 354 mg of 1-(o-
tolyl)biguanide and 300 mg of dansyl chloride. Yield = 251 mg (53%). 1H NMR (400 MHz, 
MeOD-d4): δH 2.05 (s, 3H), 2.86 (s, 6H), 7.11-7.16 (m, 2H), 7.20-7.26 (m, 3H), 7.33 (t, J = 7.9 
Hz, 1H), 7.54 (t, J = 8.3 Hz, 1H), 8.23 (d, J = 6.6 Hz, 1H), 8.41 (d, J = 8.7 Hz, 1H), 8.49 (d, J 
= 8.5 Hz, 1H). ESI-MS: Calc for [C21H24N6O2S + H]
+ 425.1 m/z, found: 425.0 m/z. 
2.3 Instruments and Assays 
2.3.1 Nuclear Magnetic Resonance Spectroscopy (NMR) 
NMR spectra were acquired in 5 mm NMR tubes at 298 K on either Bruker HD-300, HD-400 
or AV III 600 spectrometers. Data processing was carried out using Topspin-NMR version 2.1 
(Bruker U.K. Ltd.). 1H NMR chemical shifts were internally referenced to TMS via 1, 4-
dioxane in D2O (δ = 3.75 ppm) or residual MeOD-d4 (δ = 3.31 ppm), CDCl3 (δ = 7.26 ppm), 
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or DMSO-d6 (δ = 2.50 ppm). 1D spectrum were recorded using standard pulse sequences. 
Typically, data were acquired with 16 transients into 32 k data points over a spectral width of 
14 ppm; and 32 transients into 32 k data points over a spectral width of 30 ppm using a 
relaxation delay of 2 s for the kinetic experiment. 
2.3.2 UV-vis Spectroscopy 
UV-vis spectra were recorded on a Varian Cary 300 UV-vis spectrometry using a 1 cm path-
length quartz cuvette with a PTP1 Peltier temperature controller. Spectra were monitored over 
a width of 200-800 nm, bandwidth of 1.0 nm and a scan rate of 600 nm/min. 
2.3.3 Portable pH Meter 
A minilab IQ125 pH meter equipped with an ISFET silicon chip pH sensor and referenced in 
KCl gel was used to measure the pH. The electrode was calibrated with Aldrich buffer solutions 
of pH 4, 7 and 10. pH* values (pH meter reading without correction for the effect of deuterium 
on chip sensor) of NMR samples in D2O were measured at 298 K. pH
* values were adjusted 
with KOD or DNO3 solutions in D2O. pH values of the reaction mixtures and UV-Vis samples 
in H2O were also measured at 298 K. pH values were adjusted with KOH or HNO3 solutions. 
2.3.4 X-ray Crystallography 
X-ray diffraction data were collected and the structures solved by Dr Guy Clarkson at the 
University of Warwick.  
Diffraction data were collected on an Oxford Diffraction Gemini four-circle system with a 
Ruby CCD area detector. All structures were refined by full-matrix least squares against F2 
using SHELXL8 and were solved by direct methods using SHELXS9 (TREF) with additional 
light atoms found by Fourier methods. Anisotropic displacement parameters were used for all 
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non-H atoms; H-atoms were given an isotropic displacement parameter equal to 1.2 (or 1.5 for 
methyl and NH H-atoms) times the equivalent isotropic displacement parameter of the atom to 
which they are attached. The data were processed by the modelling program Mercury 3.8.  
To assess whether the bond distances were statistically different (when the difference between 
was greater than 3σ).  
σ = √(σ12+σ22);   
where σ1 and σ2 are the standard deviations of the bond lengths compared. 
2.3.5 Elemental Analysis  
Elemental analyses were performed by Warwick Analytical Service using an Exeter Analytical 
elemental analyzer (CE440).   
2.3.6 Electrospray Ionization Mass Spectrometry (ESI-MS)  
Low resolution positive ion electrospray mass spectra were obtained on an Agilent 6130B ion 
mass spectrometer. All samples were prepared in methanol (95 %)/water or methanol (100%). 
And filtered before testing. Mass spectra were recorded with a scan range of 50 to 1000 m/z. 
2.3.7 High Resolution Mass Spectrometry (HR-MS) 
All the samples was analysed by Dr. Lijiang Song and Mr Philip Aston. 
High resolution positive-ion mass spectra were obtained on a Bruker Maxis Q-TOF. All the 
samples were analised by positive electrospray ionization mass spectra. All samples were 
prepared in double deionised water (ddw), methanol/water (95%), or methanol (100%). 
Injection of 2 μL min-1, nebuliser gas (N2) 0.4 bar, dry gas (N2) 4 L min-1, dry temp. 453 K, 
capillary -3000 V (positive mode) end plate offset -500 V. Capillary exit 166 V, funnel RF 300 
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vpp, Multiplole RF 300 vpp, quadrupole ion energy 4 eV, Collision cell 1200 eV, ion cooler 
RF settins, ramp from 50 to 250 V. Mass spectra were recorded with a scan range of 50 to 3000 
m/z.  
2.3.8 High Performance Liquid Chromatography (HPLC) 
HPLC analysis was performed on a HP 1200 Series HPLC System (Agilent) with a 100 μL 
loop, using an Agilent ZORBAX Eclipse Plus C18 (250 × 4.6 mm, 5 μm pore size) column. 
The mobile phases include A: water (HPLC grade, Sigma-Aldrich) containing 0.1% 
trifluoroacetic acid, and B: acetonitrile (HPLC grade, Sigma-Aldrich) containing 0.1% 
trifluoroacetic acid. Gradients of t = 0 min (10% B), t = 30 min (80% B), t = 40 min (80% B), 
t = 41 min (10% B) and t = 55 min (10% B) over a 55 min period. Flow rate was 1 mL/min. A 
wavelength was detected at 254 nm with the reference wavelength at either 360 or 510 nm was 
used. Samples were prepared in doubly deionized water (DDW) or a mixture methanol (5%, 
HPLC grade)/ddw. Sample injections were half of the loop volume (50 μL).  
2.3.9 Liquid Chromatography–Mass Spectrometry (LC-MS) 
LC-MS was performed on a HP 1200 Series HPLC System (Agilent) coupled to a Bruker HCT-
Ultra ETD II PTR PTM mass spectrometer. The column used was an Agilent ZORBAX Eclipse 
Plus C-18 (4.6 × 250 mm, 5 μm pore size). The mobile phases were A: water (HPLC grade, 
Sigma-Aldrich, with 0.1% TFA), and B: acetonitrile (HPLC grade, Sigma-Aldrich, with 0.1% 
TFA). Specific gradients are described in the corresponding chapter. Samples were prepared 
in DDW. Sample injections were 50 μL. The mass spectrometer was operated in electrospray 
positive mode with scan range 50-2000 m/z, and related parameters are: Nebuliser gas (N2) 40 
psi, dry gas (N2) 10 L/min, dry temp. 573 K, HV capillary -4000 V (positive mode) end plate 
offset -500 V, capillary exit 166 V, and Octapole RF 200 Vpp. 
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2.3.10 Inductively Coupled Plasma−Optical Emission Spectrometry (ICP-
OES)  
ICP-OES analyses were carried out on a PerkinElmer Optima 5300 DV series ICP-OES 
instrument. The DDW was used for ICP-OES analysis from a Millipore Milli-Q water 
purification system and a USF Elga UHQ water deionizer. Standards for Ru, Os or Ir were 
purchased from Inorganic Ventures, Fluka or Alfa Asar, respectively. The Ru and Ir Specupure 
plasma standards were diluted with 3.6% v/v HNO3, Os standards were diluted with 3.6% v/v 
HNO3 containing thiourea and ascorbic acid as stabilizers,
10 to freshly prepare calibrants at 
concentrations of 50-700 ppb. Calibration standards were adjusted to match the salinity of the 
samples by standard addition of sodium chloride–(TraceSELECT®) solution.  
2.3.11 Inductively Coupled Plasma−Mass Spectrometry (ICP-MS)  
ICP-MS analysis were carried out on an Agilent Technologies 7500 series ICP-MS instrument. 
The water used for ICP-MS analysis was the same for the ICP-OES water source. The Ru and 
Ir Specpure plasma standards were diluted with 3.6% v/v HNO3, Os standards were diluted 
with 3.6% v/v HNO3 containing thiourea and ascorbic acid as stabilizers,
10 and calibrants were 
freshly prepared at concentrations of 0.1-500 ppb. The ICP-MS instrument was set to detect 
101Ru, 189Os or 193Ir in no gas mode. 
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2.3.12 Cellular Biological Study in Vitro 
All the biological experiments were performed by Dr. Isolda Romero-Caneón, Ji-Inn Song and 
Bindy Heer at the University of Warwick. General antiproliferative assays are outlined below, 
for the specific protocols will be described in appropriate chapters. 
2.3.13 In Vitro Growth Inhibition Assays 
The antiproliferative activity were determined in A2780 ovarian cancer cells. Briefly, 5,000 
cells per well were seeded in 96-well plates. The plates were left to pre-incubate with drug-free 
medium at 310 K for 48 h before adding different concentrations of the tested complexes. Exact 
complex concentrations were determined by ICP-OES. A drug exposure period of 24 h was 
allowed. After this, supernatants were removed by suction and each well was washed with 
PBS. A further 72 h were allowed for the cells to recover in drug-free medium at 310 K. Cell 
viability was determined by the sulforhodamine B (SRB) assay. IC50 values, as the 
concentration that causes 50% cell death, were determined as duplicates of triplicates in two 
independent sets of experiments and their standard deviations were calculated. 
2.3.14 Cellular Accumulation 
Cellular accumulation studies were performed on A2780 ovarian cancer cells. 1.5 × 106 cells 
per well were seeded on a six-well plate. After 24 h of pre-incubation in drug-free medium at 
310 K, cells were exposed to complexes at equipotent IC50 concentrations for 24 h. After this 
time, drug solutions were removed by suction, and cells were washed with PBS and then treated 
with trypsin-EDTA. A suspension of single cells was counted, and cell pellets were collected. 
Each pellet was digested overnight in freshly-distilled concentrated nitric acid (72% v/v) at 353 
K; the resulting solutions were diluted with double-distilled water to a final concentration of 
3.6% v/v HNO3 (thiourea and L-ascorbic acid used as stabilizers for solutions containing Os
10), 
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and the amount of Ru in A2780 ovarian cells was determined by ICP-MS. These experiments 
did not include any cell recovery time in drug-free media; they were carried out in triplicate, 
and the standard deviations were calculated. 
2.3.15 Co-administration of Ru Complexes with Formate 
Cell viability assays were carried out in A2780 ovarian cancer cells. These experiments were 
carried out with the following modifications: a fixed concentration of each Ru complex equal 
to 1/3 × IC50 was used in coadministration with three different concentrations of sodium 
formate (0.5, 1.0 and 2.0 mM).  Drug stock solutions (ca. 100 µM) were prepared as described 
for in vitro growth inhibition assays. The stocks were further diluted using media until working 
concentrations were achieved. Separately, a stock solution of sodium formate was prepared in 
saline. The complex and formate solutions were added to each well independently, but within 
5 min of each other. 
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Chapter 3 
 
RuII Arene Anticancer Catalysts for Transfer 
Hydrogenation of Coenzyme NAD+ by Formate 
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3.1 Introduction 
Nicotinamide adenine dinucleotide (NAD+) and its reduced form (NADH), as well as their 
phosphorylated derivatives, NADP+ and NADPH, are important coenzymes,1 involving in over 
400 enzymatic redox reactions.2 The reduction of pyridine salts (e.g. NAD+) to dihydropyridine 
compounds (e.g. NADH) is of the critical importance for energy storage and release in cell 
metabolism.2b,2c Over the last three decades, organometallic complexes-mediated catalytic 
reduction of NAD+ to NADH using hydrogen,3 2-propanol,4 glycerol5 and sodium formate as 
hydride donors has been intensively studied.6 Compared to reduction with H2 (hydrogenation), 
transfer hydrogenation (TH) reactions possess the advantage of being simpler, without any high 
external pressure, readily available and safer-to-handle.7 Also, TH reduction of NAD(P)+ 
artificially has attracted wide interest as an in vitro mimic for enzymatic reactions performed 
under biologically relevant conditions.8  
The pathways of hydride transfer between pyridine salts and dihydropyridine compounds are 
also of interest. The first mechanistic study of the TH reduction of BNA+ (1-
benzylnicotinamide, a model for NAD+) was reported by Steckhan and Fish et al. using [(η5-
Cp*)Rh(bipy)Cl] as catalyst and sodium formate as hydride source.6b,6d,9 A catalytic cycle 
involving a Cp* ring-slipped intermediate with Rh coordinated to the amide of the pyridine 
ring was proposed.10 Knör et al. revealed a Rh coordinated poly(arylene-ethynylene)-alt-
poly(arylene-vinylene) polymer as photocatalyst for the reduction of NAD+; involving a 
possible photoexcited polymer chain being quenched and transferring an electron to the RhIII 
active center.11 More recently, a mechanism involving hydride transfer to Cp* and formation 
of RhI intermediate [(η4-Cp*-H)Rh((CH2OH)2-bipy)]+ followed by hydride transfer from the 
endo orientation of the C-H bond to maintain the 1,4-regioselectivity of NADH was discovered 
Yoon and coworkers.12 
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The half-sandwich ruthenium complex [(η6-p-cym)Ru(TsDPEN)Cl] (TsDPEN: N-((1S,2S)-2-
amino-1,2-diphenylethyl)-4-methylbenzenesulfonamide) was reported by Noyori and 
coworkers in 1995.13 Potent catalytic activity was shown in asymmetric TH reduction of 
aromatic ketones. However, the hydrophobic nature of the two phenyl groups on the ethylene 
backbone limits its application as a possible catalyst for TH reduction of NAD+ under 
biologically relevant conditions. Complexes with chelating diamine ligands such as RM175 in 
Figure 3.1, display good aqueous solubility but poor catalytic activity in TH reduction of 
NAD+.14 But complexes with functional sulfonyl substituents such as [(η6-p-cym)Ru(TsEn)Cl] 
(e.g. JS2 in Figure 3.1),15 exhibit good solubility in water and improved catalytic activity for 
TH reduction of NAD+ in aqueous media. Moreover, coadministration of [(η6-p-cym)Ru 
(TsEn)Cl] with low non-cytotoxic dose of sodium formate led to an enhancement of the 
antiproliferative activity against A2780 human ovarian cancer cells by up to 50×.8, 16 
 
Figure 3.1 Organometallic RuII complexes [(η6-biph)Ru(en)Cl]PF6 (RM175) and [(η6-p-cym) 
Ru(TsEn)Cl] (JS2). 
In this chapter, the effect on catalysis of formate reduction of NAD+ of substituents on the 
amino group of the N,N-chelating TsEn ligand in RuII complexes [(η6-p-cym)Ru(N,N’)Cl] 
where N,N’ is N-(2-(methylamino)ethyl)-4-toluenesulfonamide (TsEnMe, 1), N-(2-(dimethyl 
amino)ethyl)-4-toluenesulfonamide (TsEnMe2, 2), N-(2-(ethylamino)ethyl)-4-toluenesulfon 
amide (TsEnEt, 3), N-(2-(benzylamino)ethyl)-4-toluenesulfonamide (TsEnBz, 4), N-(2-((4-
fluorobenzyl)amino) ethyl)-4-toluenesulfonamide (4-F-BzTsEn, 5) and N-(2-((naphthalen-2-
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ylmethyl)amino)ethyl)-4-toluenesulfonamide (TsEnNaphth, 6) (Chart 3.1) have been 
investigated. In addition, the catalytic mechanism was investigated both experimentally and by 
density functional theory (DFT) calculations, and the effect of formate on the antiproliferative 
activity of these complexes against A2780 human ovarian cancer cells. 
 
Chart 3.1  RuII complexes studied in this chapter 
 
 
 
 
Complex R1 R2 
1 H Me 
   
2 Me Me 
   
3 H Et 
   
4 H Bz 
   
5 H 4-F-Bz 
   
6 H Naphth 
(NA) 
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3.2 Experimental Section 
3.2.1 Materials and Methods 
Toluenesulfonyl chloride, sodium formate and β-nicotinamide adenine dinucleotide hydrate 
(NAD+) were obtained from Sigma-Aldrich. Magnesium sulfate, potassium hydroxide, sodium 
chloride, and hydrochloric acid were obtained from Fisher Scientific. α-Phellandrene was 
purchased from SAFC. The RuII-arene precursor dimers [(p-cym)RuCl2]2,
17 as were the ligands 
4-methyl-N-(2-(methylamino)ethyl)benzenesulphon- amide (TsEnMe),18 N-(2-(dimethyl 
amino)ethyl)-4-methylbenzenesulfonamide (TsEnMe2).
19 The solvents used for NMR 
spectroscopy were purchased from Sigma-Aldrich and Cambridge Isotope Laboratories Inc. 
Non-dried solvents used in syntheses were obtained from Fisher Scientific.  
3.2.2 Synthesis of the RuII Complexes  
[(η6-p-cym)Ru(TsEnMe)Cl] (1). All RuII complexes were prepared according to related 
reported methods:12 [(p-cym)RuCl2]2 (100 mg, 0.163 mmol) and TsEnMe (80 mg, 0.35 mmol) 
were placed in a round-bottom  flask to which 2-propanol (100 mL) and triethylamine (91 μL, 
0.653 mmol) were added. The solution was heated (365 K) in a nitrogen atmosphere for 12 h 
with stirring. After this the solvent was removed on a rotary evaporator to give a dark red solid. 
The crude product was re-dissolved in dichloromethane and was washed with brine after which 
the organic solvent was dried over MgSO4 and filtered. A dark red solid was obtained after 
removal of DCM and recrystallized from methanol and diethyl ether (1:4). Yield = 72 mg 
(44.3%). 1H NMR (400 MHz, CDCl3): δH 1.26 (d, J = 6.9 Hz, 3H), 1.32 (d, J = 6.9 Hz, 3H), 
2.20 (s, 3H), 2.16-2.27 (m, 1H), 2.33 (s, 3H), 2.52-2.55 (m, 1H), 2.89-2.96 (m, 1H), 3.06 (d, J 
= 6.1 Hz, 3H), 3.09 (s, 1H), 3.54 (s, 1H), 5.33 (t, J = 4.5 Hz, 2H), 5.56 (s, 1H), 5.85 (s, 1H), 
7.14 (d, J = 7.9 Hz, 2H), 7.71 (d, J = 7.9 Hz, 2H). 13C NMR (125.8 MHz, CDCl3): δC 19.0, 
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21.4, 22.0, 23.0, 30.7, 44.5, 48.3, 58.8, 127.6, 128.5, 140.1, 140.4. HR-MS: Calcd for 
[C20H29N2O2SRu]
+ 463.0993 m/z, found: 463.0992 m/z. Elemental analysis: Calcd for 
[C20H29ClN2O2SRu]: C, 48.23%; H, 5.87%; N, 5.62%. Found: C, 48.11%, H 5.81%; N, 5.50%. 
[(η6-p-cym)Ru(TsEnMe2)Cl] (2). Complex 2 was obtained following the method described in 
literature using the ligand TsEnMe2 (84.7 mg, 0.35 mmol).
20 Recrystallization from methanol 
and diethyl ether resulted in bright wine red solid. Yield = 75 mg (45%). 1H NMR (400 MHz, 
MeOD-d4): δH 1.62 (d, J = 6.9 Hz, 6H), 1.53 (dd, J = 2.7 Hz, 11.1 Hz, 1H), 2.32 (d, J = 5.0 Hz, 
6H), 2.49 (dd, J = 5.4 Hz, 12.5 Hz, 1H), 2.76-2.84 (m, 1H), 2.90 (s, 3H), 2.98-3.05 (m, 1H), 
3.06 (s, 3H), 3.19-3.29 (m, 1H), 5.14 (d, J = 5.8 Hz, 1H), 5.25 (d, J = 5.8 Hz, 1H), 5.76 (d, J = 
5.0 Hz, 1H), 5.84 (d, J = 5.7 Hz, 1H), 7.14 (d, J = 8 Hz, 2H), 7.93 (d, J = 8.1 Hz, 2H). 13C 
NMR (125.8 MHz, CDCl3): δC 18.8, 21.4, 22.2, 22.6, 30.7, 47.0, 54.8, 55.9, 63.7, 128.3, 128.7, 
139.9, 140.5. HR-MS: Calcd for [C21H31N2O2SRu]
+ 477.1150 m/z, found: 477.1153 m/z. 
Elemental analysis: Calcd for [C21H31ClN2O2SRu]: C, 49.26%; H, 6.10%; N, 5.47%. Found: 
C, 48.85%; H, 6.32%; N, 5.35%. 
[(η6-p-cym)Ru(TsEnEt)Cl] (3). Complex 3 was obtained following the method described 
above for complex 1 using the ligand TsEnEt (97 mg, 0.40 mmol). Recrystallization from 
methanol and diethyl ether resulted in bright wine red solid. Yield = 108 mg (65%). 1H NMR 
(400 MHz, CDCl3): δH 1.27 (d, J = 6.8 Hz, 3H), 1.27-1.35 (m, 6H), 2.15 (d, J = 7.8 Hz, 2H), 
2.20 (s, 3H), 2.33 (s, 3H), 2.73 (d, J = 4.0 Hz, 1H), 2.87-2.94 (m, 1H), 3.12 (d, J = 6.9 Hz, 1H), 
3.15-3.24 (m, 2H), 3.59-3.63 (m, 1H), 5.32-5.36 (m, 2H), 5.51 (s, 1H), 5.90 (s, 1H), 7.14 (d, J 
= 7.9 Hz, 2H), 7.21 (d, J = 7.9 Hz, 2H). 13C NMR (125.8 MHz, CDCl3): δC 14.9, 19.0, 21.4, 
22.0, 23.0, 30.8, 48.3, 51.8, 54.9, 127.6, 128.5, 140.0, 140.4. HR-MS: Calcd for 
[C21H31N2O2SRu]
+ 477.1150 m/z, found: 477.1153 m/z. Elemental analysis: Calcd for 
[C21H31ClN2O2SRu]: C, 49.26%; H, 6.10%; N, 5.47%. Found: C, 48.24%; H, 6.06%; N, 5.36%. 
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[(η6-p-cym)Ru(TsEnBz)Cl] (4). Complex 4 was obtained following the method described 
above for complex 1 using the ligand TsEnBz (106.4 mg, 0.35 mmol). Crude product was 
Purified by silica column chromatography (ethyl acetate/hexane 2:1 (v/v)) and then 
recrystallized from ethyl acetate and hexane at ambient temperature, giving a bright red solid. 
Yield = 99.2 mg (53%). 1H NMR (400 MHz, CDCl3): δH 1.20 (d, J = 6.8 Hz, 3H), 1.26 (d, J = 
6.8 Hz, 3H), 1.91-1.97 (m, 1H), 2.02-2.08 (m, 1H), 2.13 (s, 3H), 2.22 (s, 3H), 2.13 (d, J = 10.1 
Hz 1H), 2.83-2.88 (m, 1H), 2.94 (d, J = 10.9 Hz, 1H), 3.70 (t, J = 9.5 Hz, 1H), 4.03 (t, J = 10.8 
Hz, 1H), 4.64 (d, J = 13.1 Hz, 1H), 5.41 (s, 1H), 5.74 (s, 1H), 7.03 (d, J = 7.8 Hz, 2H), 7.17-
7.20 (m, 3H), 7.26 (s, 3H), 7.59 (d, J = 7.9 Hz, 2H). 13C NMR (125.8 MHz, CDCl3): δC 19.1, 
21.4, 21.9, 23.1, 30.9, 48.2, 54.7, 61.5, 127.6, 128.4, 128.5, 128.7, 129.2, 135.8, 139.9, 140.4. 
HR-MS: Calcd for [C26H33N2O2SRu]
+ 539.1306 m/z, found: 539.1307 m/z. Elemental analysis: 
Calcd for [C26H33ClN2O2SRu]: C, 54.39%; H, 5.79%; N, 4.88%. Found: C, 54.37%; H, 5.82%; 
N, 4.82%. 
[(η6-p-cym)Ru(TsEn(4-F-Bz)Cl] (5). Complex 5 was obtained following the method 
described above for complex 1 using the ligand TsEn(4-F-benzyl) (200 mg, 0.621 mmol) and 
[(p-cym)RuCl2]2 (184 mg, 0.3 mmol). A bright red solid was obtained by following the 
purification method for complex 5. Yield = 124 mg (34%). 1H NMR (300 MHz, CDCl3): δH 
1.30 (d, J = 6.8 Hz, 3H), 1.36 (d, J = 6.9 Hz, 3H), 2.00-2.16 (m, 2H), 2.02-2.08 (m, 1H), 2.23 
(s, 3H), 2.32 (s, 3H), 2.38-2.41 (m, 1H), 2.91-3.00 (m, 1H), 3.05 (d, J = 12.0 Hz, 1H), 3.76 (t, 
J = 9.6 Hz, 1H), 4.10 (t, J = 12.0 Hz, 1H), 4.72 (d, J = 14.2 Hz, 1H), 5.40-5.42 (m, 2H), 5.51 
(s, 1H), 5.84 (s, 1H), 7.06 (t, J = 8.3 Hz, 2H), 7.13 (d, J = 7.5 Hz, 3H), 7.26-7.30 (m ,2H), 7.69 
(d, J = 7.3 Hz, 2H). 13C NMR (125.8 MHz, CDCl3): δC 19.1, 21.4, 21.9, 23.1, 31.0, 48.2, 54.5, 
60.6, 116.1, 116.3, 127.6, 128.5, 130.3, 130.3, 131.6, 131.7, 139.8, 140.4, 161.7, 163.7. 19F 
NMR (376.4 MHz, CDCl3, referenced to CF3COOH, at -76.55 ppm): -112.3. HR-MS: Calcd 
for [C26H32FN2O2SRu]
+ 557.1212 m/z, found: 557.1213 m/z. Elemental analysis: Calcd for 
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[C26H32ClFN2O2SRu]: C, 52.74%; H, 5.45%; N, 4.73%. Found: C, 52.20%; H, 5.34%; N, 
4.67%. 
[(η6-p-cym)Ru(TsEnNA)Cl] (6). Complex 6 was obtained following the method described 
above for complex 1 using the ligand TsEn-naphthalene (272 mg, 0.77 mmol) and [(p-
cym)RuCl2]2 (235.2 mg, 0.38 mmol). A dark red solid was obtained by following the 
purification method for complex 5. Yield = 156 mg (33%). 1H NMR (300 MHz, CDCl3): δH 
1.32 (d, J = 7.1 Hz, 3H), 1.37 (d, J = 9.0 Hz, 3H), 2.02-2.10 (m, 1H), 2.16-2.28 (m, 3H), 2.32 
(s, 3H), 2.42-2.45 (m, 1H), 2.94-3.10 (m, 2H), 3.94-4.11 (m, 1H), 4.23-4.34 (m, 1H), 4.90 (d, 
J = 14.2 Hz, 1H), 5.42 (s, 2H), 5.50-5.59 (m, 1H), 5.84-5.87 (m, 1H), 7.13 (d, J = 8.1 Hz, 2H), 
7.37 (d, J = 8.5 Hz, 2H), 7.51-7.53 (m, 2H), 7.69-7.71 (m, 2H), 7.81-7.86 (m, 2H). 13C NMR 
(125.8 MHz, CDCl3): δC 19.1, 21.4, 21.9, 23.2, 31.0, 48.2, 54.8, 61.6, 125.5, 126.8, 126.9, 
127.6, 127.7, 127.8, 127.8, 127.9, 128.5, 129.3, 129.3, 133.1, 133.2, 139.9, 140.4. HR-MS: 
Calcd for [C30H35N2O2SRu]
+ 589.1463 m/z, found: 589.1463 m/z. Elemental analysis: Calcd 
for [C30H35ClN2O2SRu]: C, 57.73%; H, 5.65%; N, 4.49%. Found: C, 56.10%; H, 5.44%; N, 
4.32%. 
3.2.3 TOFs Determined by UV-vis Spectroscopy  
Complexes 1-6 were dissolved in MeOH/H2O (1:9 v/v) (84 µM) in a glass vial. Solutions of 
sodium formate (102 mM) and NAD+ in H2O (510 µM) were also prepared. In a typical 
experiment, an aliquot of 330 μL from each solution was added to a 1 mL cuvette bringing the 
total volume to 1 mL (final concentrations were Ru complex 28 µM; NAD+ 170 µM; NaHCO2 
34 mM; molar ratio 1:6:1200), and the pH was adjusted to 7.2 before the sample was introduced 
into the UV-vis instrument. UV spectra are recorded every 5 min until completion of the 
reaction. The spectrum was monitored by following an absorbance in the band at 340 nm, 
which corresponds to the absorption of NADH. 
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3.2.4 TOFs Determined by NMR Spectroscopy  
Solutions of complexes in MeOD-d4/D2O (1:4 v/v) (1.4 mM), sodium formate (35 mM) and 
NAD+ in D2O (5.6 mM) were prepared in separate vials. An aliquot of 200 μL from each 
solution was added into a 5 mm NMR tube, getting the final volume to 0.64 mL (Ru complex 
0.44 mM; NAD+ 1.75 mM; NaHCO2 10.94 mM; molar ratio 1:4:25). The pH
* was adjusted to 
7.2 ± 0.1. The 1H NMR spectrum were recorded at 310 K every 162 s until the completion of 
the reaction. Molar ratios of NAD+ and NADH were determined by integrating the 1H NMR 
peaks corresponding to NAD+ (9.33 ppm) and of 1, 4-NADH (6.96 ppm). The turnover number 
(TON) for the reaction was calculated as follows:  
 
where In is the integral of the signal at n ppm and [NAD
+] is the concentration of NAD+ at the 
start of the reaction. Catalyst is the concentration of RuII complex. TOFs (h-1) were determined 
as the slope of the linear plot of TONs versus time (h). 
Another series of experiments were performed where complex 4 (3.29 mg, 0.0057 mmol) was 
dissolved in MeOD-d4 (60%)/D2O (40%) (1.4 mM) in a vial. Following the procedure used 
above, the kinetics of the reaction using different concentrations of sodium formate (complex 
4, NAD+ and sodium formate in the ratio 1: 4: X, where X = 10, 25, 50, and 100 mol equiv) 
and different concentrations of NAD+ (complex 4, NAD+ and sodium formate in ratio of 1: Y: 
25, where Y = 2, 4, 6 and 10) were studied. A second series of experiments using different pH* 
values of the reaction solutions (5, 6, 7, 8 and 9) were also performed. 
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3.2.5 Interaction with DNA Nucleobases 
The reaction of complex 4 (ca. 2 mM) with nucleobases (9-ethylguanine and adenosine 5’-
monophosphate) were studied typically by addition of an aqueous solution of DNA 
nucleobases (1 mM each, 0.5 mol equiv) in MeOD-d4/D2O (1:9). The pH
* values were adjusted 
to 7.2 ± 0.1 with chip pH sensor, all the reactions were monitored by 1H NMR at 310 K.  
The following DNA related experiments (in Sections 3.2.6-3.2.8) were performed by Professor 
Viktor Brabec and Dr. Jana Kasparkova (Institute of Biophysics, Academy of Sciences of the 
Czech Republic). 
3.2.6 Binding to Calf Thymus DNA 
Solutions of double-helical calf thymus DNA (ct-DNA) at a concentration of 32 µg/mL were 
incubated with the complex 4 at a ri value of 0.1 in NaClO4 (10 mM) at 310 K (ri is defined as 
the molar ratio of free Ru complex to nucleotide phosphates at the onset of incubation with 
DNA). The reaction was stopped after 24 h incubation, and samples were dialyzed exhaustively 
against water to remove unbound ruthenium (or, alternatively, free Ru complex was removed 
by gel filtration through a Sephadex G25 coarse column). The concentration of ruthenium 
associated with DNA in these samples was determined by flameless atomic absorption 
spectrometry (FAAS). The concentrations of DNA were determined by absorption 
spectrophotometry.  
3.2.7 Binding to Bacterial Circular Plasmid DNA 
Reaction mixtures containing plasmid DNA pBR322 (28 µg/mL) and complex 4 in various 
molar ratios (ri = 0.05-1) were incubated in 0.01 M NaClO4 at 310 K in the dark for 24 h. The 
samples were then mixed with the loading buffer and loaded onto a 1% agarose gel running at 
298 K in the dark with Tris-acetate-EDTA (TAE) buffer and the voltage set at 25 V. No 
70 
 
separation step was included before loading the samples into the gel to catch potential 
noncovalent binding (if any). The gels were then stained with EtBr, followed by photography 
with a transilluminator.  
3.2.8 Binding to Short Single- or Double-stranded Oligonucleotides 
50-mer oligonucleotides (single or double stranded) were incubated with complex 4 (ri = 1 – 
concentration of oligonucleotide related to phosphates) in 0.05 M NaClO4 at 310 K in the dark. 
After 24 h, the reaction was stopped, and samples were exhaustively dialyzed against water. 
The ruthenium content in these samples was determined by FAAS and the concentrations of 
oligonucletides were determined by absorption spectrophotometry. 
3.2.9 Relative Hydrophobicity 
Measurements were performed utilizing the Agilent 1200 system with a VWD and 50 µL loop. 
The column was an Agilent Zorbax 300SB C18, 150 × 4.6 mm with a 5 µm pore size. The 
mobile phase was H2O (50mM NaCl)/H2O/CH3CN 1:1 (50 mM NaCl), with a flow of 1 mL 
min-1. The detection wavelength was set at 254 nm with the reference wavelength at 360 nm. 
All compounds were dissolved in 10% MeOH/90% H2O (v/v) in 50 mM NaCl to ensure that 
hydrolysis was prevented. Sample injections were the loop volume (50 μL) with needle washes 
of MeOH and H2O between injections. Reported retention times (tR) and standard deviations 
(SD) are from triplicate measurements. The gradient used is shown in Figure 3.2. 
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Figure 3.2 Relative hydrophobicity measurements by HPLC using H2O 50 mM NaCl (Solvent 
A) and H2O/CH3CN 1:1 50 mM NaCl (solvent B). 
3.2.10 Cellular Accumulation  
The mode of action studies in Section 3.2.10-3.2.12 were carried out by Dr. Isolda Romero-
Canelon. 
The accumulation studies for Ru complexes 1-6 were carried out towards A2780 ovarian cancer 
cells. 1.5 × 106 cells were seeded on a six-well plate. After 24 h of incubation in medium (drug-
free) at 310 K, cells were exposed to complexes at equipotent IC50 concentrations for 24 h, 
without any cell recovery time in drug-free media. Drug solutions were subsequently removed 
by suction, cells were then washed with PBS and treated with trypsin-EDTA. A suspension of 
single cells was counted, and cell pellets were collected. Each pellet was digested overnight in 
freshly-distilled concentrated nitric acid (72%, v/v) at 353 K; the resulting solutions were 
diluted with doubly deionized water (DDW) to a final concentration of 3.6% v/v HNO3, and 
the amount of Ru in A2780 ovarian cells was determined by ICP-MS. These experiments were 
carried out in triplicate, and the standard deviations were calculated. 
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3.2.11 Co-administration of Ru Complexes with Formate  
Cell viability assays were carried out with complexes 1–6 in A2780 ovarian cancer cells with 
the following modifications: a fixed concentration of each Ru complex equal to 1/3 × IC50 was 
co-administered with three different concentrations of sodium formate (0.5, 1.0 and 2.0 mM).  
Drug stock solutions (ca. 100 µM) were prepared as describes for in vitro growth inhibition 
assays. The stocks were further diluted using media until working concentrations were 
achieved. Separately, a stock solution of sodium formate was prepared in saline. The complex 
and formate solutions were added to each well independently, within 5 min of each. 
3.2.12 ROS Determination  
Flow cytometry analysis of ROS/superoxide generation in A2780 cells caused by exposure to 
complexes 1 and 4 was carried out using the Total ROS/Superoxide detection kit (Enzo-Life 
Sciences) according to the supplier’s instructions. Generally, 1.5 × 106 A2780 cells per well 
were seeded in a six-well plate. Cells were preincubated in drug-free media at 310 K for 24 h 
in a 5% CO2 humidified atmosphere, and then drugs were added in triplicates at equipotent 
IC50 concentrations. After 1 h of drug exposure, supernatants were removed by suction and 
cells were washed and harvested. The cell pellets were re-suspended in the orange/green 
fluorescent reagents buffer for staining. The fluorescence was analyzed in a Becton Dickinson 
FACScan flow cytometer using FL1 channel Ex/Em: 490/525 nm for the oxidative stress and 
FL2 channel Ex/Em: 550/620 nm for superoxide detection. Data were processed using Flowjo 
software. At all times, samples were kept under dark conditions to avoid light-induced ROS 
production.  
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3.2.13 DFT Computational Details 
The DFT calculations were performed by Dr. Juliusz A. Wolny and Professor Volker 
Schünemann (Department of Physics, University of Kaiserslautern, Germany). 
DFT calculations of free energy levels for species in the catalytic cycle were performed and 
based on the crystal structure of complex 3. The calculations used functional CAM-B3LYP21 
with basis set CEP-31G,22 using Gaussian 09 software.23 Ultrafine grid of integration was used 
in each case. The starting geometry was taken from X-ray data for 3, with an appropriate change 
of substituents for other systems. NAD+ and NADH were modeled with N-protonated 
analogues of corresponding nicotinamide species. All given energy values are the result of the 
full geometry optimisation with the subsequent frequency calculations. The free energy level 
of each complex is shown in Scheme 3.4.  
 
 
3.3 Results 
3.3.1 Synthesis and Characterization  
RuII complexes 1-6 were synthesized by following a reported procedure (Scheme 3.1).15 
Typically, trimethylamine (4 mol equiv) and ligands (ca. 2 mol equiv) were added to the a 
solution of [(p-cym)RuCl2]2 in degassed isopropanol, the reactions was stirred under a N2 
atmosphere at 365 K for 12 h. All synthesized complexes were characterized by 1H and 13C 
NMR spectroscopy, mass spectrometry (ESI-MS) and elemental analysis (CHN).  A crystal of 
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complex 3 suitable for X-ray analysis was obtained from diffusion of diethyl ether into 
methanol. 
 
Scheme 3.1 Synthetic routes for diamine ligand and RuII complexes 1-6. 
3.3.2 X-ray Crystal Structure  
Selected bond lengths and angles for complex 3 are listed in Table 3.1. Crystallographic data 
are presented in Table 3.2. And the structure of complex 3 is shown in Figure 3.3. Complex 3 
adopts the pseudo-octahedral geometry with the η6-bonded aromatic ring occupying 3 
coordination sites. The chelating ligand is deprotonated and bonded as a monoanionic bidentate 
ligand. The CH2CH2N-Et atoms from N, N’ chelated ligand (C10 C11 N12 C13) were modelled 
as disordered over two positions whose occupancy refined to 86:14. 
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Figure 3.3 ORTEP diagrams for complex 3. Ellipsoids are shown at the 50% probability level. 
All hydrogen atoms have been omitted for clarity. 
 
Table 3.1 Selected Bond Lengths (Å) and Angles (deg) for Complex 3. 
Bonds Length (Å) /Angle(o) 
Ru1−N9 2.1256(9) 
Ru1−N12 
Ru1-N12A 
2.1702(11) 
2.157(8) 
Ru1−Cl1 2.4173(3) 
Ru1−arene (centroid) 1.664 
N9−Ru1−N12 
N9−Ru1−N12A 
78.74(4) 
76.1(2) 
N9−Ru1−Cl1 
N12−Ru1−Cl1 
89.47(3) 
87.55(4) 
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Table 3.2 Crystallographic Data for Complex 3. 
Crystal character         red block 
Empirical formula C21H31ClN2O2RuS 
Formula weight 512.06 
Temp (K)             150(2) 
Crystal system            monoclinic 
Space group             P21/c 
a / Å                         13.88136(9) 
b / Å                         10.43716(8) 
c / Å                         15.24599(11) 
α / °                          90 
β / °                          102.1274(7) 
γ / °                          90 
Volume / Å3              2159.57(3) 
Z                          4 
Dcalc (mg/cm
3)              1.575 
μ / mm-1               0.966 
F (000)              1056.0 
Crystal size/mm3  0.6 × 0.4 × 0.06 orange block 
Reflections collected  201186 
Indep reflection  11305  
R [I>=2σ (I)]              R1 = 0.0273 
Final R [all data]  R2 = 0.0629 
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3.3.3 Hydrolysis and pKa* Determination 
The hydrolysis of complex 4 was studied by dissolving the RuII complex in MeOD-d4/D2O (1.4 
mM, 1/9(v/v)). The 1H NMR spectrum remained unchanged after 24 h and the hydrolysis was 
assumed to be rapid since the peaks could be assigned to the aqua RuII species (4a) by 
comparison to those from the aqua species generated in a reaction with silver nitrate in D2O (1 
molar equiv).15 The pKa
* (pKa value determined in deuterated solvent) of complex 4a was 
determined by a pH* (meter reading) titration ranging from 2 to 12 by addition of NaOD and 
DNO3 solutions. Changes in the chemical shift of the proton of toluene arene 
1H NMR 
resonance were followed and the data were fitted to the Henderson−Hasselbalch equation, 
giving a pKa
* value of 9.73 ± 0.06 (see Figure 3.4). 
 
Figure 3.4 Dependence of the 1H NMR chemical shift of the proton of toluene arene on pH* 
of aqua complex 4a.  
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3.3.4 DNA Nucleobase Binding 
The interaction of complex 4 with DNA nucleobase models: 9-ethylguanine (9-EtG) and 
adenosine 5’-monophosphate (5’-AMP) were studied by 1H NMR spectroscopy (see Figure 
3.5). The reactions were performed by adding nucleobase solution (3 mM in D2O) to Ru
II 
complex solution (2 mM in 10% MeOD-d4/90% D2O) at 310 K, to give a final 1.5:1 mol ratio. 
The formation of adducts 4-9-EtG was confirmed by following the new set of peaks, and up to 
90% yield of adduct was obtained when 1.5 mol equiv 9-EtG solution was added. However, 
no adduct was found when 1.5 mol equiv of 5’-AMP was added to complex 4, even after 24 h 
incubation at 310 K.  
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Figure 3.5 Low field protons of complex 4 (2 mM) on reaction with a) 9-ethylguanine (9-EtG) 
b) adenosine 5’-monophosphate (5’-AMP, 3 mM, 1.5 mol equiv) in 10% MeOD-d4/90% D2O, 
pH at 7.2, 310 K, followed by 1H NMR.  
3.3.5 Kinetics of Transfer Hydrogenation Reactions  
The reduction of coenzyme nicotinamide adenine dinucleotide (NAD+) to NADH was 
investigated in an aqueous medium using complexes 1-6 as catalysts and sodium formate as 
the hydride source. Initially, the reactions were studied by UV-visible spectroscopy under 
conditions of pH 7.2 ± 0.1, 310 K and  MeOH/H2O 1:9 (v/v); in all the cases, an increase of 
intensity of the band at 340 nm was observed, assignable to formation of NADH (see Figure 
3.6). The kinetics of conversion were monitored by 1H NMR at 310 K and pH* 7.2 ± 0.1. The 
reactions were performed in a mixed solvent MeOD-d4/D2O (1:4 v/v), due to the poor aqueous 
solubility of complexes 5 and 6. 
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Figure 3.6 Monitoring of kinetics of TH reaction of NAD+ to NADH catalysed by complex 4 
using sodium formate as hydride source by UV-vis spectroscopy (complex 4 28 µM; NAD+ 
170 µM; NaHCO2 34 mM; mol ratio 1:6:1200, MeOH/H2O, 1:9 (v/v), pH 7.2, 310 K), and 
increase in absorbance at 340 nm (inset). 
Table 3.3 Turnover Frequencies for Transfer Hydrogenation Reactions Using Ru complexes 
1−6 as Catalysts. 
Complex R1 R2 TOF(h-1)a TOF(h-1)b 
1 H Me 2.97 ± 0.04 4.0 ± 0.3 
2 Me Me 3.9 ± 0.1 4.1 ± 0.1 
3 H Et 4.3 ± 0.1 5.9 ± 0.2 
4 H Bz 7.4 ± 0.1 7.7 ± 0.3 
5 H 4-F-Bz 7.1 ± 0.1 6.5 ± 0.4 
6 H Naphth 6.1 ± 0.9 4.9 ± 0.5 
                                        aBy UV-vis spectroscopy. 
                                        bBy NMR spectroscopy. 
The dependence of the rate of catalysis for six pH* values ranging from 5 to 9 was determined 
for complex 4 at a mol ratio complex 4: NAD+: formate of 1: 4: 25, respectively, in the same 
mixed solvent at 310 K (see Figure 3.7). The TOF was relatively insensitive to pH* over the 
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range pH* 6-8 (ca. 7.5 h-1), but decreased slightly at lower and higher pH* (5.6 h-1 at pH* 5, 6.6 
h-1 at pH* 9). 
 
Figure 3.7 Dependence of turnover frequency on pH* for the reduction of NAD+ by complex 
4 using formate as a hydride source (molar ratio of NAD+: complex 4: formate = 4:1:25, 310 
K in MeOD-d4/D2O (2:8 v/v)). 
The dependence of turnover frequency on the concentrations of sodium formate and NAD+ was 
investigated for complex 4 in MeOD-d4/D2O (1:4) at 310 K. The mol ratio of complex 4, NAD
+ 
and sodium formate was 1: 4: X, respectively, where X = 5, 10, 25, 50 and 100 (see Figure 
3.8). The TOF increased steadily from 2.2 h-1 to 18.8 h-1 as the excess of formate increased 
from 7 mM to 140 mM. Next the dependence of TOF on the NAD+ concentration was studied 
for mol ratio complex 4: NAD+: formate = 1: Y: 25, where Y = 2, 6 and 10. The TOF was 
found to be independent of NAD+ concentration (7.7 ± 0.5 h-1).   
The Michaelis−Menten kinetic behaviour is apparent from a plot of turnover frequency versus 
formate concentration. A reciprocal plot of turnover frequency versus sodium formate 
concentration gave a Michaelis constant of KM = 0.086 mM (see Figures 3.8 and 3.9).  
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Figure 3.8  Dependence of the reaction rate on the concentration of sodium formate for the 
transfer reduction of NAD+ catalysed by complex 4 (molar ratio of NAD+, complex 4 and 
sodium formate is 4:1:X, respectively, where X = 5, 10, 25, 50 and 100, at 310 K in MeOD-
d4/D2O (2:8)). 
 
Figure 3.9 Plot of the reciprocal of the TOF against sodium formate concentration for the 
reduction of NAD+ in the presence of various mol equiv of formate, catalyzed by complex 4. 
For a reaction following Michaelis-type kinetics, TOF = TOFmax[S]/(KM + [S]), where TOFmax 
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is the turnover frequency at infinite substrate (formate) concentration, [S] is the substrate 
concentration, and KM is the Michaelis constant. Hence, TOF
−1 = (KM/TOFmax)(1/[S]) + 
(1/TOFmax), and KM and TOFmax can be obtained from the gradient and y intercept, respectively, 
of the double-reciprocal plot. 
3.3.6 Antiproliferative Activity   
The antiproliferative activity of complexes 1−6 towards A2780 human ovarian cancer cells 
was determined in comparison with the clinically approved drug cisplatin, Figure 3.10. The 
IC50 values (50% inhibition of cell growth) range from 1 to 6.5 μM for complexes containing 
aromatic R substituents (4-6), whereas those containing aliphatic R substituents are less potent 
with IC50 values of 12-31 µM.  The complex [(η6-p-cym)Ru(TsEnBz)Cl] (4) (IC50, 1.0 μM) 
has a potency similar to cisplatin in this cell line (CDDP, 1.20 ± 0.02 µM). 
 
Figure 3.10 Antiproliferative activity of RuII complexes 1-6 and cisplatin towards A2780 
human ovarian cancer cells. 
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3.3.7 Antiproliferative Activity in the Presence of Sodium Formate   
The antiproliferative activity of RuII complexes in A2780 human ovarian cancer cells in the 
presence of sodium formate was investigated (see Figure 3.11). Firstly, the cytotoxicity of 
sodium formate alone towards A2780 human ovarian cancer cells was investigated. No 
significant toxicity was found up to formate concentrations of 2 mM. Then, A2780 human 
ovarian cancer cells were coincubated with equipotent concentrations of complexes 1-6 (1/3 × 
IC50) and three different concentrations of sodium formate (0.5, 1 and 2 mM). The 
antiproliferative activity of complexes 1-6 increased significantly on coincubation with 2 mM 
formate. The formate-induced decrease in viability of A2780 cells ranged from 20% to 36% in 
the presence of complex 1-6.  Interestingly for complex 6, a 28% decrease in cell viability was 
observed with only 0.5 mM formate present (see Table 3.4). 
 
Figure 3.11 Percentage of cell survival when equipotent concentrations of complexes 1–6 (1/3 
× IC50) were co-administered with different concentrations of sodium formate, p-Values were 
calculated after a t-test against the negative control data (without sodium formate), *p < 0.05, 
**p < 0.01. 
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3.3.8 Cell Accumulation  
The cellular accumulation of ruthenium in A2780 human ovarian cancer cells after exposure 
to complexes 1-6 at its IC50 equipotent concentrations was determined by inductively coupled 
plasma mass spectrometry (ICP-MS) and is shown in Figure 3.12.  
Complex 4 gave the lowest cellular accumulation (0.52 ± 0.08 ng of Ru per 106 cells), while 
complex 6 with moderate anticancer activity, exhibited the highest extent of cell uptake with 
4.5 ± 0.2 ng of Ru per 106 cells at IC50 concentration, 8.6x higher than complex 4. Complexes 
1-3 and 5, gave rise to similar cell uptake 2.4 ± 0.3 ng, 1.2 ± 0.2 ng, 3.0 ± 0.2 ng and 1.3 ± 0.2 
ng per 106 cells, respectively, following the order: 4 < 2, 5 < 1 < 3 < 6 (see Table 3.4). 
 
Figure 3.12 IC50 values (µM) for complexes 1-6 against A2780 human ovarian cancer cells (in 
blue) and cellular accumulations in A2780 cancer cells at equipotent IC50 concentrations in the 
absence of sodium formate (in orange). 
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3.3.9 Relative Hydrophobicity  
The relative hydrophobicity of complexes 1-6 was determined by RP-HPLC. The more 
hydrophobic complexes have longer retention times on a reverse-phase C18 column.
24 To 
ensure solubility of the RuII complexes, a water/methanol mixture was used (MeOH/H2O, 1:9 
v/v) together with NaCl (50 mM) to suppress hydrolysis of the complexes. The HPLC solvents 
were also prepared with 50 mM NaCl present. The resulting retention times are shown in Table 
3.4, and follow the order: 1, 2, 3 < 4, 5 < 6. Complex 3 shows the shortest retention time (least 
hydrophobic) of 14.0 min, while complex 6 shows the longest retention time (most 
hydrophobic), 20.9 min.   
Table 3.4 Retention Times (tR) of Ru
II Complexes 1−6 by RP-HPLC and Accumulation (at 
equipotent of IC50 concentrations) in A2780 Cells.   
Complex tR (min) 
Cellular-Ru 
(ng /106 cells) 
1 15.4 ± 0.9 2.4 ± 0.3 
2 14.5 ± 0.3 1.2 ± 0.2 
3 14.0 ± 0.3 3.0 ± 0.2 
4 17.4 ± 0.2 0.52 ± 0.08 
5 17.27± 0.08 1.3 ± 0.2 
6 20 ± 1 4.5 ± 0.2 
 
3.3.10 ROS Induction  
The levels of reactive oxygen species (ROS) were determined in A2780 human ovarian cancer 
cells for complexes 1 and 4 at IC50 concentrations by flow cytometry fluorescence analysis (see 
Figure 3.13). This included the monitoring of H2O2, peroxy and hydroxyl radicals, and 
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superoxide levels. High concentrations of total ROS and superoxide were observed in A2780 
after 1 h exposure to complexes 1 and 4 when compared to negative control. The populations 
of cells that show high fluorescence in both FL-1 and FL-2 channels (both high total ROS and 
high superoxide generation) for complexes 1 and 4 are 16.5 ± 1.0 and 31.3 ± 0.3, respectively. 
 
Figure 3.13 ROS in A2780 cells induced by complexes 1 and 4, FL1 channel detects total 
oxidative stress, and FL2 channel detects superoxide production. (A) Induction of ROS by 
complexes 1 and 4. (B) Four different populations caused by complexes 1 and 4 at equipotent 
IC50 concentrations. p-Values were calculated after a t-test against the negative control data, 
**p < 0.01, ***p < 0.001. 
3.3.11 Binding to Calf Thymus DNA and Bacterial Circular Plasmid DNA 
Reactions of double-helical calf thymus DNA (ct-DNA, 32 µg/mL) and plasmid DNA pBR322 
(28 µg/mL) with complex 4 in various molar ratios (ri = 0.05–1, ri = the molar ratio of free Ru 
to nucleotide phosphates at the onset of incubation with DNA) were studied. Very low amounts 
of ruthenium (5-7% of initial Ru) were found in the samples of DNA treated with complex 4 
for 24 h. No significant changes in the mobilities of supercoiled (sc) or open circular (oc) form 
of plasmid DNA were observed even when incubated with high concentrations of complex 4 
(see Figure 3.14). 
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Figure 3.14 Mobilities of supercoiled (sc) and open circular (oc) forms of plasmid DNA in the 
presence of complex 4.  
In order to test the possibility of non-covalent interaction of complex 4 (in DMSO/H2O, 1:99, 
v/v) with ds-DNA (very weak interaction could not survive conditions under exhaustive 
dialysis, gel filtration or electrophoresis), spectrophotometric titrations of complex 4 with ct-
DNA was performed (see Figure 3.15). In general, the process of DNA binding situates the 
molecule of the complex in an environment which is different from that of the free molecule 
in solution. Consequently, the electron distribution of the molecule is altered and this results in 
differences between the absorption properties of the free and DNA-bound molecule (usually 
hypochromism, and in some cases - red/blue shift). However, no significant changes were 
observed in a spectrum of complex 4 when titrated with ct-DNA (visible region of the spectrum 
is shown, where DNA does not interfere). 
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Figure 3.15 Titration of complex 4 (2.8 × 104 M, 1% DMSO in H2O) with various 
concentrations of ct-DNA monitored by UV-vis spectroscopy. 
As fluorescence is usually more sensitive to the changes in the environment of the fluorophore, 
possible changes in emission intensity of complex 4 (2 × 10-4 M in 99% H2O + 1% DMSO) in 
the presence of ct-DNA were also monitored. Complex 4 provided only a very weak 
fluorescence signal at 490 nm (λex = 420 nm). No significant changes of the intensity of this 
signal were observed when complex 4 was allowed to interact with ct-DNA (see Figure 3.16). 
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Figure 3.16 Emission intensity of complex 4 (2 × 10-4 M in 99% H2O + 1% DMSO) in the 
presence of various concentrations of ct-DNA. 
3.3.12 Ethidium Bromide Displacement 
The ability of complex 4 to displace ethidium bromide (EtBr) from its intercalation into DNA 
was also tested. It has been shown that DNA interacting molecules, both intercalators and 
groove binders are able to displace EtBr from its binding site in DNA and then reduce the 
fluorescence of EtBr significantly. The efficiency of this competition reaction depends on the 
affinity of particular DNA binder to DNA and this experiment can be used to estimate binding 
constant (Kb). In this experiment, DNA-EtBr adduct was titrated with increasing concentration 
of complex 4. However, no changes in fluorescence of EtBr were observed even in the 
concentration of 4 70-fold higher than EtBr, indicating complex 4 was unable to displace EtBr 
from its DNA binding sites.  
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3.3.13 Binding to Short Single- or Double-stranded Oligonucleotides 
The interaction of complex 4 with short, single or double-stranded synthetic oligonucleotides 
was also tested in order to find out the effect of size and structure of DNA. In this experiment, 
the amount of Ru associated with double- or single-stranded oligonucleotides treated with 
complex 4 was found to be 4% and 11%, respectively, which indicated a weak binding of 
complex 4 to the oligonucleotide. 
3.3.14 DFT Calculations  
DFT calculations of the relative energies of intermediates in a possible catalytic cycle starting 
with the aqua species of complexes 3, 4 and 5 were made using structures based on the X-ray 
crystal structure of complex 3, in the presence of formate, water, NAD+ and carbon dioxide 
(see Scheme 3.2).  The energy levels of these aqua species were defined as 0 kJ/mol, and a 
favourable decrease in energy upon binding formate to RuII of -46, -42 and -42 kJ/mol, 
respectively, was calculated.15 The subsequent formation of the Ru-H hydride bond 
corresponds to a much higher energy transition state including the twist of formate and the 
elimination of carbon dioxide. The energy levels decreased when hydride was transferred from 
Ru to NAD+, giving energy differences of -20, -36 and -29 kJ/mol for 3, 4 and 5, respectively 
(see Scheme 3.2). The energy decreased further when NADH was eliminated from the Ru 
center. The values of the energetic barriers of the transfer hydrogenation cycle of complexes 3, 
4 and 5 are listed in Table 3.6. 
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Scheme 3.2 DFT energy profile for the formation of Ru formate species, Ru hydride complex 
and hydride transfer from metal; red line complex 3; blue line, complex 4; black line, complex 
5. 
 
3.4 Discussion 
3.4.1 Synthesis and Characterization  
The functional groups methyl, ethyl, benzyl, 4-F-benzyl and naphthalene were introduced on 
the terminal nitrogen of the chelated sulfonyl diamine ligand to study steric and electronic 
effects on the transfer hydrogenation of NAD+ to NADH. The X-ray crystal structure of 
complex 3 [(η6-p-cym)Ru(TsEnEt)Cl] shows it to have a typical ‘piano-stool’ geometry. 
Compared to reported ruthenium ethylenediamine complexes,15, 25  the Ru−N- bond length (N9, 
2.13(9)) is within the expected range of 2.11-2.14 Å,25 but the Ru−N12 length (2.17(11) Å) is 
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longer than the analogue [(η6-biph)Ru(TsEn)Cl] (2.12(3) Å),15 suggesting that the presence of 
N-ethyl substituent cause a slight weakening of this Ru-N bond. The remaining bond length 
and angles show no significant difference. 
3.4.2 Kinetics of Transfer Hydrogenation Reactions  
The ratio of coenzyme NAD+/NADH greatly influences the intracellular potential and can drive 
many reactions in vivo.26  
The turnover frequencies of NAD+ to NADH catalysed by RuII complexes 1-6 determined by 
UV-vis spectroscopy are similar to those from 1H NMR spectroscopy (see Table 3.3). In 
general, the introduction of substituents on the terminal nitrogen improve the catalytic activity. 
The bulkier the substituents on the terminal nitrogen, the higher the TH reaction rate becomes. 
The turnover frequency reaches a maximum (ca. 7.54 h-1) when the substituent on the terminal 
N is benzyl (complex 4), making it as efficient as the RhIII complex [(η5-Cp*)Rh(bipy)Cl]PF6.9a 
Interestingly, the TOF decreases when the substituent is 4-F-benzyl (complex 5) or naphthalene 
(complex 6), probably, because these ligands hamper the approach of NAD+ to the Ru metal 
center. 
Compared to the en complex with unsubstituted nitrogens [(η6-biph)Ru(en)Cl]PF6, the turnover 
frequency of complex 4 is 41× higher,14 and 2.7× higher compared to [(η6-p-cym)Ru 
(TsEn)Cl].12 
The NH proton of chelated diamine ligand appears to be essential for the TH reduction of 
ketones to alcohols;27 normally, RuII catalysts for TH of ketones form 16-e intermediates.28 It 
has been reported that an RuII complex with two N-alkyl groups (R,R)-[(η6-benzene) 
Ru(TsDPEN-Me2)Cl] exhibited poor catalytic reactivity in TH reaction of ketones.
29 However, 
complex 2 [(η6-p-cym)Ru(TsEnMe2)Cl] exhibited good catalytic activity towards the TH 
reduction of NAD+ to NADH (TOF = 4.1 h-1, see Table 3.3), despite not having a NH proton, 
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which suggests, as expected, that an N-H is not essential in the transfer reduction of NAD+ to 
NADH. 
Plots of the TOF versus formate concentration, show a typical Michaelis-Menten behaviour. 
The maximum turnover frequency TOFmax for complex 4 (30.3 h
-1) is ca. 5× higher than for 
[(η6-p-cym)Ru(TsEn)Cl] (JS2 in Figure 3.1, TOFmax = 6.4 h-1)15 and 20× faster than the 
complex [(η6-hmb)Ru(en)Cl]PF6 (TOFmax = 1.46 h-1).14 The much lower Michaelis-Menten 
constant (KM = 0.086 mM) of complex 4 indicates a stronger affinity of the complex for formate 
compared to [(η6-p-cym)Ru(TsEn)Cl] (KM = 27.8 mM)15 and [(η6-hmb)Ru(en)Cl]PF6 (KM = 
58 mM).14 
The maximum turnover frequency was observed at pH* 6 (TOFmax = 7.7 h
-1) (see Figure 3.8). 
The TOF for complex 4 gradually decreases when pH was raised above 6 (see Figure 3.8). 
Transfer hydrogenation was halted below pH* 4 because of the decomposition of the complex.   
3.4.3 Antiproliferative Activity  
Ruthenium complexes have shown promise for their activity against various type of cancer 
cells.30 Here the antiproliferative activity of complexes 1-6 towards A2780 human ovarian cells 
was determined. It is apparent that the presence of aromatic substituents on the chelated ligands 
of complexes 4-6 give rise to more potent cytotoxicity than aliphatic substituents in complexes 
1-3, most probably due to their higher lipophilicity.  
Combination treatment with formate can greatly increase the antiproliferative of RuII arene 
sulfonyl diamine complexes,8 which offers a potential new strategy for cancer treatment. 
Previous work has suggested that reduction of NAD+ by transfer hydrogenation from formate 
can be catalysed by RuII sulfonyl diamine complexes in cells.8 
In this work, the antiproliferative activity against A2780 cancer cells of complexes 1-6 on 
coadministration with sodium formate was studied. The potency of each of these complexes 
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increased with increase in formate concentration (see Figure 3.12).8 The largest decrease of 
cell survival was 31% for complex 6 in the presence of 2 mM sodium formate, followed 29% 
and 32% for complexes 4 and 5, respectively, the other two complexes with aromatic 
substituents, complexes 1-3 with aliphatic functional groups showed increase in potency of 
18%, 21% and 22%, respectively (Table 3.5). 
Table 3.5 Percentage of Cell Viability Decrease Induced by Complexes 1-6 in the Presence of 
Different Concentrations of Formate. 
Complex 
Cell Viability Decrease (%) 
[Formate] 
0.5 mM 1.0 mM 2.0 mM 
1 6.1±3.8 14.4±5.4 20.4±3.1 
2 6.3±2.4 8.8±2.4 20.8±3.2 
3 2.6±1.7 11.2±1.8 20.3±2.3 
4 17.3±3.4 26.2±4.8 32.0±3.6 
5 11.7±4.8 16.6±3.1 32.0±3.2 
6 28.3±2.6 29.2±1.9 36.1±2.3 
 
3.4.4 Ruthenium Cellular Uptake and Hydrophobicity Determination  
The hydrophobicity and cellular accumulation are often important factors that play roles in the 
potency of organometallic and other anticancer drugs.24 The cellular uptake of Ru in A2780 
human ovarian cancer cells for complexes 1-6 was determined at IC50 concentrations to 
investigate a possible correlation with hydrophobicity determined by reverse-phase (RP) HPLC 
and antiproliferative activity. 
The relative hydrophobicity of a series of complexes can be determined on the basis of their 
HPLC retention times (tR) on a RP-HPLC column, which relies on the relative interaction 
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between the hydrophilic mobile phase and hydrophobic stationary phase.24 It is evident from 
Table 3.4 that the RuII complexes with aromatic substituents (complexes 4-6) have exhibited 
higher hydrophobicity than complexes with aliphatic substituents (complexes 1-3). The most 
hydrophobic complex (6) shows the highest cell accumulation, although complex 4 has the 
lowest cell uptake extent, but the most potent antiproliferative activity, suggesting that it is the 
chemical properties of the intracellular drug that are more important to activity than the total 
amount of Ru entering cell. In general, a high hydrophobicity can facilitate interaction between 
the organometallic complex and cell membrane, also correlates well the potency of the 
complex.31 For this series of complexes, there is no clear relationship between cell 
accumulation of Ru, hydrophobicity of the complexes and the anticancer potency.   
3.4.5 Binding with Calf Thymus and Bacterial Circular Plasmid DNA 
DNA was thought to be a cellular target for the en complex RM175 (see Figure 3.1).32, 33 
However, the introduction of functional sulfonyl substituents on the terminal nitrogen was 
found to greatly weaken the affinity of complex [(η6-p-cym)Ru(TsEn)Cl] for DNA.8 In this 
research, no obvious unwinding of DNA was observed after coincubation of ct-DNA with 
complex 4, suggesting that binding is weak, and no changes in the ratio of sc and oc forms of 
plasmid DNA, suggesting that complex 4 does not cleave DNA.   
3.4.6 ROS Determination  
Reactive oxygen species (ROS) are metabolic byproducts of aerobic respiration and are 
responsible for maintaining redox homeostasis in cells.34 ROS also play a significant role in 
the mode of action for anticancer agents.35 Many organometallic complexes, e.g. Ir and Os,36 
can generate high ROS levels in cancer cells to induce cell apoptosis. The total ROS level in 
A2780 cancer cells exposure to complexes 1 and 4 was determined. Both complexes increase 
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ROS levels at IC50 concentrations; the population in FL1 and FL2 channels for complex 4 is 
31.3 ± 0.3, about 2 fold higher than for complex 1 (16.5 ± 1.0, in Table 3.6) indicating higher 
total oxidative stress as well as high superoxide levels. These ROS may play a major role in 
killing the cancer cells. 
Table 3.6 The induction of ROS and superoxide detected by flow cytometry experiments in 
A2780 ovarian cancer cells. 
 
Populations (%) 
FL-1-/FL-2- FL-1+/FL-2- FL-1-/FL-2+ FL-1+/FL-2+ 
Complex 1 0.13±0.1 *** 83.3±1.3 *** 0.02±0.01 16.5±1.0 ** 
Complex 4 0 *** 68.7±0.7 *** 0 31.3±0.3 *** 
Negative control 99.89 ± 0.04 0.09 ± 0.03 0.04±0.01 0 
The monitoring of H2O2, peroxy and hydroxyl radicals using a green probe FL-1, and 
superoxide levels using the orange channel FL-2. All values compared to the untreated controls. 
In all cases, independent two-sample t-tests with unequal variances, Welch’s tests, were carried 
out to establish statistical significance of the variations (p < 0.001 for ***, p < 0.01 for **, and 
p < 0.05 for *). 
3.4.7 DFT Calculations  
Calculations were carried out for complexes 3 (N-Et), 4 (N-Bz) and 5 (4-F-Bz). The 
calculations suggest that the displacement of water from [(η6-p-cym)Ru(TsEn)(H2O)]+ by 
formate is energy favourable by 42-46 kJ mol-1, Table 3.6. As expected from previous 
calculations of related complexes,15 the next step involving the transfer of hydride and 
liberation of CO2 is costly in energy for 4 > 5 > 3. The interaction with NAD
+ and hydride 
transfer then produces a lower energy intermediate is more favourable for 4 < 5 < 3, which is 
perhaps related to the lower catalytic efficiency of complex 3. The final release of NADH and 
reformation of aqua complex lowers the energy by 110-115 kJ mol-1. 
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Table 3.6 Computed DFT Free Energy Barriers ΔE (kJ/ mol) Leading to Cycle of Hydride 
Transfer. 
Step 
ΔE(kJ/mol) 
3 4 5 
ΔE1 -46 -42 -42 
ΔE2 +182 +194 +192 
ΔE3 -20 -36 -29 
ΔE4 -110 -110 -115 
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3.5 Conclusions 
In this chapter, a series of RuII complexes of the type [(η6-p-cym)Ru(N,N’)Cl] where N,N′ are 
monosulfonamide chelating ligands derived from tosylethylenediamine, with either alkyl (Me 
(1), Me2 (2), Et (3)) or aryl (Bz (4), 4-F-Bz (5), naphthyl (6)) substituents on the terminal N 
have been synthesised. These substituents have a significant effect on the rate of transfer 
hydrogenation of coenzyme NADH with formate as hydride donor as determined by NMR and 
UV-vis spectroscopy. In general the bulkier aromatic substituents gave rise to faster 
hydrogenation rates. 
To investigate the possibility of achieving transfer hydrogenation from formate in cells, the 
effect of formation on antiproliferative activity of these complexes towards human ovarian 
cancer cells was investigated. In each case a dose-dependent increase in potency of the 
complexes (20-36%) was observed with increase in formate concentration over a range of non-
toxic formate concentration (0-2 mM).The complexes with aromatic substituents were the most 
potent, complex 4 being as potent as the anticancer drug cisplatin (see Figure 3.11). In general, 
the most hydrophobic complexes are the most biologically active, but the activity does not 
correlate closely with total Ru uptake by the cell (see Table 3.4). Although DNA can be a 
target for related arene RuII diamine complexes, it does not appear to be a target for these 
sulfonyl RuII catalysts since we observe very weak binding to both calf thymus and plasmid 
DNA (Figure 3.16-3.18). 
Complexes 1 and 4 can generate high levels of ROS in A2780 human ovarian cancer cells, 
especially 4, the most potent complex. This is consistent with interference in cellular redox 
pathways and possible attack on NAD+ if sodium formate present.  
The enhancement of anticancer activity by low non-toxic dose of formate might be useful 
clinically since it introduces a new mechanism of activity which does not involve DNA attack, 
unlike the clinical drug cisplatin. Such treatment might therefore avoid some unwanted side-
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effects. Formate itself is a natural biochemical molecule enriched in some cancer cells.37 
However, more work remains to be done to investigate possible intracellular catalysis, 
especially since a range of metabolites might readily poison these catalysts in cells.  
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Chapter 4 
 
Glutathione Activation of RuII Sulfonyl-ethylenediamine 
Complexes and Its Role in Anticancer Activity 
 
 
 
  
106 
 
4.1 Introduction 
The antiproliferative activity study of organometallic complexes has been well stimulated due 
to the success of platinum-series anticancer agents, e.g. cisplatin, carboplatin and oxiliplatin.1 
Organometallic complexes often possess some obvious merits, for example variable 
coordination numbers and chelating ligands with tuneable biological properties.2,3 Among the 
various platinum group metals, organo-ruthenium complexes have exhibited relative higher 
promise due to the great potency against carcinoma cells and low cytotoxicity to normal cells.4,5 
Two outstanding representatives of RuIII complexes, namely, KP1019 ((indazoleH)[trans-
RuCl4-(indazole)2] and NAMI-A ((imidazoleH)[trans-RuCl4-(imidazole)(DMSO)], are potent 
anti-metastatic agents.6 The plausible ‘in vivo activation by reduction’ mechanism makes them 
selectively potent against human colorectal cancers tumours (especially cisplatin resistant 
colorectal carcinomas).5,7 Some other Ru complexes with promising properties have also been 
intensively studied, e.g. RAPTA has low toxicity in vitro, but great anti-angiogenesis activity 
against tumour metastasis in vivo (Figure 4.1);8 RM175 shows promising anticancer activity 
against A2780 human ovarian cancer cells, with IC50 values in the nanomolar range (Figure 
4.1).9 Che et al. recently revealed a new series of macrocyclic RuIII complexes of the type 
[RuIII-(N2O2)Cl2]Cl as anti-angiogenesis and anti-tumour agents (Figure 4.1).
10 Such a RuIII 
complex was found to down-regulate the signalling protein of vascular endothelial growth 
receptor-2 (VEGFR2). Organo-ruthenium complexes have attracted particular attention 
probably because they have a range of oxidation states and are believed to mimic iron in cell 
and bind to some plasma proteins.4, 11   
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Figure 4.1 Structures of RuII/RuIII complexes with potent anticancer activity. 
In mammalian cells, a basal level of reactive oxygen species (ROS) is important for cell 
proliferation and survival. As a metabolism side product, excess levels of reactive oxygen 
species (ROS) often irreversibly damage lipids of cell membrane and guanine or thymine of 
DNA, which are lethal to cell growth, even though a basal level of ROS is important for 
signalling (proliferation and survival).12 To deal with ROS, cancer cells are normally 
generating higher levels of thiol containing molecules, for instance L-glutathione (GSH) and 
cysteine.13 GSH is a non-protein tripeptide and can be oxidized to GSSG in cellular to attenuate 
damage caused by ROS (Figure 4.2),14 or to scavenge a complex that is toxic to cells since 
organometallic complexes exhibit high affinity for thiol-containing peptides.15 Based on thiol-
containing organic compounds, Süss-Fink et al. have synthesized a series of dithiolato and 
trithiolato RuII complexes, these complexes have been shown potent anticancer activity (sub-
micromolar range) against both A2780 and A2780 cisplatin-resistant human ovarian cancer 
cells.16 Of particular interest, such trithiolato RuII complexes can change the GSH/GSSH ratio 
by catalytic oxidation reactions.17   
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Figure 4.2 Chemical structures of GSH, GSSG (charge shown as at pH 7) and NAC (charge 
shown as at pH 2). 
RuII sulfonyl ethylenediamine complexes such as [(η6-p-cym)Ru(TsEn)Cl] were reported as 
efficient catalysts in transfer hydrogenation (TH) reduction of NAD+ to NADH using formate 
as hydride donor.18 In Chapter 3, the complexes were modified by introducing a series of 
(alkyl or aryl) functional groups to the terminal nitrogen of ethylenediamine ligand. The 
catalytic efficiency and antiproliferative activity were greatly enhanced (see complexes 1-6 in 
Chapter 3). Complex 4 [(η6-p-cym)Ru(TsEnBz)Cl] had the highest catalytic efficiency in 
NAD+ TH reduction and antiproliferative activity towards A2780 human ovarian cells (IC50, 
1.0 μM). 
In this Chapter, given both the promising catalytic and antiproliferative activity of complex 4, 
another series of RuII/OsII complexes 7-15 of the type [(η6-arene)M(BzEnR)Cl], where arene 
is benzene, HO(CH2)2O-phenyl and biphenyl, M is Ru or Os and R is various sulfonyl 
substituents are synthesized (Table 4.1).  
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Table 4.1 RuII/OsII Complexes Synthesized and Studied in This Chapter 
 
Complex M R1 R2 X 
7 Ru H 4-Me-Ph Cl 
8 Ru Ph 4-Me-Ph Cl 
9 Ru Ph 4-Me-Ph I 
10 Os Ph 4-Me-Ph Cl 
11 Ru -O(CH2)2OH 4-Me-Ph Cl 
12 Ru Ph 4-Nitro-Ph Cl 
13 Ru Ph 4-F-Ph Cl 
14 Ru Ph Ph Cl 
15 Ru Ph Dansyl (Dan) Cl 
 
Complex 10 is the Os analogue of RuII complex 8 and was prepared from [(η6-biph)OsCl2]2 
dimers. The catalytic TH reduction of NAD+ to NADH using sodium formate as hydride source 
was studied. The interaction of these complexes with thiol-containing low-MW molecules, e.g. 
L-GSH and N-acetyl-L-cysteine (NAC), was studied by NMR and LC-MS. The high thiophilic 
property of such complexes also allowed investigation of the influence of GSH on the NAD+ 
TH reduction. Antiproliferative activity of complexes 7-15 was determined against two cancer 
cell lines: A2780 human ovarian, A549 human lung cancer cells. In comparison, anticancer 
activity of complex 8 towards A549 human lung cancer cells in co-administration with thiol-
contained molecule GSH/NAC and the redox modulator L-buthionine sulfoximine (L-BSO) 
was studied. Cell cycle arrest and the effect of complex 8 and 8 with GSH on induction of ROS 
levels in A2780 human ovarian cancer cells were also investigated. 
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4.2 Experimental Section 
4.2.1 Materials 
Dansyl chloride was purchased from Sigma-Aldrich. The RuII/OsII-η6-arene precursor dimers 
were prepared following literature methods, as were the ligands. The solvents used for NMR 
spectroscopy were purchased from Sigma-Aldrich and Cambridge Isotope Laboratories Inc. 
Non-dried solvents used in syntheses were obtained from Fisher Scientific. Glutathione and N-
acetyl-L-cysteine were purchased from Fisher Scientific. 
4.2.2 Synthesis and Characterization  
Complexes 12-15 were synthesized and characterized by Neil MacQuarrie. 
[(η6-benzene)Ru(TsEnBz)Cl] (7). All the complexes in this Chapter were prepared according 
to a reported method:18 [(η6-benzene)RuCl2]2 (100 mg, 0.2 mmol) and TsEnBz (153 mg, 0.45 
mmol) were placed in a round-bottom flask, to which 2-propanol (50 mL) and triethylamine 
(125 μL, 0.9 mmol) were added. The solution was heated under refluxing in a nitrogen 
atmosphere (365 K) overnight with stirring. After this the solvent was removed on a rotary 
evaporator to get a dark red solid. The crude product was purified by silica column 
chromatography (MeOH/DCM, 1:9 (v/v)), with red solid obtained. Yield = 134.7 mg (65%). 
1H NMR (400 MHz, CDCl3): δH 2.09-2.25 (m, 2H), 2.33 (s, 3H), 2.40-2.42 (m, 1H), 3.08 (dd, 
J = 3.1 Hz, 11.2 Hz, 1H), 3.75 (t, J = 10.1 Hz, 1H), 4.19 (q, J = 10.8 Hz, 13.2 Hz,  1H), 4.85 
(dd, J = 10.1 Hz, 13.4 Hz, 1H), 5.70 (s, 6H), 7.14 (d, J = 8 Hz, 2H), 7.29-7.31 (m, 2H), 7.35-
7.38 (m, 3H), 7.71 (d, J = 8.1 Hz, 2H); 13C NMR (125.73 MHz, CDCl3): δc 21.4, 48.3, 55.5, 
62.2, 83.1, 127.3, 128.4, 128.7, 128.9, 129.3, 135.7, 140.1, 140.7; HR-MS: Calcd for 
[C22H25N2O2SRu]
+ 483.0680 m/z, found: 483.0683 m/z. Elemental analysis: Calcd for 
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[C22H25N2O2SRuCl(H2O)0.1] C, 50.83%; H, 4.89%; N, 5.39%. Found: C, 50.84%; H, 4.81%; 
N, 5.42%. 
[(η6-biph)Ru(TsEnBz)Cl] (8). Complex 8 was obtained following the method described for 
complex 7, where [(η6-biph)RuCl2]2 (100 mg, 0.153 mmol), TsEnBz (110 mg, 0.32 mmol) and 
triethylamine (89 μL, 0.64 mmol) were added. The crude product was purified by silica column 
chromatography (MeOH/DCM, 1:9 (v/v)), with orange red solid obtained. Yield = 132.7 mg 
(73%). 1H NMR (400 MHz, CDCl3): δH 1.89-1.95 (m, 1H), 2.11-2.17 (m, 2H), 2.34 (s, 3H), 
3.08 (dd, J = 3.6 Hz, 11.2 Hz, 1H), 3.59 (q, J = 10.4 Hz, 13.2 Hz,  1H), 3.73 (t, J = 11.5 Hz, 
1H), 4.38 (dd, J = 3.9 Hz, 13.3 Hz, 1H), 5.47 (t, J = 7.7 Hz, 1H), 5.98-6.01(m, 2H), 6.06 (t, J 
= 5.6 Hz, 1H), 6.57 (d, J = 5.4 Hz, 1H), 7.03-7.05 (m, 2H), 7.15 (d, J = 8.0 Hz, 2H), 7.28-7.31 
(m, 3H), 7.53-7.56 (m, 3H), 7.69 (d, J = 8.1 Hz, 2H), 7.89-7.91 (m, 2H); 13C NMR (125.73 
MHz, CDCl3): δc 21.4, 48.3, 53.9, 60.5, 78.7, 78.7, 86.4, 88.1, 89.0, 90.4, 127.4, 128.0, 128.2, 
128.7, 129.1, 129.4, 129.6, 134.7, 135.7, 140.0, 140.7; HR-MS: Calcd for [C28H29N2O2SRu]
+ 
559.0993 m/z, found: 559.0990 m/z. Elemental analysis: Calcd for [C28H29N2O2SRuCl 
(H2O)0.3]: C, 56.09%; H, 4.98%; N, 4.67%. Found: C, 56.02%; H, 5.01%; N, 4.73%. 
[(η6-biph)Ru(TsEnBz)I] (9). Complex 9 was obtained following the method described for 
complex 7, where [(η6-biph)RuI2]2 (100 mg, 0.098 mmol), TsEnBz (70 mg, 0.204 mmol) and 
triethylamine (58 μL, 0.408 mmol) were added. The crude product was purified by silica 
column chromatography (MeOH/DCM, 2:8 (v/v)). Red solid was obtained. Yield = 72.6 
(54%). 1H NMR (400 MHz, CDCl3): δH 1.92-1.99 (m, 1H), 2.07-2.15 (m, 2H), 2.35 (s, 3H), 
3.14-3.18 (m, 1H), 3.40 (q, J = 10.9 Hz, 13.2 Hz,  1H), 3.94 (t, J = 11.5 Hz, 1H), 4.32 (dd, J = 
4.0 Hz, 13.4 Hz, 1H), 5.40 (t, J = 5.6 Hz, 1H), 5.88 (d, J = 5.8 Hz, 1H), 6.04 (t, J = 5.5 Hz, 
1H), 6.34 (t, J = 5.7 Hz, 1H), 6.85 (d, J = 6.1 Hz, 1H), 7.00-7.01 (m, 2H), 7.16 (d, J = 8.2 Hz, 
1H), 7.29-7.34 (m, 3H), 7.48-7.54 (m, 3H), 7.72 (d, J = 8.1 Hz, 2H), 7.81-7.83 (m, 2H); 13C 
NMR (125.73 MHz, CDCl3): δc 21.4, 49.4, 53.5, 60.5, 78.6, 85.8, 87.4, 90.3, 127.7, 127.8, 
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128.3, 128.6, 128.8, 129.1, 129.5, 129.7, 134.8, 135.7, 139.3, 140.7; HR-MS: Calcd for 
[C28H29N2O2SRu]
+ 559.0993 m/z, found: 559.0994 m/z. Elemental analysis: Calcd for 
[C28H29N2O2SRuI(H2O)0.2]: C, 48.80%; H, 4.30%; N, 4.06%. Found: C, 48.74%; H, 4.17%; N, 
3.96%. 
[(η6-biph)Os(TsEnBz)Cl] (10). Complex 10 was obtained following the method described for 
complex 7, where [(η6-biph)OsCl2]2 (100 mg, 0.12 mmol), TsEnBz (80 mg, 0.26 mmol) and 
triethylamine (74 μL, 0.52 mmol) were added. The crude product was purified by silica column 
chromatography (MeOH/DCM, 1:9 (v/v)). Grey solid was obtained. Yield = 72.2 mg (44%). 
1H NMR (400 MHz, CDCl3): δH 1.86-1.96 (m, 1H), 2.18-2.20 (m, 1H), 2.35 (s, 3H), 2.53 (td, 
J = 3.36 Hz, 12.8 Hz, 1H), 3.13 (dd, J = 4.3 Hz, 11.84 Hz, 1H), 3.52 (q, J = 10.2 Hz, 13.3 Hz,  
1H), 4.25 (t, J = 10.4 Hz, 1H), 4.33 (dd, J = 4 Hz, 13.4 Hz, 1H), 5.70-5.73 (m, 1H), 6.25 (d, J 
= 5.6 Hz, 1H), 6.26-6.28 (m, 2H), 6.86-6.87 (m, 1H), 7.00-7.02 (m, 2H), 7.15 (d, J = 8.1 Hz, 
2H), 7.31 (t, J = 2.8 Hz, 3H), 7.43 (d, J = 7.2 Hz, 1H), 7.48 (t, J = 6.9 Hz, 2H), 7.69-7.72 (m, 
4H); 13C NMR (125.73 MHz, CDCl3): δc 21.4, 49.9, 55.9, 62.0, 67.9, 68.8, 77.4, 79.1, 81.3, 
82.1, 127.3, 128.2, 128.3, 128.7, 128.8, 128.97, 129.2, 129.3, 135.7, 136.5, 140.1, 140.9; HR-
MS: Calcd for [C28H29N2O2SOs]
+ 649.1565 m/z, found: 649.1558 m/z. Elemental analysis: 
Calcd for [C28H29N2O2SOsCl(H2O)0.9]: C, 48.08%; H, 4.44%; N, 4.00%. Found: C, 48.07%; 
H, 4.21%; N, 4.04%. 
[(η6-HOCH2CH2O-Ph)Ru(TsEnBz)Cl] (11). Complex 11 was obtained following the method 
described for complex 7, where [(η6-HOCH2CH2O-Ph)RuCl2]2 (100 mg, 0.161 mmol), TsEnBz 
(112 mg, 0.33 mmol) and triethylamine (92 μL, 0.66 mmol) were added. The crude product 
was purified by silica column chromatography (MeOH/DCM, 1:9 (v/v)). Bright red solid was 
obtained. Yield = 104 mg (56%). 1H NMR (400 MHz, CDCl3): δH 2.12 (td, J = 2.8 Hz, 11.6 
Hz, 1H), 2.22 (dd, J = 4.1 Hz, 11.8 Hz, 1H), 2.34 (s, 3H), 2.48 (d, J = 10.1 Hz, 1H), 3.00 (dd, 
J = 3.8 Hz, 11.4 Hz, 1H), 3.24 (s, broad, 1H), 3.76 (t, J = 11.3 Hz, 1H), 3.92-3.95 (m, 1H), 
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4.04-4.08 (m, 1H), 4.17 (q, J = 10.3 Hz, 13.3 Hz, 1H), 4.22-4.32 (m, 2H), 4.77 (dd, J = 4.1 Hz, 
13.4 Hz, 1H), 5.04 (t, J = 5.2 Hz, 2H), 5.52 (t, J = 5.6 Hz, 1H), 5.56 (dd, J = 1.0 Hz, 5.9 Hz, 
1H), 6.48 (t, J = 5.7 Hz, 1H), 7.15 (d, J = 8.0 Hz, 2H), 7.31 (d, J = 7.5 Hz, 2H), 7.35-7.40 (m, 
3H), 7.75 (d, J = 8.2 Hz, 2H); 13C NMR (125.73 MHz, CDCl3): δc 21.4, 47.9, 55.9, 60.8, 61.6, 
61.9, 66.5, 68.8, 71.5, 87.1, 90.1, 127.6, 128.4, 128.7, 128.8, 129.3, 134.4, 135.7, 139.9, 140.8; 
ESI-MS: Calcd for [C24H29N2O4SRu]
+ 543.0891 m/z, found: 543.0891 m/z. Elemental analysis: 
Calcd for [C24H29N2O4SRuCl]: C, 49.87%; H, 5.06%; N, 4.85%. Found: C, 50.60%; H, 5.06%; 
N, 4.60%. 
[(η6-biph)Ru(4-NO2-PhSulEnBz)Cl] (12). Complex 8 was obtained following the method 
described for complex 7, where [(η6-biph)RuCl2]2 (100 mg, 0.153 mmol), 4-NO2-PhSulEnBz 
(105 mg, 0.32 mmol) and triethylamine (90 μL, 0.64 mmol) were added. The crude product 
was purified by silica column chromatography (MeOH/DCM, 1:9 (v/v)). Dark red solid was 
obtained. Yield = 90 mg (46%). 1H NMR (400 MHz, CDCl3): δH 1.96-2.02 (m, 1H), 2.09 (td, 
J = 3.2 Hz, 12.8 Hz, 1H), 2.24 (d, J = 10.4 Hz, 1H), 3.17 (dd, J = 3.6 Hz, 11.0 Hz, 1H), 3.65-
3.70 (m, 2H), 4.41 (q, J = 9.4 Hz, 18.6 Hz, 1H), 5.48 (t, J = 5.7 Hz, 1H), 5.94 (t, J = 5.8 Hz, 
1H), 6.04-6.07 (m, 2H), 6.51 (d, J = 5.7 Hz, 1H), 7.04-7.06 (m, 2H), 7.31-7.33 (m, 3H), 7.53-
7.55 (m, 3H), 7.79-7.82 (m, 2H), 7.92 (d, J = 8.8 Hz, 2H); 13C NMR (125.73 MHz, CDCl3): 
δc 48.2, 53.9, 60.7, 78.5, 78.9, 86.7, 88.2, 88.8, 90.9, 123.4, 127.9, 128.2, 128.4, 128.8, 129.2, 
129.5, 129.9, 134.3, 135.4, 148.7; HR-MS: Calcd for [C27H26N3O4SRu]
+ 590.0688 m/z, found: 
590.0688 m/z. Elemental analysis: Calcd for [C27H26N3O4SRuCl]: C, 51.88%; H, 4.19%; N, 
6.72%. Found: C, 51.70%; H, 4.22%; N, 6.69%. 
[(η6-biph)Ru((4-F-PhSul)EnBz)Cl] (13). Complex 13 was obtained following the method 
described for complex 7, where [(η6-biph)RuCl2]2 (100 mg, 0.153 mmol), (4-F-PhSul)EnBz 
(98 mg, 0.32 mmol) and triethylamine (89 μL, 0.64 mmol) were added. The crude product was 
purified by silica column chromatography (MeOH/DCM, 1:9 (v/v)). Dark red solid was 
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obtained. Yield = 101 mg (54%). 1H NMR (400 MHz, CDCl3): δH 1.88-1.98 (m, 1H), 2.10 (dt, 
J = 3.2 Hz, 12.7 Hz, 1H), 2.17-2.20 (m, 1H), 3.08 (dd, J = 4.1 Hz, 11.6 Hz, 1H), 3.62 (dd, J = 
10.3 Hz, 13.0 Hz, 1H), 3.69-3.76 (m, 1H), 4.39 (dd, J = 3.9 Hz, 13.0 Hz, 1H), 5.47 (t, J = 5.7 
Hz, 1H), 5.97 (t, J = 5.7 Hz, 1H), 6.01 (d, J = 6.0 Hz, 1H), 6.05 (t, J = 5.7 Hz, 1H), 6.55 (d, J 
= 5.6 Hz, 1H), 7.00 (t, J = 8.8 Hz, 2H), 7.04-7.06 (m, 2H), 7.30-7.32 (m, 3H), 7.51-7.55 (m, 
3H), 7.81-7.84 (m, 4H); 13C NMR (125.73 MHz, CDCl3): δc 48.2, 53.9, 60.6, 78.6, 78.8, 86.5, 
88.1, 88.9, 90.6, 114.9, 115.1, 128.0, 128.2, 128.7, 129.2, 129.4, 129.7, 129.7, 129.8, 134.6, 
135.6, 163.0, 165.0; 19F NMR (376.4 MHz, CDCl3, spectrum referenced to trifluoro-acetic acid 
at -76.55 ppm): δF -109.9. HR-MS: Calcd for [C27H26FN2O2SRu]+ 563.0743 m/z, found: 
563.0742 m/z. Elemental analysis: Calcd for [C27H26FN2O2SRuCl(H2O)1.4]: C, 52.03%; H, 
4.66%; N, 4.49%. Found: C, 52.02%; H, 4.24%; N, 4.78%. 
[(η6-biph)Ru((PhSul)EnBz)Cl] (14). Complex 14 was obtained following the method 
described for complex 7, where [(η6-biph)RuCl2]2 (100 mg, 0.153 mmol), PhSulEnBz (90 mg, 
0.32 mmol) and triethylamine (89 μL, 0.64 mmol) were added. The crude product was purified 
by silica column chromatography (MeOH/DCM, 1:9 (v/v)). Dark red solid was obtained. Yield 
= 60.3 mg (34%). 1H NMR (500 MHz, CDCl3): δH 1.88-1.95 (m, 1H), 2.11-2.18 (m, 2H), 3.11 
(dd, J = 5.1 Hz, 9 Hz, 1H), 3.58 (dd, J = 10.4 Hz, 13.4 Hz, 1H), 3.71-3.76 (m, 1H), 4.38 (dd, J 
= 4.2 Hz, 13.4 Hz, 1H), 5.46 (t, J = 5.7 Hz, 1H), 5.98 (d, J = 6.0 Hz, 1H), 6.01 (d, J = 5.7 Hz, 
1H), 6.05 (t, J = 5.7 Hz, 1H), 6.58 (d, J = 5.5 Hz, 1H), 7.03-7.05 (m, 2H), 7.29-7.30 (m, 3H), 
7.33-7.40 (m, 4H), 7.52 (d, J = 7.5 Hz, 2H), 7.83 (t, J = 8.5 Hz, 4H); 13C NMR (125.73 MHz, 
CDCl3): δc 48.3, 53.9, 60.5, 78.7, 78.8, 86.4, 88.1, 88.9, 90.5, 127.3, 128.0, 128.1, 128.2, 128.3, 
128.6, 129.1, 129.4, 129.6, 130.5, 134.7, 135.7, 142.9;  HR-MS: Calcd for [C27H27N2O2SRu]
+ 
545.0837 m/z, found: 545.0834 m/z. Elemental analysis: Calcd for [C27H27N2O2SRuCl 
(H2O)0.4]: C, 55.22%; H, 4.77%; N, 4.77%. Found: C, 55.14%; H, 4.62%; N, 4.86%. 
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[(η6-biph)Ru(DanEnBz)Cl] (15). Complex 15 was obtained following the method described 
for complex 7, where [(η6-biph)RuCl2]2 (100 mg, 0.153 mmol), DanEnBz (123 mg, 0.32 mmol) 
and triethylamine (89 μL, 0.64 mmol) were added. The crude product was purified by silica 
column chromatography (MeOH/DCM, 1:9 (v/v)). Dark red solid was obtained. Yield = 138 
mg (67%). 1H NMR (400 MHz, CDCl3): δH 1.87-1.97 (m, 1H), 2.09-2.12 (m, 1H), 2.35 (dt, J 
= 2.7 Hz, 12.7 Hz, 1H), 2.84 (s, 6H), 3.10 (dd, J = 3.9 Hz, 12.7 Hz, 1H), 3.55 (dd, J = 10.5 Hz, 
13.2 Hz, 1H), 3.92 (s, broad, 1H), 4.38 (dd, J = 4.0 Hz, 13.5 Hz, 1H), 5.63 (t, J = 5.6 Hz, 1H), 
5.99-6.03 (m ,2H), 6.08 (t, J = 5.6 Hz, 1H), 6.52 (d, J = 5.4 Hz, 1H), 7.04-7.06 (m, 2H), 7.12 
(d, J = 7.4 Hz, 1H), 7.29-7.32 (m, 3H), 7.39 (t, J = 7.8 Hz, 1H), 7.47-7.53 (m, 4H), 7.83-7.84 
(m, 2H), 8.38 (dd, J = 8.6 Hz, 11.7 Hz, 2H), 8.73 (d, J = 8.6 Hz, 1H); 13C NMR (125.73 MHz, 
CDCl3): δc 45.5, 48.5, 54.36, 60.1, 79.7, 80.2, 85.5, 85.7, 86.5, 92.2, 114.6, 121.5, 123.5, 127.0, 
127.1, 127.4, 127.8, 127.9, 128.1, 128.2, 128.3, 128.5, 128.8, 128.9, 129.4, 129.7, 130.0, 130.1, 
130.6, 134.7, 135.9, 151.0; HR-MS: Calcd for [C33H34N3O2SRu]
+ 638.1415 m/z, found: 
638.1419 m/z. Elemental analysis: Calcd for [C33H34N3O2SRu Cl(H2O)0.9]: C, 57.49%; H, 
5.23%; N, 6.09%. Found: C, 57.41%; H, 4.97%; N, 6.21%. 
4.2.3 X-ray Crystallography 
The x-ray crystallographic analysis was carried out by Dr. Guy Clarkson. 
Diffraction data for complex 9 were collected on an Oxford Diffraction Gemini four-circle 
system with an AtlasS2 CCD area detector. The structure of complex 9 was refined by full-
matrix least-squares against F2 using Olex219 and was solved by with the ShelXT20 structure 
solution program using Intrinsic Phasing and refined with the ShelXL21 refinement package 
using Least Squares minimisation. The atoms from the sulphonamide nitrogen to the end of the 
chain (C10 C11 N12 C13) were modelled as disordered over two positions related by a small 
ruffle in the chain. The occupancy of the two positions was linked to a free variable which 
116 
 
refined to 86:14. The minor component was refined isotopically. The NH of the major 
component was located in a difference map though both it and the NH of the minor position 
were placed at calculated positions for the rest of the refinement. The data were processed by 
the modelling program Mercury 3.8. 
4.2.4 In vitro Growth Inhibition Assays  
The biological testing was carried out by Dr Isolda Romero-Canelón and Ji-Inn Song.  
The antiproliferative activity of complexes 7–15 was determined against A2780 human ovarian 
and A549 human lung cancer cells. Briefly, 5,000 cells per well were seeded in 96-well plates. 
The plates were left to pre-incubate with drug-free medium at 310 K for 48 h before adding 
different concentrations of the tested compounds. Exact drug concentrations were determined 
by ICP-OES. A drug exposure period of 24 h was allowed. After this, supernatants were 
removed by suction and each well was washed with PBS. A further 72 h were allowed for the 
cells to recover in drug-free medium at 310 K. The Sulforhodamine B (SRB) assay was used 
to determine cell viability. IC50 values, as the concentration that causes 50% cell death, were 
determined as duplicates of triplicates in two independent sets of experiments and their 
standard deviations were calculated. 
4.2.5 Cell Cycle Arrest  
Approximately 1.5 × 106 per well of A2780 human ovarian cancer cells were cultured in a six-
well plate and pre-incubated in drug-free media at 310 K for 24 h, after which complex 8 at 
equipotent IC50 concentration were added. After drug exposure for 24 h, supernatants were 
removed by suction and cells were washed with PBS. Then A2780 cells were harvested using 
trypsin-EDTA and fixed with cold 70% ethanol for 2 h. DNA staining was obtained by re-
suspension of cell pellets in PBS (containing propidium iodide (PI) and RNase). Cell pellets 
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were washed and re-suspended in PBS before being analysed in a Becton Dickinson FACScan 
flow cytometer using excitation of DNA-bound PI at 536 nm, with emission at 617 nm. And 
data were processed with Flowjo software. 
4.2.6 ROS Determination  
ROS/superoxide induction in A2780 cells induced by complex 8 was determined using the 
Total ROS/Superoxide detection kit (Enzo-Life Sciences) according to the instructions. The 
analysis was performed via Flow cytometry. Generally, 1.0 × 106 of A2780 cells per well were 
seeded in the six-well plate and then pre-incubated in drug-free media at 310 K for 24 h (under 
5% CO2 humidified conditions), and then drugs were added to triplicates wells at equipotent 
IC50 concentration. After 24 h of drug exposure, supernatants were removed by suction and 
cells were washed with PBS and harvested. Cell pellets were then re-suspended in PBS buffer 
containing the orange/green fluorescent reagents to achieve cell staining. Cells were analysed 
in a BD LSR II flow cytometer (488 nm laser) using FITC-A channel: 575/26 nm for the 
oxidative stress and PE-A channel: 530/30 nm for superoxide detection. Data were gated using 
positive-stained (pyocyanin positive control), untreated-stained and untreated-unstained 
control samples, acquired as instrumental triplicates by using Flowjo V10 for Windows 
software. All samples were kept under dark conditions to avoid light-induced ROS production. 
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4.3 Results 
4.3.1 Synthesis and Characterization 
The chelating diamine ligands [BzEnL], where L is phenylsulfonyl, 4-F-phenylsulfonyl, 4-
NO2-phenylsulfonyl and danzyl, were synthesized following a reported protocol (shown in 
Chapter 2) and complexes 7-15 of the type [(η6-arene)M(BzEnR)Cl], where arene is benzene, 
HO(CH2)2O-phenyl and biphenyl, M is Ru or Os, and R is various sulfonyl substituents were 
synthesized under the same conditions with the reported protocols18 (Table 4.1). The dansyl 
complex 15 was synthesized specifically for the fluorescence study. Generally, triethylamine 
(4 mol equiv) and ligand (2-2.1 mol equiv) were added to the a solution of degassed isopropanol 
with RuII/OsII dimers [(η6-arene)Ru/OsCl2]2, the reactions were stirred under a N2 atmosphere 
at 365 K for 10 h. All the synthesized complexes were purified by silica chromatography 
column (MeOH/DCM, 2:8(v/v)) and characterized by NMR spectroscopy (1H, 13C and 19F), 
high resolution mass spectrometry (HR-MS) and elemental analysis (CHN).   
4.3.2 X-ray Crystal Structure  
A crystal of complex 9 [(η6-biph)Ru(BzEnTs)I] suitable for X-ray crystallographic analysis 
was obtained from a slow diffusion of diethyl ether into saturated methanol solution of complex 
9 at ambient temperature. Selected bond lengths and angles for complex 9 are listed in Table 
4.2, crystallography data in Table 4.3, and the X-ray crystal structure is shown in Figure 4.3. 
Complex 9 adopts a pseudo-tetrahedral geometry with the η6-bonded aromatic ring blocking 
one face of the metal centre occupying 3 coordination sites. The ethylenediamine ligand is 
deprotonated and bound as a monoanionic bidentate ligand to Ru, together with an iodide 
completing the coordination sphere of complex. 
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Figure 4.3 ORTEP diagram for complex 9. Ellipsoids are shown at the 50% probability level. 
All hydrogen atoms and solvent molecules have been removed for clarity. 
 
Table 4.2 Selected Bond Lengths (Å) and Angles (deg) for Complex 9 
Bonds  Length (Å) /Angle (°) 
Ru−N9 2.123(3) 
Ru−N12 2.174(3) 
Ru−I1 2.7434(3) 
Ru−arene (centroid) 1.672 
N9−Ru−N12 78.60(11) 
N9−Ru−I1 90.65(7) 
N12−Ru−I1 83.90(8) 
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Table 4.3 Crystallographic Data for Complex 9 
Crystal character         red block 
Empirical formula C28H29IN2O2RuS 
Formula weight 685.56 
Temp (K)             150(2) 
Crystal system            monoclinic 
Space group             Pn 
a /Å                         10.91549(4) 
b /Å                         9.33603(4) 
c /Å                         13.28373(5) 
α /°                          90 
β /°                          98.2296(3) 
γ /°                          90 
Volume/Å3              1339.768(9) 
Z                          2 
Dcalc (mg/cm
3)              1.699 
μ/mm-1                         14.728 
F (000)              680.0 
Crystal size/mm3  0.6 × 0.16 × 0.08 orange block 
Reflections collected  38933 
Indep reflection  5343  
R [I>=2σ (I)]              R1 = 0.0168 
Final R [all data]  R2 = 0.0426 
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4.3.3 pKa* Determination 
The pKa
* values (pKa determined in deuterated solvent) of the aqua adducts of complexes 7, 8 
and 10-14 were determined by titration over the pH* range from 2 to 12, and the 1H NMR 
chemical shifts of protons of the sulfonyl phenyls as a function of pH* were monitored and 
fitted to the Henderson−Hasselbalch equation (Figure 4.4). All the pKa* values of aqua 
complexes are in the range of 9.10-9.75 (Table 4.5). 
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Figure 4.4 Dependence of chemical shift of the sulfonyl-phenyl protons of complexes 7, 8 and 
11-14 on pH*. The lines (red) are the best fits to Henderson-Hasselbalch equation, giving pKa
* 
values shown in Table 4.5. 
4.3.4 DNA Nuclear Base Binding 
The interaction of complex 8 and 10 with DNA nucleobase model: 9-ethylguanine (9-EtG) was 
studied by 1H NMR spectroscopy (Figures 4.5 and 4.6). The reactions were performed by 
titrating nucleobase solution (in D2O) with complexes 8 and 10 (2 mM, 10% MeOD-d4 in D2O) 
at 310 K, in 0.5 mol equiv steps. The binding adducts were confirmed by following a new set 
of peaks. No peaks for the original complexes peaks were observed when 1.5 mol equiv of 9-
EtG was added, indicating completion of the reaction. 
 
Figure 4.5 Low field 1H NMR spectra for titration of complex 8 (2 mM in MeOD-d4/D2O, 2:8 
(v/v)) with 9-ethylguanine (9-EtG, 1 mM–3 mM, 0.5–1.5 mol equiv), pH* at 7.2, 310 K. Blue 
arrows correspond to unreacted Ru complex 8. 
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Figure 4.6 Low field 1H NMR spectra for titration of complex 10 (2 mM in MeOD-d4/D2O, 
2:8 (v/v)) with 9-EtG (in D2O, 1 mM–3 mM, 0.5–1.5 mol equiv), pH* at 7.2, 310 K. Blue 
arrows correspond to unreacted Ru complex 10. 
4.3.5 Interaction with Glutathione 
The interactions of complex 8 with Glutathione (GSH) was investigated via a series of 
concentration dependent experiments and monitored by 1H NMR (pH* 7.2, 310 K). Complex 
8 (2 mM, MeOD-d4/D2O, 2:8 (v/v)) and GSH (in D2O) were in the ratio of 1: X, where X = 1, 
2, 5, 10 mol equiv, respectively. All the reactions were all complete within 10 min. From the 
spectra, complex 8 reacted rapidly with GSH, and a new set of peaks was found when complex 
8 was treated with 1.0 mol equiv of GSH solution (Figure 4.7). The arene proton peaks 
(biphenyl) of complex 8 disappeared (in blue arrow) when excess GSH (2-10 mol equiv) was 
added, indicating the completion of reaction. However, the adduct species 8-SG was difficult 
to identify in the 1H NMR spectrum (Figure 4.7).  
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Figure 4.7 Low field region of 1H NMR (600 MHz) spectra of the reactions between complex 
8 and various concentrations of GSH (1.0-10 mol equiv) in MeOD-d4 and D2O (2:8, v/v). The 
pH* was adjusted to 7.2 ± 0.1 and all spectra were recorded at 310 K. Peaks for excess GSH 
are in the orange box. 
4.3.6 Identification of GSH/NAC Adducts by LC-MS 
In order to identify the binding mode of complex 8 with GSH, a second set of experiments for 
reaction of complex 8 with GSH was investigated by HPLC and LC-MS (eluent gradients are 
shown in Figure 4.8). Another thiol-containing molecule N-acetyl-L-cysteine (NAC) was also 
studied for comparison.  
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Figure 4.8 HPLC and LC-MS gradients for identification and separation of the Ru-SG and Ru-
NAC adducts from the reaction of complex 8 and GSH/NAC, TFA was used to ensure the 
shape of the peak on HPLC (TFA, trifluoroacetic acid). Column type: ZORBAX Eclipse XDB-
C18, 9.4 × 250 mm, 5 µm. 
Complex 8 (2 mM in MeOH/H2O, 1: 9 (v/v)) and GSH or NAC (20 mM in H2O, 10 mol equiv) 
were mixed in a vial and pre-incubated at 310 K for 24 h (pH 7.10 ± 0.1). As can be seen from 
Figure 4.9, the reactions proceeded with over 95% and 100% conversions to form the RuII-SG 
and RuII-NAC adducts as determined by HPLC (Figure 4.9); peak p4 is assignable to complex 
8 and disappeared after 24 h co-incubation at 310 K, with two new peaks p1 and p2 emerging 
(Figure 4.9). Subsequently, reactions were studied by LC-MS using the same conditions, and 
two dimers [(η6-biph)2Ru2(SG)3]2+ 8a and [(η6-biph)2Ru2(NAC)3]+ 8b which can be assigned 
to p1 and p2, respectively, were detected. The free chelating TsEnBz ligand was detected as 
peak p3. The peak assignments are listed in Table 4.4. 
126 
 
 
Figure 4.9 HPLC chromatograms for reaction of complex 8 with GSH and NAC monitored at 
254 nm. Complex 8 (2 mM, MeOH/H2O, 1:9 (v/v)) with GSH or NAC (20 mM, H2O) were 
pre-incubated for 24 h at 310 K. pH of the solutions was adjusted to 7.2 ± 0.1.  
Next, the isolation of the two Ru-S bridged dimers 8a and 8b was attempted by using a 
ZORBAX Eclipse XDB-C18 Semi-preparative HPLC column (9.4 × 250 mm). 8b was 
collected and characterized by 1H and 13C NMR (1H NMR spectrum shown in Figure 4.10).  
A high resolution mass peak at 715.6011 m/z was observed, which corresponds to [(η6-
biph)2Ru2(SG)3]
2+ (8a in Figure 4.11), and the peak at 998.0339 m/z is assigned to [(η6-
biph)2Ru2(NAC)3]
+ (8b in Figure 4.12).  
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Figure 4.10 1H NMR spectrum (600 MHz, in D2O) of [(biph)2Ru2(NAC)3]
+ 8b. 
 
Table 4.4 HPLC Peak Assignments for Reaction of Complex 8 (1 mol equiv) with GSH or 
NAC (10 mol equiv). 
Peak 
Retention 
time (min) 
Mass (m/z) Assignment 
p1 17.3 715.67 [(η6-biph)2Ru2(GS)3]2+ 
p2 27.6 997.89 [(η6-biph)2Ru2(NAC)3]+ 
p3 31.6 305.20 ligand [TsEnBz]+H+ 
p4 34.7 559.10 complex 8, [C28H29N2O2RuS]
+ 
 
128 
 
 
Figure 4.11 High resolution mass spectrum of complex 8a; the top is the observed spectrum 
of 8a; the bottom is the simulated spectrum of 8a. 
 
Figure 4.12 High resolution mass spectrum of complex 8b; the top is the observed spectrum 
of 8b; the bottom is the simulated spectrum of 8b. 
129 
 
4.3.7 Kinetics of Transfer Hydrogenation Reactions 
TH reduction of NAD+ to give NADH was studied in an aqueous media using complexes 7-15 
as catalysts and sodium formate as hydride source following a protocol described in Section 
3.2.4 of Chapter 3 (MeOD-d4/D2O, 1:9 (v/v), pH
* 7.2 ± 0.1, 310 K). All the kinetic experiments 
were monitored by 1H NMR with RuII, NAD+ and formate in a ratio of 1: 4: 25. It is evident 
from Table 4.5, that the turnover frequency (TOF) values of complexes 7-15 are in the range 
2.5-12.9 h-1, Os
II complex 10 has the highest TOF (12.9 ± 0.3 h-1), while complex 11 has the 
lowest TOF value (2.5 ± 0.1 h-1). Complexes 7 [(η6-benzene)Ru(TsEnBz)Cl] and 8 [(η6-
biph)Ru(TsEnBz)Cl] bearing TsEnBz ligand have the similar TOF values (7.5 ± 0.3 h-1 and 7.9 
± 0.4 h-1, respectively), while complexes 12 and 13 with more electron withdrawing functional 
groups 4-NO2-Ph and 4-F-Ph give higher catalytic efficiency than 8, with TOF values of 9.1 ± 
0.5 h-1 and 9.7 ± 0.1 h-1, respectively; while complex 14 with weaker electron effect gives 
slightly lower TOF value (6.74 ± 0.04 h-1). 
Table 4.5 Turnover Frequencies for Conversion of NAD+ to NADH Catalysed by Complexes 
7-15 and pKa
* Values for the Aqua Adducts of Complexes 7-15 
Complex TOF (h-1) pKa
* 
7 7.5 ± 0.3 9.67 ± 0.03 
8 7.9 ± 0.4 9.3 ± 0.1 
9 5.7 ± 1.4 n. d. 
10 12.9 ± 0.3 n. d. 
11 2.5 ± 0.1 9.71 ± 0.05 
12 9.1 ± 0.5 9.1 ± 0.2 
13 9.7 ± 0.1 9.12 ± 0.04 
14 6.74 ± 0.04 9.34 ± 0.07 
15 3.7 ± 0.6 n. d. 
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4.3.8 GSH Mediated TH Reduction of NAD+ 
Given the abundance of GSH in mammalian cells, the influence of GSH on NAD+ TH reaction 
catalysed by complex 8 was investigated under similar conditions (MeOD-d4/D2O, 1:9 (v/v), 
pH* 7.2, 310 K). Complex 8 (1.4 mM, MeOD-d4/D2O, 2:8 (v/v),), NAD
+, GSH and sodium 
formate (D2O) were in the ratio of 1: 4: X: 25, where X = 0.2, 0.5, 1 and 2 mol equiv. The 
kinetic experiments was recorded every 5 min by 1H NMR. The catalytic efficiency of complex 
8 changed little, with TOF decreasing slightly from 7.9 ± 0.4 h-1 to 6.29 ± 0.53 h-1 when 0.2 
mol equiv GSH was present. However, the TOF dropped dramatically to 0.91 ± 0.43 h-1 when 
0.5 mol equiv GSH was co-administered. The reaction totally stopped when 1 mol equiv or 
more GSH was added, probably due to the decomposition of complex 8 when exposed to GSH. 
4.3.9 GSH and L-Cysteine Triggered Fluorescence of a Labelled Complex 
The fluorescence of DanEnBz was fully quenched when it was present as a chelated ligand in 
complex 15 (see Table 4.1 for structure) and no obvious fluorescence was found when complex 
15 was dissolved in DMSO and H2O, Figure 4.13c. As found above, GSH can quickly interact 
with complex 8 to form the [(η6-biph)2Ru2(SG)3]2+ dimers, accompanied by release of the 
sulfonyl ethylenediamine ligand. Such interaction may re-trigger the fluorescence of DanEnBz 
of complex 15. As expected, an immediate emission was observed when complex 15 (2mM in 
DMSO/H2O, 2:8(v/v)) was treated with GSH or NAC (20 mM in H2O, Figure 4.13). About a 
200-fold increase in emission intensity was induced by mixing complex 15 with GSH with 
excitation at 350 nm (Figure 4.13a), NAC induced a stronger increase in fluorescence under 
the same conditions (ca. 1.7-fold stronger than GSH); but when excited solution at 405 nm, the 
emission intensity was relatively lower, only about 40-fold intensity for GSH and 60-fold for 
NAC when compared to negative solution (complex 15 only, Figure 4.13b). In a further 
experiment, in order to identify the binding mode (thiol or carboxyl moiety), complex 15 was 
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reacted with two carboxyl-containing amino acids (thiol-free), L-leucine and L-tryptophan, and 
one thiol-containing molecule (carboxyl-free), 1-butanethiol. Interestingly, no obvious 
fluorescence was observed when 15 was mixed with thiol-free amino acids; however, a 
relatively strong fluorescence emission was found when 1-butanethiol was added, indicating 
that such a complex has a high thiol affinity. 
 
Figure 4.13 GSH- and NAC-triggered fluorescence of complex 15. a) Solution excited at 350 
nm; b) solution excited at 405 nm; c) A: complex 15 in DMSO, B: complex 15 in DMSO/H2O 
(1: 9 (v/v)), C: complex 15 (0.1 mM, DMSO/H2O, 1: 9 (v/v)) with GSH (2 mM in water) and 
D: complex 15 (0.1 mM, DMSO/H2O, 1: 9 (v/v)) with NAC (2 mM in water) under UVA; d) 
induction of fluorescence of complex 15 with L-leucine (G, 10 mol equiv), L-tryptophan (H, 
10 mol equiv) and 1-butanethiol (I, 10 mol equiv) under UVA. 
4.3.10 Antiproliferative Activity 
The antiproliferative activity of complexes 7-15 against A2780 human ovarian, A549 human 
lung cancer cells was determined (Table 4.6). The clinical drug cisplatin (CDDP) was used as 
a comparison. As can be seen in Table 4.6, these complexes gave a broad range of IC50 values 
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ranging from 3.57 - >50 µM and 4.1-38.5 µM against A2780 human ovarian and A549 human 
lung cancer cells, respectively. Complex 13 has the best anticancer activity against A2780 
cancer cells (IC50, 3.57 ± 0.98 μM), while complex 14 [(η6-biph)Ru(PhEnTs)Cl] is inactive. 
Complex 14 is potent towards A549 lung cancer cells (IC50, 4.1 ± 1.3 μM), comparable to 
CDDP (IC50, 3.1 ± 0.1 μM). 
Table 4.6 Anticancer Activity of Complexes 7-15 against A2780 Human Ovarian and A549 
Human Lung Cancer Cell Lines (IC50, μM)a 
Complex 
IC50 (µM) 
A2780 A549 
7 8.32±0.54 28.8±2.6 
8 11.25±0.08 13.5±1.4 
9 18.4±1.2 32.2±0.7 
10 28.18±0.16 n.d. 
11 14.25±0.06 16.1±2.4 
12 3.57±0.98 29.8±1.1 
13 5.6±0.5 13.7±0.1 
14 > 50 4.1±1.3 
15 39.4±3.4 38.5±1.9 
CDDP 1.2±0.02 3.1 ± 0.1 
a Data are shown in means±standard deviation (STD), cell viability was assessed after 24 h 
incubation with RuII complexes and washed with PBS. A2780 human ovarian cancer cells, 
A549 human lung carcinoma cells. 
4.3.11 Effect of L-Buthionine Sulfoximine on Antiproliferative Activity 
L-Buthionine sulfoximine (L-BSO) is a specific inhibitor of γ-glutamylcysteine synthetase,22 
an enzyme involved in the biosynthesis of GSH. Treatment with L-BSO can scavenge the 
intracellular GSH levels up to 40%, which effectively hampers cellular GSH synthesis.23 Next, 
the anticancer activity against A549 human lung cancer cells by co-incubation complex 8 with 
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L-BSO was determined, to investigate the role of GSH in antiproliferative activity. Complex 8 
was coadministered with three different concentrations of L-BSO: 1, 5 and 50 µM. 
Interestingly, after 24 h co-incubation with L-BSO (at concentrations of 1 and 5 µM), the 
antiproliferative activity (IC50, ca. 13 µM) of 8 retained unchanged; but the activity of complex 
8 decreased to 8.3 ± 0.5 µM when co-treated with 50 µM L-BSO (decreasing by a factor of 
0.64). 
4.3.12 Effect of GSH and NAC on Anticancer Activity 
GSH often acts as a detoxification agent for metal-based drug in cells, and some drug resistant 
cancer cells are capable of generating higher levels of GSH to circumvent damage. N-Acetyl-
L-cysteine (NAC) is a reactive oxygen species (ROS) scavenger, which can block the cisplatin 
related caspase-3 activation and cell apoptosis.24 Since complex 8 can react rapidly with GSH 
to form the dimers 8a [(η6-biph)2Ru2(SG)3]2+, co-administration of complex 8 with GSH (5, 10 
and 50 µM) was studied, to investigate the effect of GSH on antiproliferative activity against 
A2780 human ovarian carcinoma cells. Cells exposed to three concentrations of GSH (5, 10 
and 50 µM) were incubated as controls. The results indicate that only GSH exposure is not 
toxic towards A2780 cancer cells. After 72 h of recovery time in drug-free medium, cell 
survival was evaluated using the Sulforhodamine B colorimetric assay. As shown in Figure 
4.14, the antiproliferative activity decreased gradually with increase of GSH concentrations, 
giving IC50 values of 22.41 ± 1.25, 29.9 ± 2.1 and > 50 µM towards A2780 cells and, 27.33 ± 
0.54, 43.93 ± 3.54 and > 50 µM towards A549 cancer cells.  
Further co-treatment of complex 8 with NAC displayed a similar trend, in which the anticancer 
activity reduced with the increase of NAC concentration (same concentrations and protocols 
as with GSH), IC50 values are 25.8 ± 0.9, 39.9 ± 0.9 and 53.8 ± 1.4 µM, for NAC concentration 
of 5, 10 and 50 µM, respectively.  
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Figure 4.14 Antiproliferative activity of complex 8 against human A2780 ovarian and A549 
lung cancer cells induced by co-administration with GSH in three different concentrations 5, 
10 and 50 µM (GSH with various concentrations was added to cells firstly, followed by 
complex 8 following SRB protocols). After 24 h co-incubation with complex 8 and GSH, both 
cancer cells viability was assessed and washed with PBS. Data are presented in means ± 
standard deviations (STD). 
4.3.13 Cell Cycle Arrest 
The cell cycle analysis for complex 8 towards A2780 human ovarian cancer cell was performed 
by propidium iodide staining and flow cytometry. A2780 cancer cells were incubated with 
equipotent IC50 and 2 × IC50 concentrations of complex 8 for 24 h. In comparison to negative 
control population, complex 8 showed increased cell cycle arrest at G1 phase when the drug 
concentration increased from equipotent IC50 to 2 × IC50 (Figure 4.15). 
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Figure 4.15 Cell cycle arrest analysis of A2780 human ovarian cancer cells after 24 h exposure 
to complex 8 at 310 K at IC50 and 2 × IC50 concentrations. Cell staining for flow cytometry 
was carried out using PI/RNase. Percentage of cell populations in each cell cycle phase for 
negative control and complex 8 were compared. p-Values were calculated after a t-test against 
the negative control data, *p < 0.05, **p < 0.01. 
4.3.14 Reactive Oxygen Species (ROS) Determination  
The level of reactive oxygen species (ROS) induced by complex 8 and 8 in combination with 
GSH in A2780 human ovarian cancer cells was determined at IC50 concentrations by flow 
cytometry fluorescence analysis (Figure 4.16). These experiments were carried out following 
previously described protocols.25 A2780 cancer cells were treated with a fixed IC50 
concentration of 8 and GSH (0.5 and 5 µM) without any recovery time. The total level of 
oxidative stress (including H2O2, peroxy and hydroxyl radicals, peroxynitrite, and NO) in 
FITC-A channel and superoxide production in PE-A channel were monitored. ROS levels were 
detected in more than 70% of A2780 cancer cells. The population of A2780 cells showed high 
fluorescence in FITC-A channel (ca. 73.1±1.9%) for complex 8 alone and low fluorescence in 
channel PE-A (ca. 26.8±2.0%), indicating a major induction of  oxidative stress of complex 8 
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in A2780 cancer cells. Interestingly, cell population in FITC-A-/PE-A+ and FITC-A+/PE-A+ 
channels decreased with increase of GSH concentration, from ca. 16.8±0.8% to ca. 5.9±0.5%. 
However, inversely, cell populations in FITC-A+/PE-A- channels increased when 5 µM GSH 
was co-administered with 8, from 71.7±1.7% to 86.3±0.5%, suggesting a higher oxidative 
stress. 
 
Figure 4.16 ROS induction in A2780 cancer cells exposed to complex 8, 8 with 0.5 µM GSH 
and 8 with 5 µM GSH was investigated. FITC-A channel detects total oxidative stress, and PE-
A channel detects production of superoxide. p-Values were calculated after two-tailed Welch’s 
t-tests to determine the significance of variations, ap > 0.05, *p < 0.05, **p < 0.01 and ***p < 
0.001. 
4.4 Discussion 
The characterized complex 9 [(η6-biph)Ru(TsEnBz)I] has the ‘piano-stool’ geometry (Figure 
4.3), which is structurally similar to the related RuII complexes.18,26 The Ru-N bond lengths are 
2.123 Å (Ru-N(-)) and 2.174 Å (Ru-N(H)), which are close to those of complexes 3 [(η6-p-
cym)Ru(TsEnEt)Cl] (2.126 Å and 2.1702 Å, respectively) in Chapter 3, but the Ru-N12 bond 
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length is 0.067 Å and 0.06 Å longer than the respective complexes [(η6-biph)Ru(TsEn)Cl] 
(2.1073 Å) and [(η6-biph)Ru(en)Cl]+ (2.1104 Å). Interestingly, the Ru-I bond length is much 
longer than Ru-Cl of complex [(η6-biph)Ru(TsEn)Cl]  (2.7434 Å versus ca. 2.4173 Å), and is 
close to that of Os complex [(η6-p-cym)Os(Impy-OH)I]+ (2.7247 Å).22 With regard to the bond 
angle, N12-Ru-I angle is 83.90o which is smaller than that of [(η6-p-cym)Ru(EtTsEn)Cl] 
(87.55o). The rest of the bond lengths and angles showed no significant difference from the 
other RuII complexes. 
RuII sulfonyl ethylenediamine complexes have been designed as potent catalysts in the 
(asymmetric) transfer hydrogenation (TH) reactions of ketones, imines, or importantly cell 
coenzyme NAD+.18,27,28 In Chapter 3, the catalytic efficiency of complex 4 [(η6-p-cym) 
Ru(TsEnBz)Cl] in the TH reduction of NAD+ to NADH was determined. In comparison, 
complexes 7 [(η6-benzene)Ru(TsEnBz)Cl] and 8 [(η6-biph)Ru(TsEnBz)Cl] retained the 
potency (7.4 ± 0.1 h-1 versus 7.5 ± 0.3 h-1 and 7.9 ± 0.4 h-1), decreased in the order: 8 (biph) > 
4 (p-cym) > 7 (benzene); which is slightly different from the previous observation that TOFs 
of complexes variable in arene decreased in the order: benzene > biph > p-cym.18 Complex 11 
[(η6-HO(CH2)2OPh)Ru(TsEnBz)Cl] with hydrophilic side group HO(CH2)2O- on the phenyl 
arene gave lowest TOF (2.5 ± 0.1 h-1), probably because the steric side chain is too bulky to 
allow close NAD+ approach to the Ru centre. 
L-BSO can limit the cellular synthesis of GSH, and enhance the ROS levels to induce cell 
apoptosis. Co-treatment of organometallic RuII or OsII complexes with L-BSO has been 
developed as a strategy to overcome the GSH mediated detoxification,29,30 also, L-BSO can 
restore the CDDP activity against several CDDP-resistant cancer cell lines, due to the inhibition 
of CDDP bound to GSH. In previous work, Romero-Canelón et al. have shown that L-BSO 
can cause a significant reduction in cellular GSH levels (5 μM L-BSO can induced ca. 50% 
drop in GSH levels) and significant enhancement of anticancer activity towards ovarian cancer 
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cells upon co-administration of organo-Os complex [Os(η6-p-cym)(p-NMe2-Azpy)I]PF6 with 
L-BSO (5 µM dose), with 87% improvement in anticancer activity when equipotent 2 × IC50 
concentration of complex was drugged.23,24 However, such restoration of antiproliferative 
activity by L-BSO only occurs when a complex is already biologically active.23 In the present 
work, enhancement of the anticancer activity against A549 cancer cells was observed only at a 
L-BSO concentration of 50 µM (IC50 values remained unchanged at L-BSO concentrations of 
1 and 5 µM), with IC50 decreased  from ca. 13 to 8.3 µM; at this L-BSO concentration, levels 
of GSH can be reduced to ca. 63%.23 High L-BSO concentrations probably severely interfered 
with the cellular GSH synthesis, with higher ROS accumulated, which caused the cell 
apoptosis. 
Since complex 8 reacted rapidly with 9-ethylguanine, it can potentially react with DNA. 
However, the cell cycle arrest study of complex 8 in A2780 cancer cells revealed a dose-
dependent cell population increase in G1 phase (66.7 ± 1.5% to 75.2 ± 0.2% and 80 ± 2% at 
IC50 and 2 × IC50 concentrations), but a cell population depletion in G2/M and S phase, which 
may mean that the DNA targeting complex 8 is less likely (DNA-targeted compounds normally 
cause cell accumulation in S phase or G2/M phase, e.g. cisplatin31). This is in agreement with 
a previous study that [(η6-arene)Ru(RTsEn)Cl] complexes are less likely to target DNA.32  
Reactive Oxygen Species (ROS) display important roles in cell metabolism. As respiratory 
side-products of mitochondria, over-production from ROS damage proteins or oxidation of 
DNA nucleobases to induce cell apoptosis, and ROS-mediated apoptotic signalling is usually 
associated with reduction of cytosol or mitochondrial GSH levels.33,34 Organo Ir, Os and Ru 
complexes have been widely reported as potent anticancer agents which can induce cell 
apoptosis via ROS involving pathways.24,35-38 Complex 8 can induce significant amounts of 
superoxide in A2780 cancer cells (up to 16% of cell population, Table 4.7) in PE-A channel. 
Co-administration of complex 8 with GSH reduces both superoxide levels and antiproliferative 
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activity against A2780 human ovarian cancer cells. Plotting of the superoxide levels versus 
anticancer activity of complex 8 with or without GSH gives an inverse relationship which 
indicates that induction of ROS by complex 8 mainly aids in killing cancer cells.  
Table 4.7 Induction of ROS and Superoxide Determined by Flow Cytometry Experiments on 
A2780 Human Ovarian Cancer Cells.  
Complex 
Population (%) 
FITC-A-/PE-A+ FITC-A+/PE-A+ FITC-A+/PE-A- FITC-A-/PE-A- 
8 15.4±0.6 *** 1.4±0.2 *** 71.7±1.7 *** 11.4±1.4 *** 
8+GSH(0.5) 13.2±0.6 *** 0.7±0.1 ** 70.3±0.4 *** 15.8±0.4 *** 
8+GSH(5) 5.2±0.4 ** 0.67±0.15 ** 86.3±0.5 *** 7.8±0.4 *** 
Positive 0.66±0.08 ** 98.8±0.3 *** 0.77±0.15 *** 0 *** 
Negative 2.97 ± 0.15 1.53 ± 0.06 9.3±0.3 86.2±0.5 
The FITC-A channel (576/26 nm) detects ROS and PE-A channel (530/30 nm) detects 
superoxide. All values compared to the untreated controls. In all cases, independent two-sample 
t-tests with unequal variances, two-tailed Welch’s t-tests, were carried out to establish 
statistical significance of the variations (***p < 0.001, **p < 0.01, and *p < 0.05). 
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4.5 Conclusions 
In this Chapter, 9 new RuII sulfonyl-substituted ethylenediamine complexes of the type [(η6-
arene)Ru(REnBz)X] (where the arene p-cymene, biphenyl or HOCH2CH2O-phenyl, R is tosyl, 
phenylsulfonyl, 4-F-phenylsulfonyl, 4-NO2-phenylsulfonyl or danzyl, and X is halide) based 
on the scaffold of complex 4 [(η6-p-cym)Ru(TsEnBz)Cl] in Chapter 3 were synthesized and 
fully characterized. The half-sandwich structure of complex 9 was confirmed by X-ray 
crystallography. Initially, to obtain more potent TH catalysts, more electron withdrawing 
bidentate ligand substituents, e.g. 4-F-phenylsulfonyl (12), 4-NO2-phenylsulfonyl (13) were 
used to improve the catalytic activity. As expected, these complexes gave higher potency in 
TH reduction of coenzyme NAD+ with formate as hydride donor, when compared with 
complexes 4, 7 and 8 (which had similar TOF values). The introduction of the substituted arene 
HOCH2CH2O-phenyl in complex 11 improved the water solubility, however, the long side 
chain dramatically reduced the rate of hydride transfer (probably due to its bulkiness), giving 
a TOF value ca. 3× lower than for complex 4 (Table 4.5). 
Complex 8 [(η6-biph)Ru(TsEnBz)Cl] exhibited a high affinity for the free radical scavenger 
GSH (abundant cellular tripeptide) and N-acetyl-L-cysteine (NAC), to form the Ru-thiol 
bridged dimers [(η6-biph)2Ru2(GSH)(GS)2]2+ and [(η6-biph)2Ru2(NAC)3]+. Co-incubation of 
complex 8 with GSH can effectively reduce induction of reactive oxygen species, and decrease 
the antiproliferative activity significantly with the increase of GSH co-treatment concentration. 
Such decomposition of a RuII ethylenediamine complex can release the free diamine ligand can 
hence trigger the fluorescence of complex 15 [(η6-biph)Ru(DanEnBz)Cl], which may provide 
a basis for a study the cellular distribution of the complex in the future.  
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Complex 8 binds to neutral DNA nucleobase 9-ethylguanine to form the 8-9-EtG adduct 
(Figure 4.5). However, such RuII complexes only can cause G1 cell cycle arrest on a 
concentration-dependent mode, are unlikely to target DNA in cells.  
The hydrophobicity of the complexes increases with increase of arene size; higher 
hydrophobicity facilitates uptake into cells, which increase anticancer potency.39 Complex 7 
(benzene) and 8 (biphenyl) with different arene sizes were compared with complex 4 (p-
cymene); however, the antiproliferative activity of complex 8 (with the largest arene) is lower 
than complex 4 against A2780 human ovarian cancer cells. No obvious corrections between 
the anticancer activity of complexes 4, 7 and 8 and arene size were observed, probably 
suggesting a difference in metabolic pathway for these complexes in cancer cells. The rapid 
interaction of complex 8 [(η6-biph)Ru(TsEnBz)Cl] with cell-abundant GSH suggests a 
potential metabolic pathway when Ru sulfonyl ethylenediamine complexes enter mammalian 
cells, and role for GSH in the induction of ROS by Ru sulfonyl ethylenediamine complexes in 
cancer cells.  
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Chapter 5 
 
Transfer Hydrogenation and Antiproliferative Activity of 
Tethered Half-sandwich Organoruthenium Catalysts 
 
  
147 
 
5.1 Introduction 
The clinical anticancer drug cisplatin arose from the serendipitous discovery of its biological 
anticancer activity by Rosenberg et al. about fifty years ago.1 Since then, anticancer complexes 
based on other platinum-group metals (Ru,2-4 Rh,5-8 Os,9-11 Ir12-13 and Pd14-17) have been well 
studied. Ruthenium complexes have shown promising potential with relatively low toxicity, 
and might provide alternatives to platinum drugs. These Ru complexes also have the potential 
to overcome the severe side effects and drug resistance which is a problem with some platinum-
based chemotherapeutics.18,19 Two RuIII complexes NAMI-A and KP-1019 (Figure 5.1), have 
entered phase II clinical trials, the former as an antimetastatic agent.20-22 The mode of action of 
NAMI-A and KP-1019 in cancer cells is not yet understood, but the reduction of RuIII to RuII 
is a plausible pathway for their activation.23,24 The RuII complex [Ru(η6-p-cym)Cl2(PTA)](PTA 
= 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane) (RAPTA in Figure 5.1) also exhibits 
promising anti-metastatic effects in vitro and in vivo,25 and antiangiogenic activity towards 
chicken chorioallantoic membranes with low dose-dependent antiproliferative activity.26 [(η6-
biphenyl)Ru(en)Cl]PF6 (en = ethylenediamine, RM175 in Figure 5.1) is believed to target 
DNA and can bind to guanine bases accompanied by arene intercalation. It can also induce 
oxidation of bound glutathione (GSH) which can be displaced by guanine, providing a redox-
mediated route to DNA binding.27,28  
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Figure 5.1 Organometallic half-sandwich RuII complexes as anticancer agents and catalytic 
transfer hydrogenation catalysts. 
Organometallic half-sandwich RuII complexes also exhibit catalytic activity in transfer 
hydrogenation (TH) reactions by using a variety of reducing agents as hydride source (e.g. H2, 
isopropanol, and sodium formate).29-32 The Noyori-type RuII complex [(η6-p-cym)Ru 
(TsDPEN)Cl] (TsDPEN = (R, R)-N-(p-tolylsulfonyl)-1,2-diphenylethylenediamine), is an 
efficient catalyst for the asymmetric transfer hydrogenation of ketones and amines with high 
yields and enantiomeric excesses using isopropanol as hydride source (Figure 5.1).33, 34 The 
sulfonyl RuII complex [(η6-arene)Ru(TsEn)Cl] (TsEn: toluenesulfonyl-ethylenediamine) is a 
more water soluble catalyst and, under biologically relevant conditions, can reduce the 
coenzyme nicotinamide adenine dinucleotide (NAD+) in vitro and in cells using a non-toxic 
dose of sodium formate as hydride donor (JS2 in  Figure 5.1).35-37 
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Figure 5.2 Structure of enantiomers of chiral tethered Ru TsDPEN complexes. 
Tethered RuII half-sandwich compounds in which the η6-arene ring and a diamine ligand are 
connected through a three (or four)-atom chain, have a “locked” arene ring, providing control 
over the spatial positions of the substituents on the ethylenediamine ligands, and have enhanced 
stability.38, 39 Wills et al. have reported a series of tethered RuII η6-arene complexes and used 
them as efficient catalysts in the transfer hydrogenation reactions of ketones and amines.40, 41 
However, there have been few investigations on the antiproliferative activity of tethered RuII 
complexes. Recently, chiral tethered RuII complexes (two isomers) were synthesized and found 
to have potent antiproliferative activity towards the panel of NCI-60 cancer cell lines (IC50 
against A2780 ovarian cancer cells as low as 1.1 μM, Figure 5.2).  Interestingly, their potency 
increased by up to 25% upon incubation of the cancer cells with formate.42  
In this Chapter, I have synthesized and characterized the water soluble tethered RuII complexes 
[Ru(η6-Ph(CH2)3- ethylenediamine-N-R) Cl], where R = Ms (16), Ts (17), Tf (18) and Nb (19) 
and investigated their catalytic TH reduction of NAD+ to NADH using sodium formate as a 
hydride source under biologically relevant conditions. The interaction of complex 17 with the 
abundant intracellular tripeptide γ-L-Glu-L-Cys-Gly (GSH), and the effect of GSH on catalytic 
TH reduction of NAD+ were also studied. I investigated the effect of non-toxic concentrations 
of formate on the antiproliferative activity of these complexes in several human cancer cell 
lines, the induction of reactive oxygen species (ROS), and changes in integrity of their 
membranes. 
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5.2 Experimental Section 
5.2.1 Materials 
β-Nicotinamide adenine dinucleotide hydrate (NAD+) was purchased from Sigma Aldrich. 
Methylsulfonyl chloride, toluenesulfonyl chloride, 4-trifluoromethylbenzenesulfonyl chloride 
and 4-nitrobenzenesulfonyl chloride were obtained from Fluka and Sigma Aldrich. L-
Glutathione was obtained from Alfa Aesar. The A2780 human ovarian, A549 lung, HEPG 2 
hepatocellular and MCF7 breast human adenocarcinoma cell lines as well as MRC 5 human 
fibroblast cells were purchased from European Collection of Animal Cell Culture (ECACC, 
Salisbury, UK). Propidium iodide (>94%) and RNase A were obtained from Sigma Aldrich. 
5.2.2 Synthesis and Characterization 
The ligands and complexes synthesis was performed with help of Dr. Abraha Habtemariam 
and Dr. Joan J. Soldevila_Barreda. 
[Ru(η6-Ph(CH2)3-ethylenediamine-N-Ms)Cl] (16). To a stirred solution of dimer (100 mg, 
0.1 mmol) in DCM (50 mL) at 273 K was added N, N-diisopropylethylamine (1.4 mL, 0.77 
mmol) and the solution was stirred at room temperature for 2 h. The desired ruthenium complex 
was isolated by recrystallization from methanol and diethyl ether and resulted in a dark red 
solid. Yield = 47 mg (60%). 1H NMR (400 MHz, MeOD-d4): δH 1.98-2.04 (m, 1H), 2.29-2.41 
(m, 4H), 2.48-2.51 (m, 1H), 2.76 (s, 3H), 2.79-2.82 (m, 2H), 2.87 (d, J = 7.7 Hz, 1H), 3.24-
3.28 (m, 1H), 5.14-5.20 (m, 2H), 5.71-5.72 (m, 1H), 5.83-5.88 (m, 2H). 13C NMR (125.7 MHz, 
DMSO-d6): δc 33.3, 43.8, 52.7, 56.8, 62.0, 78.5, 82.1, 82.9, 95.3, 98.0, 105.5. HR-MS: Calcd 
for [C13H22N2O2SRu]
+ 357.0211 m/z, found: 357.0211 m/z. Elemental analysis: calcd for 
[C12H19ClN2O2RuS(H2O)0.6]: C, 35.79%; H, 5.06%; N, 6.96%. Found: C, 35.83%; H, 4.91%; 
N, 6.94%. 
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[Ru(η6-Ph(CH2)3-ethylenediamine-N-Ts)Cl] (17). Complex 17 was obtained following the 
method described above for complex 16. Recrystallization from methanol resulted in a bright 
red solid. Yield = 63 mg (63%). 1H NMR (400 MHz, CDCl3): δH 7.74 (d, J = 8.2 Hz, 2H), 7.16 
(d, J = 8.2 Hz, 2H), 6.39 (t, J = 5.6 Hz, 1H), 5.97 (t, 1H, J = 5.6 Hz), 5.84 (t, J = 5.8 Hz, 1H), 
5.01 (d, J = 5.6 Hz, 1H), 4.91 (d, J = 5.8 Hz, 1H), 3.79 (s, 1H), 3.30–3.23 (m, 1H), 3.03 (dd, J 
= 11.5 Hz, 4.2 Hz, 1H), 2.79–2.71 (m, 1H), 2.66–2.62 (m, 1H), 2.43–2.36 (m, 3H), 2.34 (s, 
3H), 2.27–2.19 (m, 2H), 2.08–1.99 (m, 1H). 13C NMR (125.7 MHz, DMSO-d6): δc 26.1, 33.2, 
33.5, 52.2, 56.7, 62.0, 78.9, 82.1, 83.2, 94.5, 97.6, 104.9, 132.1, 133.6, 144.5, 146.9. HR-MS: 
Calcd for [C18H23N2O2RuS]
+: 433.0524 m/z, found: 433.0522 m/z. Elemental analysis: calcd 
for [C18H23ClN2O2RuS(H2O)0.1]: C, 46.02%; H, 4.98%; N, 5.96%. Found: C, 46.03%; H, 
4.92%; N, 5.93%. 
[Ru(η6-Ph(CH2)3-ethylenediamine-N-Tf)Cl] (18). Complex 18 was obtained following the 
method described above for complex 16. Recrystallization from methanol resulted in a 
brownish-red solid. Yield = 38 mg (36%). 1H NMR (400 MHz, DMSO-d6): δH 1.84-1.86 (m, 
1H), 2.10 (t, J = 11.2 Hz, 1H), 2.25 (t, J = 9.7 Hz, 2H), 2.33-2.46 (m, 2H), 2.64 (d, J = 8.9 Hz, 
1H), 2.75 (q, J = 9.7 Hz, 21.9 Hz, 1H), 2.85 (d, J = 8.0 Hz, 1H), 3.14 (s, 1H) (broad single 
peak), 4.35 (s, 1H) broad single peak, 5.27 (d, J = 4.9 Hz, 1H), 5.40 (d, J = 5.6 Hz, 1H), 5.83-
5.89 (m, 2H), 5.97 (t, J = 5.1 Hz, 1H), 7.75 (d, J = 8.0 Hz, 2H), 7.93 (d, J = 8.0 Hz, 2H). 13C 
NMR (125.7 MHz, DMSO-d6): δc 33.2, 33.4, 52.3, 56.7, 61.9, 79.2, 81.9, 83.6, 94.8, 97.8, 
105.3, 130.1, 132.9, 134.8, 135.1, 135.0. 19F NMR (376.4 MHz, DMSO-d6): δF -61.02. HR-
MS: Calcd for [C18H20N2F3O2SRu]
+ 487.0241 m/z, found: 487.0240 m/z. Elemental analysis: 
calcd for [C18H20ClF3N2O2RuS(H2O)0.1]: C, 41.28%; H, 3.89%; N, 5.35%. Found: C, 41.20%; 
H, 3.65%; N, 5.26%. 
[Ru(η6-Ph(CH2)3-ethylenediamine-N-Nb)Cl]  (19). Complex 19 was obtained following the 
method described above for complex 16. Recrystallization from methanol and diethyl ether 
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resulted in a bright red solid. Yield = 44 mg (43%). 1H NMR (300 MHz, CDCl3): δH 2.00-2.08 
(m, 1H), 2.14-2.58 (m, 2H), 2.34-2.50 (m, 3H), 2.69-2.82 (m, 2H), 3.12 (dd, J  = 5.5 Hz, 14.8 
Hz, 1H), 3.23-3.32 (m, 1H), 3.70 (s, 1H) broad single peak, 4.92 (d, J = 7.9 Hz, 1H), 5.00 (d, 
J = 7.6 Hz, 1H), 5.86 (t, J = 7.6 Hz, 1H), 5.96 (t, J = 8.1 Hz, 1H), 6.30 (t, J = 7.3 Hz, 1H), 7.96 
(d, J = 11.6 Hz, 2H), 8.18 (d, J = 11.8 Hz, 2H). 13C NMR (125.7 MHz, DMSO-d6): δc 33.1, 
33.5, 52.4, 56.7, 61.8, 79.3, 81.9, 83.8, 94.8, 97.8, 105.5, 128.4, 133.4, 153.1, 155.0. HR-MS: 
Calcd for [C17H20N3O4SRu]
+ 464.0218 m/z, found: 464.0216 m/z. Elemental analysis: calcd 
for [C17H20ClN3O2RuS(H2O)0.5]: C, 40.20%; H, 4.17%; N, 8.27%. Found: C, 40.26%; H, 
3.89%; N, 8.04%. 
5.2.3 TOFs Determined by UV-vis Spectroscopy  
Complexes 16-19 were dissolved in DMSO/H2O (1:9, v/v) (84 µM) in a glass vial. Solutions 
of sodium formate (102 mM) and NAD+ in H2O (510 µM) were also prepared and then mixed 
at 310 K. In a typical experiment, an aliquot of 330 μL from each solution was added to a 1 
mL cuvette, and the pH adjusted to 7.2 before the sample was introduced into the UV-vis 
instrument, bringing the total volume to 1 mL (final concentrations were Ru complex 28 µM; 
NAD+ 170 µM; NaHCO2 34 mM; molar ratio 1:6:1200). UV spectra were recorded every 5 
min until completion of the reaction. The spectrum was monitored for an increase in the band 
at 340 nm, which corresponds to the absorption of NADH. 
5.2.4 TOFs Determined by NMR  
TOF values of complexes 16-19 were determined and calculated following a similar protocol 
described in Section 3.2.4 of Chapter 3 with these modifications: complexes 16-19 (1.4 mM) 
in DMSO-d6/D2O (1:4 v/v), sodium formate (35 mM) and NAD
+ (5.6 mM) in D2O were 
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prepared. The pH* adjusted to 7.2 ± 0.1. A 1H NMR spectrum was recorded at 310 K every 162 
s until the completion of the reaction. 
A further series of experiments were performed on NMR, where complex 17 (1.4 mM) was 
dissolved in MeOD-d4 (20%)/D2O (80%) (1.4 mM) in a vial; to which NAD
+ (5.6 mM in D2O), 
formate (35 mM in D2O) and different concentrations of GSH (0.5, 1, 2, 5 and 10 mol equiv) 
were added, following the same procedure used above (at 310 K, pH* 7.2 ± 0.1). 
5.2.5 IC50 and In Vitro Cytotoxicity Determination  
Biological testing was carried out by Dr. Isolda Romero_Canelón and Ji-Inn Song. 
The antiproliferative activity and cytotoxicity of complexes 16–19 were determined in different 
5 cancer cell lines and 1 human normal cell line. In general, about 5,000 cells per well were 
seeded in 96-well plates. The plates were pre-incubated with drug-free medium at 310 K for 
48 h before adding the tested compounds (concentrations various). Exact concentrations of 
complexes were determined by ICP-OES. After 24 h drug exposure, supernatants were 
removed by suction and each well was washed with PBS. A further cells recovery for 72 h was 
allowed in drug-free medium at 310 K. The sulforhodamine B (SRB) assay was used to 
determine cell viability. IC50 values, as the concentration that causes 50% cell death, were 
determined as duplicates of triplicates in two independent sets of experiments and their 
standard deviation were calculated. 
5.2.6 Coincubation of Tethered Ru Complexes with Formate  
Cell viability assays of complexes 16-19 were carried out with in A2780 ovarian cancer cells 
with sodium formate. These experiments were performed with the following modifications: a 
fixed concentration of each Ru complex equal to 1/3 × IC50 was used in co-administration with 
three different concentrations of sodium formate (0.5, 1.0 and 2.0 mM).  Drug stock solutions 
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(ca. 100 µM) were prepared as described for in vitro growth inhibition assays. The stocks were 
further diluted using media until working concentrations were achieved. Separately, a stock 
solution of sodium formate was prepared in saline. The complex and formate solutions were 
added to each well independently, but within 5 min of each other. 
5.2.7 Cell Cycle Analysis  
A2780 cells at 1.5 × 106 per well were seeded in a six-well plate. Cells were pre-incubated in 
drug-free media at 310 K for 24 h, after which drugs were added at equipotent concentration 
equal to IC50 value. After 24 h of drug exposure, supernatants were removed by suction and 
cells were washed with PBS. Finally, cells were harvested using trypsin-EDTA and fixed for 
2 h using cold 70% ethanol. DNA staining was achieved by re-suspending the cell pellets in 
PBS containing propidium iodide (PI) and RNase. Cell pellets were washed and re-suspended 
in PBS before being analysed in a Becton Dickinson FACScan flow cytometer using excitation 
of DNA-bound PI at 536 nm, with emission at 617 nm. Data were processed with Flowjo 
software. 
5.2.8 ROS Determination  
Flow cytometry analysis of ROS/superoxide generation in A2780 cells caused by exposure to 
complex 17 was carried out using the Total ROS/Superoxide detection kit (Enzo-Life Sciences) 
according to the instructions. 1.5 × 106 A2780 cells per well were seeded in a six-well plate. 
Cells were pre-incubated in drug-free media at 310 K for 24 h in a 5% CO2 humidified 
atmosphere, and then drugs were added to triplicates at IC50 concentration. After 1 h of drug 
exposure, supernatants were removed by suction and cells were washed and harvested. Staining 
was achieved by re-suspending the cell pellets in buffer containing the orange/green fluorescent 
reagents. Cells were analyzed in a Becton Dickinson FACScan flow cytometer using FL1 
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channel Ex/Em: 490/525 nm for the oxidative stress and FL2 channel Ex/Em: 550/620 nm for 
superoxide detection. Data were processed using Flowjo software. At all times, samples were 
kept under dark conditions to avoid light-induced ROS production.  
5.2.9 Cell Membrane Integrity Determination  
Flow cytometry analysis of cellular membrane integrity of A2780 cells caused by exposure to 
complex 17 was carried out using flow cytometry and propidium iodide staining. Briefly, 
A2780 cells were seeded in 6-well plates (1.5 × 106 cells per well), pre-incubated for 24 h in 
drug-free media at 310 K, after which they were exposed to complex 17 at  IC50 concentration. 
Cells were harvested using trypsin and stained in the dark using a mixture of propidium iodide 
and RNAse without previous fixation of the cells. After staining, cell pellets were analyzed in 
a Becton Dickinson FACScan Flow Cytometer and the histograms were analysed using Flowjo 
software. 
5.2.10 Calf Thymus DNA and Bacterial Plasmid DNA 
DNA experiments in sections 5.2.10 and 5.2.11 were conducted by in collaboration with 
Professor Viktor Brabec and Dr. Jana Kasparkova of the Institute of Biophysics, Academy of 
Sciences of the Czech Republic. 
The interaction of complex 17  with double-helical calf thymus DNA (ct-DNA) and bacterial 
plasmid DNA was studied and compared to non-tethered [(η6-p-cym)Ru(TsEn)Cl] (JS2 in 
Figure 5.1).37 Double-helical ct-DNA at a concentration of 32 µg/mL was incubated with JS2 
or complex 17 at ri values of 0.1 or 0.5 in 10 mM NaClO4 at 310 K (ri = the molar ratio of free 
ruthenium complex to nucleotide phosphates at the onset of incubation with DNA).  The 
reaction was terminated after 24 h incubation and samples were exhaustively dialyzed against 
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water. The ruthenium content in these samples was determined by flameless atomic absorption 
spectrometry (FAAS), and concentration of DNA by absorption spectrophotometry. 
In further experiments, solutions containing plasmid DNA pBR322 (28 µg/mL) and complex 
JS2 or complex 17 in various molar ratios (ri = 0.05–1) were incubated in 0.01 M NaClO4 at 
310 K for 24 h in the dark. Subsequently the samples were directly mixed with the loading 
buffer and loaded onto a 1% agarose gel running at 298 K in the dark with Tris-acetate-EDTA 
(TAE) buffer and the voltage set at 25 V. There was no separation step before loading the 
samples onto the gel to remove weakly-bound complex, if any. The gels were then stained with 
EtBr, followed by photography with a transilluminator. 
5.2.11 Binding to Short Single- or Double-stranded Oligonucleotides 
Binding of complex 17 to short, single or double stranded synthetic oligonucleotides was 
investigated by co-incubation complex 17 (ri = 0.5, concentration of oligonucleotide related to 
phosphates) in 0.05 M NaClO4 with a 50-mer oligonucleotide (single or double stranded having 
a random nucleotide sequence) at 310 K in the dark, complex JS2 was used as a comparison. 
After 24 h, the reaction was stopped, and samples were exhaustively dialyzed against water. 
The ruthenium content in these samples was determined by FAAS and the concentrations of 
DNA were determined by absorption spectroscopy. 
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5.3 Results 
5.3.1 Synthesis and Characterization 
Four neutral tethered RuII complexes [Ru(η6-Ph(CH2)3-ethylenediamine-N-R) Cl] where R = 
methanesulfonamide (Ms, 16), or toluenesulfonyl (Ts, 17), or 4-(trifluoromethyl)benzene 
sulfonamide (Tf, 18), or 4-nitrobenzenesulfonamide (Nb, 19) were synthesized following a 
literature method for related complexes (Scheme 5.1).43 They were characterized by elemental 
analysis (CHN), high resolution mass spectrometry, and NMR (1H, 13C and 19F) spectroscopy. 
 
Scheme 5.1 Synthesis Route for Complexes 16-19; DME: 1, 2-Dimethoxyethane. 
Crystals of complexes 16-19 suitable for X-ray diffraction were obtained from a slow diffusion 
of diethyl ether into MeOH at ambient temperature. The complexes adopt the expected pseudo-
tetrahedral geometry with η6-phenyl ring occupying 3 Ru coordination sites, together with 
nitrogen atoms of the diamine ligand (bond lengths 2.11-2.15 Å), and a monodentate chloride; 
ethylenediamine ligands are deprotonated and bound as monoanionic bidentate ligands. 
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Generally, the bond distance Ru-N(H) (range 2.140-2.149 Å) is slightly longer than that of Ru-
N(-) (2.112-2.121 Å). The η6-phenyl ring and ethylenediamine are linked by a three-carbon 
tether chain. The structures are shown in Figure 5.3. Selected bond lengths (Å) and bond angles 
(deg) are listed in Table 5.1, and X-ray crystallographic data in Table 5.2. 
 
Figure 5.3 ORTEP diagrams for complexes 16, 17, 18 and 19. Ellipsoids are shown at the 50% 
probability level. All hydrogen atoms have been omitted for clarity. 
Table 5.1 Selected Bond Lengths (Å) and Angles (deg) for Complexes 16-19. 
 
16 17 18 19 
Ru1-N(-) 2.121 (2) 2.1181 (14) 2.1202 (16) 2.1124 (18) 
Ru1-N(H) 2.146 (2) 2.1490 (14) 2.1485 (16) 2.140 (2) 
Ru1-Cl1 2.4174 (6) 2.4234 (4) 2.4243 (4) 2.4142 (6) 
Ru1-arene 
(centroid) 
1.654 1.657 1.658 1.653 
N(-)-Ru1-N(H) 78.77 (8) 78.87 (5) 78.87 (6) 78.54 (7) 
N(-)-Ru1-Cl1 88.17 (6) 88.29 (4) 87.33 (4) 87.24 (5) 
N(H)-Ru1-Cl1 83.20 (6) 83.02 (4) 83.56 (5) 83.43 (6) 
N(-) corresponds to N103(16), N9(17, 18), N8(19). N(H) corresponds to N106 
(16), N12 (17, 18), N11(19) 
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Table 5.2 Crystallographic Data for Complexes 16-19. 
 16 17 17 19 
Crystal 
character 
orange block orange block red block red block 
Formula C12H19ClN2O2RuS C18H23ClN2O2RuS C18H20ClF3N2O2RuS C17H20ClN3O4RuS 
FW 391.99 467.96 521.94 498.94 
Temp (K) 150(2) 150(2) 150(2) 150(2) 
Crystal system triclinic triclinic monoclinic Monoclinic 
Space group P-1 P-1 P21/c P21/c 
a (Å) 8.0399(2) 9.9127(3) 10.4998(2) 10.5869(5) 
b (Å) 11.6970(3) 10.3545(2) 16.9214(3) 16.4168(6) 
c (Å) 16.8127(3) 10.6046(4) 11.6956(3) 11.4551(5) 
α (º) 98.2250(17) 108.425(2) 90 90 
β (º) 101.4472(18) 106.778(3) 111.867(3) 110.695(5) 
γ (º) 106.688(2) 100.997(2) 90 90 
Volume (Å3) 1450.30(6) 939.87(5) 1928.47(7) 1862.48(15) 
Z 2 2 4 4 
Dcalc(mg/cm3) 1.836 1.654 1.798 1.779 
μ(mm-1) 1.412 1.101 1.105 1.127 
F(000) 812.0 476.0 1048.0 1008.0 
Crystal size 
(mm3) 
0.28 × 0.2 × 0.12 0.2 × 0.2 × 0.1 0.22 × 0.14 × 0.08 0.4 × 0.24 × 0.1 
Reflections 
measured 
44720 25185 32356 30846 
Indep 
reflection 
9700 6290 6963 6596 
R1 [I>2σ(I)] 0.0318 0.0283 0.0255 0.0304 
wR2 (all data) 0.1019 0.0611 0.1013 0.1167 
CCDC no. 1823319 1823318 1823317 1823316 
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5.3.2 pKa* Determination and Interaction with Guanine 
The pKa
* of the aqua adduct of complex 17 (aqua complex 17a) in MeOD-d4/D2O (1:9, v/v) 
was determined by 1H NMR at 310 K (Figure 5.4A) by titration over the pH* (meter reading) 
range from 2 to 12 and plots of the chemical shift of a tosyl proton as a function pH* fitted to 
the Henderson−Hasselbalch equation. The pKa* value of aqua complex 17a was found to be 
9.52 ± 0.03; a second pKa
* value of < 2, assignable to the coordinated N of 17a, was too low to 
be determined. 
The interaction of complex 17 with the DNA nucleobase model: 9-ethylguanine (9-EtG, Figure 
5.4B) was studied by 1H NMR spectroscopy. Complex 17 (2 mM in 10% MeOD-d4/90% D2O) 
reacted rapidly with 9-EtG (1 mM) at 310 K.  The adduct 17-9-EtG gave rise to a new set of 
η6-arene peaks in low field (Figure 5.4B), with up to 90% yield of the 17-9-EtG when 1.5 mol 
equiv 9-EtG solution was added.  
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Figure 5.4 (A) Dependence of low field 1H NMR chemical resonance shift of the aqua species 
17a, giving the pKa
* value of 9.52 for the coordinated water; (B) Titration reaction of tethered 
RuII complex 17 (2 mM) with 9-ethylguanine (1 mM–3 mM, 0.5–1.5 molar equiv) in 10% 
MeOD-d4/90% D2O, pH at 7.2, 310 K, followed by 
1H NMR spectroscopy. 
5.3.3 Transfer Hydrogenation Reaction Kinetics 
Catalytic transfer hydrogenation reactions of complexes 16-19 and sodium formate as hydride 
donor for conversion of nicotinamide adenine dinucleotide (NAD+) to NADH were studied in 
aqueous media by UV-visible spectroscopy (10% DMSO/90% H2O, pH 7.2 ± 0.1, 310 K) by 
following the absorbance at 340 nm for NADH, and by 1H NMR spectroscopy (using 20% 
DMSO-d6 in D2O to ensure solubility, pH 7.2 ± 0.1, 310 K), monitoring peaks corresponding 
to 1, 4-NADH.  
All the tethered RuII complexes exhibited potent catalytic activity, with TOFs by UV-vis and 
NMR  spectroscopy in the range 3.7-8.9 h-1 and 5.8-9.9 h-1, respectively (Table 5.3), following 
the order: 16 < 17 < 18 < 19, suggesting that stronger electron withdrawing groups on the 
ethylenediamine ligand facilitate hydride transfer between formate and NAD+. 
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Table 5.3 TOFs (h-1) for Transfer Hydrogenation Reactions of NAD+ to NADH using 
Complexes 1−4 as Catalysts and Sodium Formate as Hydride Donor. 
Complex R TOF (NMR) TOF (UV-vis) 
16 Ms 3.79 ± 0.05 5.8 ± 0.2 
17 Ts 4.7 ± 0.1 8.3 ± 0.1 
18 Tf 8.9 ± 0.3 8.69 ± 0.07 
19 Nb 8.5 ± 0.2 9.9 ± 0.2 
 
5.3.4 Interaction with Glutathione (GSH)  
The reaction of complex 17 [Ru(η6-Ph(CH2)3-ethylenediamine-N-Ts)Cl] with glutathione 
(GSH) was investigated in a series of concentration-dependent experiments. Reactions of 
complex 17 (2 mM, MeOD-d4/D2O, 2:8(v/v)) and GSH (in D2O) in the mol ratio of 1: X, where 
X = 0.2, 0.5, 1, 2, 5 and 10 were studied by 1H NMR spectroscopy under conditions of MeOD-
d4/D2O (1:9, v/v), pH
* 7.2, 310 K. Each reaction was complete within 10 min. The low-field 
η6-phenyl peaks of complex 17 decreased gradually, and a new set of triplets (H1’ and H2’) 
emerged when 0.2 and 0.5 mol equiv of GSH were added (Figure 5.5). The low field 
resonances of the tosyl proton of complex 17 (H1 and H2) disappeared and a new set of peaks 
(H1’-H7’) appeared when 1 mol equiv or more GSH was added (Figure 5.5). The reaction was 
confirmed by LC-MS, which revealed that the 17-SG adduct was formed rapidly when 17 was 
mixed with GSH (Figure 5.6). The eluents are shown in Figure 5.7.  
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Figure 5.5 1H NMR (600 MHz) spectra monitoring of the reactions between complex 17 (2 mM 
in MeOD-d4/H2O, 1:9 v/v) and various concentrations of GSH in a mixture of MeOD-d4 and 
D2O (2:8, v/v). The pH
* was adjusted to 7.2 ± 0.1 and all spectra were recorded at 310 K.  
 
Figure 5.6 Reaction of complex 17 with GSH (10 mol equiv) in MeOH/H2O (1:9, v/v) after 
incubation at pH 7.2, 310 K for 24 h monitored by LC-MS. Eluents are shown in Figure 5.6. 
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Figure 5.7 LC-MS gradients for identification of 17-SG adducts from the reaction of complex 
17 and GSH using H2O with 0.1% TFA (v/v) (Solvent A) and CH3CN with 0.1% TFA (v/v) 
(solvent B) as eluents (TFA, trifluoroacetic acid). Column type: ZORBAX Eclipse XDB-C18, 
9.4 × 250 mm, 5 µm. 
Next, the time-dependence of reactions of complex 17 with GSH was studied under similar 
conditions: 2 mM 17 in MeOD-d4/D2O, 2:8(v/v), 20 mM GSH, monitored by 
1H NMR 
spectroscopy from 5 min to 24 h, Figure 5.8. As in the above experiments, a new set of low 
field resonances appeared immediately (H1’-H6’) in the presence of excess GSH (10 mol 
equiv), but with time, the low field resonances H1’-H6’ decreased gradually, and disappeared 
after 24 h (Figure 5.8); meanwhile another two new sets of peaks slowly appeared. The 2D 
NMR COSY spectrum suggested that the 17-SG adduct degraded with time to release the 
neutral free ligand η6-Ph(CH2)3-ethylenediamine-N(H)-Ts (assigned to one of the two sets of 
low field peaks, Figure 5.9) with up to 70% of decomposition observed within 5 h incubation 
at 310 K, as shown in Figure 5.10. Such liberation of free ligand was also detected by LC-MS 
at 333.21 m/z (calculated [Ligand+H]+ at 333.16 m/z, Figure 5.6). 
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Figure 5.8 Dependence on time of the 1H NMR (600 MHz) spectra for the reaction of complex 
17 (2 mM in MeOD-d4/H2O, 2:8, v/v) with GSH (20 mM, in D2O). The pH
* was adjusted to 
7.2 ± 0.1, and all spectra were recorded at 310 K. Free ligand resonances at low field are shown 
in the dashed box. 
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Figure 5.9 Low field 2D NMR resonance peaks of reaction of complex 17 (2 mM in MeOD-
d4/H2O, 2:8, v/v) with GSH (20 mM, in D2O) after 24 h incubation at 310 K. pH
* was adjusted 
to 7.1. Another set of unassigned peaks is marked in the green dashed box.  
 
Figure 5.10 Percentage of decomposition of 17-SG adduct by liberation of free ligand within 
5 h for reaction of complex 17 (2 mM in MeOD-d4/D2O, 2:8, v/v) with GSH (20 mM, in D2O) 
at pH* 7.1, 310 K, monitored by 1H NMR. Peak integration is from Figure 5.8. 
167 
 
5.3.5 Reduction of NAD+ by TH in the Presence of GSH  
The influence of GSH on conversion of NAD+ to NADH by TH from complex 17 with sodium 
formate as hydride source was investigated. 1H NMR spectra (MeOD-d4/D2O, 2:8(v/v), pH
* 
7.2, 310 K), with complex 17, NAD+, GSH and sodium formate in the mol ratio of 1: 4: X: 25, 
respectively, where X = 0.5, 1, 2) were recorded every 5 min. The turnover frequency of NAD+ 
to NADH decreased slightly in the presence of 0.5 mol equiv of GSH (TOF = 4.27 ± 0.05 h-1), 
however, the TOF decreased dramatically to 1.35 h-1 when 1.0 mol equiv of GSH was used. 
The hydride transfer reaction was completely blocked when excess GSH was added (2 or 5 mol 
equiv). 
5.3.6 Antiproliferative Activity 
The antiproliferative activity of tethered RuII complexes 16-19 against human ovarian (A2780), 
cisplatin-resistant ovarian (A2780Cis), lung (A549), liver (HEPG2), breast (MCF7) cancer cell 
lines and human normal lung fibroblast cells (MRC5) was determined, Table 5.4, and 
compared to the clinical drug cisplatin (CDDP). Complexes 16-19 exhibited good to moderate 
anticancer activity against all these cancer cell lines, with IC50 values in the range of 7.3-66.8 
μM.  
Complex 17 displayed good anticancer activity against A2780 and cisplatin resistant A2780 
cancer cells, with IC50 values of 7.3 µM and 15 µM, respectively. Remarkably, this complex 
exhibits a resistance index (RI) of only 2 compared to 11 for cisplatin. The RI is the ratio of 
the activity (IC50) towards the resistant cell line compared to the parental line. Furthermore, 
complex 19 exhibited similar anticancer activity against MCF 7 cancer cells to cisplatin, with 
an IC50 value of 9.9 µM (Table 5.4). 
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Table 5.4 In Vitro Anticancer Activity of Complexes 16-19 Against Various Cell Lines.  
Complex 
Cell line a 
IC50 (µM) RIb 
A2780 A2780Cis A549 HEPG2 MCF 7 MRC 5 
16 23±1 >50 33±1 27.8±0.1 28.9±0.9 31±1 >2 
17 7.3±0.4 15±1 37.6±0.6 26±4 33±2 38±1 2 
18 >50 >50 31±2 >50 24±3 28±3 n.d. 
19 16.0±0.3 >50 30±1 23±4 9.9±0.5 26±1 >3 
CDDP 1.20±0.02 13.4±0.3 3.1±0.1 5.7±0.9 7.3±0.2 12.8±0.3 11 
a Data are shown as means±standard deviations (STD), from duplicates of triplicates, cell 
viability was assessed after 24 h drug exposure and 72 h recovery in the drug-free medium. 
Cancer cell lines: A2780 human ovarian cancer cells; A2780Cis cisplatin resistance human 
ovarian cancer cells; A549 human lung cancer cells; HEPG2 human hepatocellular cancer 
cells; MCF7 human breast cancer cells; MRC5 human lung fibroblast cells; b RI is resistance 
index defined as ratio of the activity (IC50) towards the resistant cell line compared to the 
parental cell line; n.d. = not determined. 
5.3.7 Effect of Formate on Antiproliferative Activity  
The antiproliferative activity of tethered complexes 16-19 against A2780 human ovarian cancer 
cells in the presence of sodium formate was determined (Figure 5.11). Experiments included 
three sets of controls, the first, negative controls, consisted of untreated cells (only plate 
exposure), a second set was exposed to three concentrations of sodium formate (0.5, 1 and 2 
mM), and a third set exposed to cisplatin as positive controls. The results indicate that formate 
alone is not toxic towards A2780 ovarian cancer cells under the conditions used (Table 5.5). 
A2780 cancer cells were incubated with equipotent concentrations of complexes 16–19 (1/3 × 
IC50) and three concentrations of sodium formate (0.5, 1 and 2 mM) for 24 h. Following 72 h 
of recovery time in drug-free medium, cell survival was evaluated using the Sulforhodamine 
B colorimetric assay. Decrease of cell viability was observed, and importantly this was greater 
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with increasing concentration of sodium formate. Complex 19 showed the least effect on cell 
viability decreasing from 95% to 81%, while complex 16 exhibited the highest changes varying 
from 96% to 74% when 2 mM formate was co-administered. Overall, the percentage of cell 
viability reduction which accompanies formate co-administration follows the order: 16 > 17 > 
18 > 19 (Percentages of cell survival are listed in Table 5.5). 
 
Figure 5.11 Cell viability of A2780 ovarian cancer cells when exposed for 24 h to complexes 
16-19 (at equipotent 1/3 × IC50 concentrations) and sodium formate at the concentrations of 0, 
0.5, 1.0 and 2.0 mM. 
Table 5.5 Percentage of Cell Viability (%) of A2780 Cells Exposed to Different 
Concentrations of Formate and a Fixed Concentration of Complexes 16-19.  
Complex 
[Formate] 
0 mM 0.5 mM 1.0 mM 2.0 mM 
16 96 ± 2 91 ± 2 78 ± 3 74 ± 2 
17 95 ± 2 96 ± 3 81 ± 4 78 ± 1 
18 79 ± 2 75 ± 2 72 ± 3 63 ± 2 
19 95 ± 1 88 ± 2 85 ± 2 81 ± 3 
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5.3.8 Cellular Ru Uptake 
Cellular Ru accumulation from administration of complexes 17 and 19 in A2780 human 
ovarian cancer cells and A2780Cis cells was determined. Stock solutions of both complexes 
were prepared in a mixture of DMSO/cell culture medium and their accurate Ru concentrations 
were determined by ICP-OES. Working solutions were then obtained by dilution in cell culture 
medium. Both cancer cell lines were exposed to complexes 17 and 19 for 24 h, at equipotent 
IC50 concentrations. The experiment did not involve recovery time in drug-free medium. 
Complex 19 showed a higher cellular Ru accumulation than complex 17 in both A2780 and 
A2780Cis (Figure 5.12). The cellular Ru content for complex 19 was 150 ± 38 ng per 106 
A2780 cells and 241 ± 10 ng per 106 A2780Cis cells, while the cellular Ru content from 
complex 17 was much lower, 8.8 ± 0.9 ng and 7 ± 1 ng per 106 cells, respectively. 
 
Figure 5.12 Cellular Ru uptake of complex 17 and 19 towards A2780 and A2780 cisplatin-
resistance human ovarian cancer cells at IC50 equipotent concentrations. 
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5.3.9 Cell Cycle Arrest 
Since complex 17 [Ru(η6-Ph(CH2)3-ethylenediamine-N-Ts)Cl] binds to the nucleobase 
guanine (9-EtG), it was possible that DNA might be a target for anticancer activity. In order to 
investigate this, the effects on the cell cycle of A2780 cells exposed to complex 17 at IC50 and 
2 × IC50 concentrations for 24 h were studied, using propidium iodide staining and flow 
cytometry (Figure 5.13). In comparison to negative control populations, a statistically 
significant increase of the cell population in the G1 phase was observed, with percentages 
increasing to 75 ± 1% at IC50 concentration and 85 ± 3% population at 2 × IC50 concentration. 
This evidence of G1 arrest would, in principle, discard the possibility of DNA targeting which 
should be evidenced by an accumulation of cells in the S phase. Studies of the interaction of 
complex 17 with DNA were carried out to investigate this further (vide infra). 
 
Figure 5.13 Cell cycle arrest analysis of A2780 human ovarian cancer cells after 72 h of 
exposure to complexes 17 at 310 K at IC50 and 2 × IC50 concentrations. Cell staining for flow 
cytometry was carried out using PI/RNase. Cell populations in each cell cycle phase for 
negative control and complex 17 were present. p-Values were calculated after a t-test against 
the negative control data, *p < 0.05, **p < 0.01.. 
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5.3.10 ROS Determination  
The level of reactive oxygen species (ROS) in A2780 human ovarian cancer cells induced by 
exposure to complex 17 was determined at IC50 concentration by flow cytometry fluorescence 
analysis (Figure 5.14). The total level of oxidative stress, including H2O2, peroxy and hydroxyl 
radicals, peroxynitrite, NO and superoxide production, was monitored using the green channel 
FL1 and orange channel FL2, respectively. Increased ROS levels were detected in the majority 
of the population of A2780 cells with up to 82% of cells exhibiting high fluorescence in the 
FL1-green channel. There is only a minimal increase in the levels of cellular superoxide (Table 
5.6).   
 
Figure 5.14 ROS induction in A2780 cancer cells exposed to complexes 17. FL1 channel 
detects total oxidative stress, and FL2 channel detects superoxide production. p-Values were 
calculated after a t-test against the negative control data, *p < 0.05, **p < 0.01. 
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Table 5.6 Induction of ROS and Superoxide by Flow Cytometry Analysis of A2780 Ovarian 
Cancer Cells Exposed to Complex 17 and Negative Control. The Experiment Reads Superoxide 
in the FL2 Channel and Total ROS in the FL1 Channel. 
 Cell Populations (%) 
 FL-1-/FL-2- FL-1+/FL-2- FL-1-/FL-2+ FL-1+/FL-2+ 
17 9 ± 1 ** 82 ± 1 ** 7.3 ± 0.2** 0.66 ± 0.09 ** 
Negative control 99.88 ± 0.04 0.10 ± 0.03 0 0.011 ± 0.002 
In all cases, independent two-sample t-tests with unequal variances, Welch’s t-tests, were 
carried out to establish statistical significance of the variations (p < 0.01 for **, and p < 0.05 
for *). 
5.3.11 Cell Membrane Integrity 
The effect of complex 17 on the cellular membrane integrity of A2780 ovarian cancer cells was 
investigated using flow cytometry analysis of cells exposed for 24 h to the ruthenium complex 
and stained in the dark with propidium iodide. This experiment did not include fixation of the 
cells prior to staining. Results show that there are no induced changes in the membrane integrity 
of cancer cells as there are no statistical differences between the drug-exposed and negative 
control cells (Table 5.7). 
Table 5.7 Cell Membrane Integrity by Flow Cytometry Analysis of A2780 Ovarian Cancer 
Cells Exposed to Complex 17 and Negative Control. 
Complex 
Cell Population (%) 
FL-1- FL-1+ 
17 96.0 ± 0.2 3.6 ± 0.2 
Negative control 98.6 ± 0.4 1.35 ± 0.05 
 
 
174 
 
5.3.12 Calf Thymus DNA and Bacterial Plasmid DNA 
The interaction of complex 17 [Ru(η6-Ph(CH2)3-ethylenediamine-N-Ts)Cl] and JS2 (in Figure 
5.1, used as comparison) with double-helical calf thymus DNA (ct-DNA) and bacterial plasmid 
DNA were determined by absorption spectrophotometry. After 24 h incubation, no detectable 
amount of ruthenium was found in samples of DNA treated with JS2, nor complex 17, even at 
very high ri. Therefore these compounds do not bind strongly to high molecular mass DNA 
under the experimental condition used. 
As shown in Figure 5.15, no significant changes in the mobilities of supercoiled (SC) or open 
circle form (OC) were observed even at very high concentrations of Ru compounds (ri = 1), 
indicating that these complexes do not unwind DNA and do not form DNA adducts. No 
changes in intensities of SC and OC forms also indicated that the Ru complexes do not cleave 
DNA in dark. 
 
Figure 5.15 Interaction of complex 17 and complex JS2 with bacterial plasmid DNA at various 
concentrations (ri = 0–1). DNA samples were run on agarose gel followed by ethidium bromide 
staining. SC: supercoiled; OC: open circle. No significant changes of SC or OC were observed. 
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5.3.13 Binding to Short Single- or Double-stranded Oligonucleotides 
Binding of complex 17 to short, single and double stranded synthetic oligonucleotides was also 
determined by flameless atomic absorption spectrometry (FAAS) and the concentrations of 
DNA were determined by absorption spectrophotometry. However, after 24 h reaction, no Ru 
associated with single- or double-stranded oligonucleotides treated with complex JS2 was 
found in this experiment, whereas 3-4% of Ru was bound to single-stranded oligonucleotide 
when incubated with complex 17, but no detectable amount of Ru was bound to double-
stranded oligonucleotide. 
 
 
5.4 Discussion 
The X-ray crystal structures of complexes 16-19 show that they adopt the well-known ‘piano-
stool’ geometry, with nitrogens of the diamine and a chloride bound to the metal center forming 
the three-legs and a phenyl ring forming the seat, being linked to the ethylenediamine by a 
three-carbon tether.44, 45 Complexes 16-19 all have similar tethered structures. The length of 
the bond between Ru and the deprotonated N (Ru-N-) lies within the range 2.112-2.121 Å, 
shorter than in the chiral tethered complexes (R, R)-[Ru(η6-Ph(CH2)3-TsDPEN-NH)Cl] 
(2.144(3) Å) and [(η6-p-cym)Ru(TsDPEN)Cl] (2.139(6) Å), while the Ru-N(H) bond length is 
within the range 2.14-2.149 Å longer than these two complexes (2.134(3) Å and 2.105(6) Å, 
respectively).38, 40, 46 Complexes 16-19 have very similar Ru-N(-) and Ru-N(H) bond lengths to 
the complex [(η6-hmb)Ru(TsEn)Cl] (hmb: hexamethylbenzene, 2.129(3) Å and 2.141(3) Å, 
respectively).36 The N-Ru-N angles are in the range 78.54-78.87º, close to the chiral tethered 
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Ru complex (R, R)-[Ru(η6-Ph(CH2)3-TsDPEN-NH)Cl].38 The remaining bond lengths and 
angles show no significant difference to either tethered or non-tethered Ru sulfonyl 
ethylenediamine compared. 
Complex 17 reacted rapidly with guanine (9-EtG) as studied by NMR at millimolar 
concentrations.28 However, at lower concentration (micromolar), little binding to DNA was 
observed when calf thymus and bacterial plasma DNA was exposed to complex 17, consistent 
with results reported previously for the non-tethered RuII complex [(η6-p-cym)Ru(TsEn)Cl] 
(JS2), implying that DNA is not likely a target for Ru sulfonamide complexes.37 
Hydride transfer between coenzyme NAD+ and NADH plays a pivotal role in cell 
metabolism,47 this pair of coenzymes is believed to be involved in over 400 cellular reactions.48 
Studies of TH reactions for the conversion of NAD+ to NADH catalysed by transition metal 
complexes were initiated by Fish and Steckhan.49-51 The use of RuII catalysts to mimic the 
cellular reaction and achieve TH reduction of NAD+ under biologically relevant conditions has 
now been well studied.52, 53 The en complex RM175 showed strong DNA affinity, but low 
catalytic efficiency towards TH reduction of NAD+ (TOF, 0.18 h-1);35 whereas the introduction 
of a sulfonyl functional group raised the TOF up to 2.88 h-1 (JS2 in Figure 5.1).35 In this 
chapter, complexes 16-19 displayed more potent catalytic activity towards TH of NAD+ to 
NADH. The reaction rate for tosylated complex 17 is ca. 25.8× and 1.6× faster than that for 
Ru-en and Ru-TsEn complexes, and comparable to RhIII complex [(η5-Cp*)Rh(bipy)Cl]PF6.54, 
55 This probably arises because the longer Ru-N(H) bond length and shorter Ru-N(-) bond 
distance (discussed above) make the tethered complex more approachable to NAD+ when 
involved in the TH catalytic cycle, and the water-solubility allows tethered complexes to 
hydrolyse more readily which facilitates the hydride transfer. Generally, TOF values 
determined by UV-vis were found to be higher than TOFs determined by NMR spectroscopy 
(Table 5.3), probably due to the lower NAD+ concentration and higher excess of formate used 
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in the TH reaction, since TOF depends strongly on molar ratio of formate used, with higher 
formate concentrations giving a higher TH reaction rate.36 It appears that the presence of 
electron withdrawing sulfonamide on the chelating ligand gives rise to higher catalytic activity, 
consistent with the previous reported TH reduction of aldehydes and quinoxalines.36, 56, 57  
Cellular accumulation is an important factor in drug cytotoxicity.58 Cellular accumulation of 
Ru from complexes 17 and 19, in A2780 and A2780Cis cancer cells does not correlate with 
their cytotoxicity (IC50). However, the plot of Ru accumulation of complexes 17 and 19 in 
A2780 cells with decrease of cell viability (in the presence of 2 mM formate) indicates a reverse 
relationship: the higher cellular Ru uptake (complex 19) induces lower cell proliferation 
decrease. TOFs of complexes 16–19 determined by UV-vis spectroscopy also exhibit an 
inverse correlation with the reduction of cell viability induced by 2 mM sodium formate, 
following the order: 19 < 18 < 17 < 16. In UV-vis experiments, over a one thousand mol excess 
of formate was used, similar to ratio used in the in vitro A2780 cell viability determinations. 
Complex 19 displayed highest cell accumulation and catalytic reaction rate, while gave the 
lowest induction of cell viability decrease. Such behavior implies that complex 19 with stronger 
electron-withdrawing functional group (-NO2) might be more labile in cells and interact more 
readily with cellular components, e.g. GSH, to become inactive. The catalytic rate for 
conversion of NAD+ to NADH as observed in an aqueous medium appears not to be directly 
related to the crucial steps in the cellular mechanism of antiproliferative activity. 
As a major peptide in cells, GSH plays a significant role in cell metabolism, e.g. in maintenance 
of cellular redox state and signal transduction.59 It functions as an important reducing agent 
(GSH/GSSG couple) and has a high affinity for transition metal complexes.60 Acquired drug 
resistance in cancer cells is often associated with over-expression of GSH which can act as a 
detoxification agent.61 Complex 17 (2 mM, MeOD-d4/H2O, 1:4(v/v)) reacted rapidly with GSH 
(0.5-10 mol equiv, pH* 7.1, 310 K, Figure 5.5) to form the adduct 17-SG, but this decomposed 
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slowly after 24 h at 310 K in aqueous solution. This high thiol affinity of complex 17 may 
mean that the Ru complex rapidly binds to GSH on entering cells, and the decomposition of 
the adduct may lead to metabolites which is toxic to cells.60 This may partially explain why the 
TH reduction of NAD+ was hampered in the presence of GSH and limited increase in potency 
is observed in A2780 cancer cells exposed to complex 17 and sodium formate, compared to 
the Ru complex [(η6-p-cym)Ru(TsEn)Cl], even though the TH reduction of NAD+ was 
believed to be taking place in the cancer cells.37 
Cisplatin is frequently used clinically in combination chemotherapy, especially for the ovarian 
and testicular cancers.62 However, poor 5-year survival rates in ovarian cancer patients are 
partly attributable to the development of drug resistance.63 Complex 17 showed much lower 
cross-resistance with cisplatin (resistance index of ca. 2 versus 11 for cisplatin) despite the low 
cell uptake in resistant human ovarian A2780Cis cancer cells. Furthermore, the higher 
selectivity index between MRC5 normal cells and A2780Cis cancer cells (2.6 for complex 17 
versus 0.95 for cisplatin), indicates that complex 17 might be able to overcome cisplatin 
resistance with fewer side-effects.   
In contrast to the negative control (A2780 cells not drugged, Figure 5.13), complex 17 can 
induce concentration-dependent G1 cell cycle arrest, which inhibits cell division. Previously, 
RuII complexes have been reported to induce G1 arrest, e.g. Ru-Norharman complex 
[Ru(bipy)2(9H-pyrido-[3,4-b]indole)2]
2+ and [Ru(η6-p-cym)(p-Impy−NMe2)Cl].64,65 Clinical 
anticancer drugs can also induce G1 cell cycle arrest, for instance Clotrimazole and 
Paclitaxel.66, 67 Paclitaxel can inhibit cell proliferation by activation of the p53 tumour 
suppressor gene.67 Microtubules are also potential targets. They are important cycloskeletal 
polymers, which can form a constantly reorganized solid backbone that serves as a polarity 
information source, for separating chromosomes through cell division.68 Recently reported RuII 
complexes [Ru(η6-Ph(CH2)3-TsDPEN-NH)Cl] (R,R or S,S) distribute mainly in the 
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cycloskeleton and can effectively target and inhibit microtubule polymerization.42 In view its 
structural similarity, complex 17 might also potentially target microtubules and subsequently 
trigger G1 cell arrest. 
ROS are important factors in cell signalling, and can control cell survival, cell proliferation and 
the maintenance of cell redox homeostasis.69 A moderate level of intracellular ROS would 
encourage the growth of cancer cells, however, at higher levels will cause damage and even 
induce apoptosis of cancer cells.70 Complex 17 significantly increased the ROS level in A2780 
cancer cells at IC50 concentrations, giving over 80% of cancer cells under total oxidative stress, 
which may contribute to cell death. 
 
 
5.5 Conclusions 
Four tethered RuII catalysts 16–19 were synthesized, and their structures determined by X-ray 
crystallography. Tethered RuII complexes usually display higher stability compared to non-
tethered RuII complexes, since the arene is ‘locked’ with a bidentate ligand. Tethered 
complexes especially the chiral ones have been widely studied and used as potent catalysts in 
asymmetric transfer hydrogenation reaction of aromatic ketones using alcohol, i.e. ipropanol 
as hydride sources.40 The non-chiral tethered complex 17 was reported to have a high reaction 
rate in ketone TH reduction,43 however, its catalytic TH reduction in conversion of NAD+ to 
NADH and biological activity had not been previously studied. In this Chapter, detailed studies 
have been made of such tethered RuII complexes, including their crystal structures, TH catalytic 
activity, biological activity (with or without formate) and their mode of anticancer action. 
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All the complexes exhibit potent reductive catalytic activity via transfer hydrogenation as 
shown by the conversion of coenzyme NAD+ to NADH, and follow a general reactivity trend: 
16 < 17 < 18 < 19. Coincubation of complexes 16–19 with A2780 cancer cells in the presence 
of nontoxic levels of formate resulted in the reduction of cell viability, and the correlation 
between TOFs and cell viability (Figure 5.16) suggest that electron withdrawing substituents 
on catalysts can increase the catalytic efficiency, however this reduces the anticancer activity 
when excess formate used. Such a combination of catalyst and non-toxic co-catalyst may 
provide a promising strategy for the design of catalysts which are effective in cancer treatment. 
These complexes exhibit moderate to good anticancer activity towards A2780, A2780Cis, 
A549, MCF7 and HEPG2 cancer cell lines, but relatively low toxicity against normal MRC5 
cells. Some of the complexes displayed comparable cytotoxicity to the clinically used drug 
cisplatin. Complex 17 [Ru(η6-Ph(CH2)3-ethylenediamine-N-Ts)Cl] gives better selectivity than 
in A2780 human ovarian cancer cells and MRC 5 normal cells, and likely to have a low cross-
resistant with cisplatin. However, such antiproliferative behaviour appears not to involve a 
DNA-targeting mechanism of action. 
Complex 17 reacts rapidly with GSH to form a 17-SG adduct, which can effectively block the 
TH reduction of NAD+. At NMR concentrations, the chelated tethered ligand is displaced by 
excess GSH. However such displacement is expected to be >200× slower (second order 
reaction). Concentration dependent G1 cell cycle arrest was observed on exposure of A2780 
cells to complex 17. In addition complex 17 can induce high level of intracellular ROS, which 
may provide a basis for killing cancer cells.  
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Chapter 6 
 
 
Synthesis, Antimicrobial Activity and Biocompatibility of 
Novel Organometallic Biguanide Complexes 
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6.1 Introduction 
Microscopic organisms (‘microbes’) are living organisms too small to be visible for human 
eyes.1 Microbes cover broad definitions, mainly including bacteria, fungi, archaea, viruses, 
protists and microscopic animals.2 Bacterial infections are a major health threat to human 
beings; conflicts between human and bacteria have lasted for centuries.3 Bacteria mainly 
consist of two types: Gram-positive and Gram-negative bacteria (identified from Gram-
staining); both of which have cell envelopes to guard against changes in osmotic pressure, 
chemical and enzymatic lysis, to survive under extreme conditions.4 The envelopes of bacteria 
contain thick peptidoglycans layers (Gram-positive bacteria) and the additional outer 
membrane is populated with lipopolysaccharides (LPS, Gram-negative bacteria), such 
envelopes can protect bacteria from antibiotics (Figure 6.1).5,6 Cell envelopes of fungii contain 
various layers of the polysaccharides chitin, β‑glucan and mannan proteins.7 Fungal infections 
are also a human health threat,8 and their clinical treatment presents profound challenges.9  
 
Figure 6.1 The envelopes of Gram-negative (a) and Gram-positive (b) bacteria.6b 
Infectious diseases caused by drug resistance are currently the second main cause of death 
worldwide and the third leading cause of death in developed countries.10 The use of antibiotics 
has saved millions of lives from microbial infections.11 However, the inappropriate use of 
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antibiotics has severely led to the multidrug resistance, e.g. sulfonamide-resistant 
Streptoccoccus pyogenes emerged in the 1930s and Staphylococcus aureus showed resistance 
shortly after penicillin was introduced in the 1940s.12 Multidrug resistant bacteria, including 
the notorious Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acetinobacter baumanii, Pseudomonas aeruginosa, and Enterobacteriaceae species, 
abbreviated as ‘ESKAPE’ (underlined initial letters these bacteria), are a major threat to human 
health and cause of bacterial infections with high mortality.13,14 Therefore, novel, effective, and 
safe antibiotics are urgently needed.11 
Organometallic half-sandwich complexes can provide large families of compounds for drug 
design.15 The antiproliferative and antimicrobial activities of organometallic complexes have 
been intensively studied due to the fine-tuneable choice of the π-bonded arene or 
cyclopentadienyl ligands, the metals themselves and their variable oxidation states, or the other 
monodentate or chelating ligands.16 The third-row transition metal ions with low-spin 5d6 outer 
shell electronic configurations possess several potential advantages; i.e. they are relatively inert 
and likely to reach drug target sites with at least some of their initial ligands still bound.17 To 
date, there are relatively few reports on the antimicrobial properties of organometallic 
complexes.17,18   
Biguanide compounds are an important class of biological active molecules that have wide 
pharmaceutical applications. One of the best known biguanide derivatives is metformin (Metf), 
which has been widely as a drug to treat type II diabetes for over 60 years. Other derivatives 
such as phenformin (Phen), buformin, 1-phenylbiguanide (PB) and chlorophenylbiguanide are 
reported to exhibit antimicrobial and antiviral activity (Figure 6.2).19 Jiang et al. have reported 
the synergistic effect of gold nanoparticles and metformin, generating broad-spectrum 
antibacterial and bactericidal activity against ‘ESKAPE’, with low cytotoxicity towards human 
mammalian cells. Such nanoparticles decorated with biguanide ligands can penetrate cell 
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membranes readily and also have significant biofilm disruption ability.14a Clardy et al. have 
synthesized a series of norspermidine-mimicking guanide and biguanide compounds with 
activity in disrupting biofilms in the pathogenic model of B. subtilis and S. aureus.20 Over the 
last two decades, a library of biguanide chelated transition metal complexes has been 
synthesized, including [MnIV(biguanide)3]
4+, [AuIII(biguanide)]+, [Cu(biguanide)2]
2+, 
[Zn(biguanide)Cl2], [Pt(biguanide)Cl2] and [M(biguanide)]
2+ (M: Mn, Co, Cu and Zn).21-25 
Some of those complexes show promising antimicrobial activity, but their mode of action 
(MoA) has yet to be elucidated.  
 
Figure 6.2 Neutral biguanide molecules with antidiabetic and antimicrobial activity. 
In this Chapter, a series of novel organometallic biguanide complexes 20-37 containing either 
p-cymene, biphenyl, Cp*, Cpxph or Cpxbiph, a chelated metformin or an N-substituted biguanide, 
together with a monodentate halido ligand, Cl, Br or I (Chart 6.1) is synthesized and 
characterized. Broad range of antimicrobial screening against fungii, Gram–negative and 
Gram–positive bacteria was undertaken. The introduction of a sulfonyl functional groups on 
the biguanide ligand (complexes 33-37) allowed the role of the terminal NH2 in activity to be 
studied. The bio-compatibility of selected complexes were studied towards human mammalian 
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cells, stability of the IrIII biguanide complexes in culture medium, and the mutation rate of S. 
aureus treated with complexes 26, 27 and 30 were also investigated. The synergistic effect of 
complexes 27, 30 and 33 on co-administration with vancomycin against vancomycin-resistant 
Enterococci (VRE), was studied, as well as the anti-biofilm activity of complexes 27-32 in the 
biofilm model of S. aureus. Confocal microscopy and TEM cell, permeability and morphology 
changes in S. aureus induced by complex 30 were also investigated by to gain insight into the 
mechanism of action. 
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Chart 6.1 Structures of Complexes 20-37 Studied in This Chapter 
 
Complex Arene/CpX R R1 R2 M X Y 
20 p-cymene Me Me H Ru Cl Cl 
21 biphenyl Me Me H Ru Cl Cl 
22 p-cymene Me Me H Os Cl Cl 
23 biphenyl Me Me H Os Cl Cl 
24 Cp* Me Me H Ir Cl Cl 
25 CpXPh Me Me H Ir Cl Cl 
26 CpXbiph Me Me H Ir Cl Cl 
27 CpXbiph Phenyl H H Ir - Cl 
28 CpXbiph 4-F-phenyl H H Ir  - Cl 
29 CpXbiph PhEt H H Ir Cl Cl 
30 CpXbiph o-Tolyl H H Ir Cl Cl 
31 CpXbiph o-Tolyl H H Ir Br Br 
32 CpXbiph o-Tolyl H H Ir I I 
33 CpXbiph o-Tolyl H TolSul Ir Cl - 
34 CpXbiph o-Tolyl H 4-Br-TolSul Ir Cl - 
35 CpXbiph o-Tolyl H 4-F-PhSul Ir Cl - 
36 CpXbiph o-Tolyl H 4-NO2-PhSul Ir Cl - 
37 CpXbiph o-Tolyl H danzyl Ir Cl - 
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6.2 Experimental Section 
6.2.1 Materials 
Iridium trichloride, ruthenium trichloride and osmium trichloride were purchased from 
Precious Metals Online (PMO Pty Ltd.) and used as received. Biguanide ligands (metformin, 
1-phenylbiguanide hydrochloride, 1-(4-Fluorophenyl) biguanide hydrochloride, 1-(o-
Tolyl)biguanide and phenformin) were purchased from Sigma-Aldrich and used as received. 
All the sulfonyl chloride compounds used in this research were obtained from Sigma-Aldrich. 
High concentration rat tail collagen was obtained from Scientific Laboratory Supplies. 
Collagenase was obtained from VWR. Fetal bovine serum was purchased from Fisher 
Scientific, and peptone water and anaerobic atmosphere generation bag were from Sigma-
Aldrich. The NMR spectroscopy solvent, e.g. MeOD-d4 and DMSO-d6, were purchased from 
Cambridge Isotope Laboratories Inc, and D2O and CDCl3 from Sigma-Aldrich. The bacterial 
strains, B. subtilis DSM 10, S. pyogenes ATCC 151112, E. faecalis ATCC 29212, S. aureus 
ATCC 29213 and S. epidermidis ATCC 12228 were provided by Mr John Moat from the 
Department of Life Sciences, University of Warwick. The HaCaT keratinocyte cells were 
provided by Miss Jessica P. Furner-Pardoe and Dr. Freya Harrison. The rest of the 
antimicrobial and cytotoxicity screen were carried out by the ‘Community for Open 
Antimicrobial Drug Discovery’ (CO-ADD) from University of Queensland, Australia.  
6.2.2 Synthesis and Characterization 
[(η6-p-cym)Ru(Metf)Cl]Cl (20). [(η6-p-cym)RuCl2]2 (86 mg, 0.14 mmol) and metformin 
hydrochloride  (50 mg, 0.3 mmol) were placed in a round-bottom  flask to which anhydrous 
methanol  (50 mL) and triethylamine (40 µL, 0.3 mmol) were added. The solution was heated 
under refluxed in a nitrogen atmosphere (323 K) overnight. After which the solvent was 
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removed on a rotary evaporator to get a red solid. The crude product was purified by 
recrystallization from mixed solvent of MeOH and diethyl ether (4/6, v/v), to obtain bright a 
red solid. Yield = 72 mg (55%). 1H NMR (400 MHz, MeOD-d4): δH 1.25 (d, J = 6.9 Hz, 6H), 
2.15 (s, 3H), 2.71-2.74 (m, 1H), 3.03 (s, 6H), 3.35 (s, 3H), 5.35 (d, J = 4.6 Hz, 2H), 5.62 (d, J 
= 5.8 Hz, 2H), 6.87 (s, 0.5H broad single), 7.37 (s, 0.3H broad single); 13C NMR (125.73 MHz, 
MeOD-d4) δC 18.6, 22.6, 31.9, 39.0, 82.6, 84.7. HR-MS: Calcd for [C14H24N5Ru]+ 364.1075 
m/z, found: 364.1075 m/z.  
[(η6-biph)Ru(Metf)Cl]Cl (21). Complex 21 was synthesized following the method similar to 
complex 20, where [(η6-biph)RuCl2]2 (100 mg, 0.153 mmol), metformin hydrochloride  (57 
mg, 0.31 mmol) and triethylamine (42 µL, 0.31 mmol) were used.  The crude product was 
purified by recrystallization from mixed solvent of MeOH and diethyl ether (4/6, v/v), to obtain 
a green solid. Yield = 73 mg (52%). 1H NMR (400 MHz, MeOD-d4): δH 2.94 (s, 6H), 5.82-
5.91 (m, 3H), 6.04 (d, J = 5.2 Hz, 2H), 7.50-7.61 (m, 3H), 7.63-7.78 (m, 2H); 13C NMR (125.73 
MHz, D2O) δc 38.0, 78.7, 81.8, 85.7, 128.1, 129.4, 130.4. HR-MS: Calcd for [C16H20N5Ru]+ 
384.0762 m/z, found: 384.0758 m/z.  
[(η6-p-cym)Os(Metf)Cl]Cl (22). Complex 22 was synthesized following the method similar 
to complex 20, where [(η6-p-cym)OsCl2]2 (55.3 mg, 0.07 mmol), metformin hydrochloride  (25 
mg, 0.15 mmol) and triethylamine (21 µL, 0.15 mmol) were used.  The crude product was 
purified by recrystallization from mixed solvent of MeOH and diethyl ether (4/6, v/v), to obtain 
a dark grey solid. Yield = 39 mg (51%). 1H NMR (500 MHz, D2O): δH 1.23 (d, J = 6.9 Hz, 
6H), 2.21 (s, 3H), 2.52-2.57 (m, 1H), 3.04 (s, 6H), 5.74 (d, J = 5.4 Hz, 2H), 5.99 (d, J = 5.6 Hz, 
2H); 13C NMR (125.73 MHz, D2O) δc 8.2, 17.5, 21.8, 30.6, 38.2, 46.6, 71.0, 74.2; HR-MS: 
Calcd for [C14H24N5Os]
+ 454.1646 m/z, found: 454.1641 m/z. 
[(η6-biph)Os(Metf)Cl]Cl (23). Complex 23 was synthesized following the method similar to 
complex 20, where [(η6-biph)OsCl2]2 (100 mg, 0.12 mmol), metformin hydrochloride  (42 mg, 
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0.25 mmol) and triethylamine (35 µL, 0.25 mmol) were used.  The crude product was purified 
by recrystallization from mixed solvent of MeOH and diethyl ether (4/6, v/v), to obtain a yellow 
solid. Yield = 78 mg (60%). 1H NMR (400 MHz, MeOD-d4): δH 2.97 (s, 6H), 5.93 (s, broad 
3H), 6.21 (s, broad, 2H), 7.43-7.53 (m, 3H), 7.64 (d, J = 7.2 Hz, 2H). 13C NMR (125.73 MHz, 
D2O) δc 38.1, 70.4, 72.9, 75.3, 87.1, 128.4, 129.4, 129.8; HR-MS: Calcd for [C16H20N5Os]+ 
474.1333 m/z, found: 474.1312 m/z. 
[(η5-Cp*)Ir(Metf)Cl]Cl (24). Complex 24 was synthesized following the method similar to 
complex 20, where [(η5-Cp*)IrCl2]2 (56 mg, 0.07 mmol), metformin hydrochloride  (25 mg, 
0.15 mmol) and triethylamine (21 µL, 0.15 mmol) were used. The crude product was purified 
by recrystallization from mixed solvent of MeOH and diethyl ether (4/6, v/v), to obtain an 
orange solid. Yield = 49 mg (66%). 1H NMR (400 MHz, MeOD-d4): δH 1.68 (s, 15H), 3.07 (s, 
6H); 13C NMR (125.73 MHz, D2O): δc 8.2, 38.2, 88.5; HR-MS: Calc for [C14H26N5(Ir-HCl2)]+ 
456.1739 m/z, found: 456.1734 m/z. Elemental analysis: Calcd for C14H26 Cl2N5Ir(H2O)0.5: C, 
31.34%; H, 5.07%; N, 13.05%. Found: C, 31.29%; H, 4.78%; N, 12.87%. 
[(η5-CpXph)Ir(Metf)Cl]Cl (25). Complex 25 was synthesized following the method similar to 
complex 20, where [(η5-CpXph)IrCl2]2 (150 mg, 0.163 mmol), metformin hydrochloride  (55 
mg, 0.33 mmol) and triethylamine (92 µL, 0.66 mmol) were used. The crude product was 
purified by recrystallization from mixed solvent of MeOH and diethyl ether (4/6, v/v), to obtain 
a yellow solid. Yield = 104 mg (54%). 1H NMR (300 MHz, D2O): δH. 1.71 (s, 6H), 1.84 (s, 
6H), 3.09 (s, 6H), 7.52 (s, 5H); 13C NMR (125.73 MHz, D2O): δc 8.3, 8.9, 38.2, 88.3, 92.0, 
129.0, 129.06, 129.5, 130.2; HR-MS: Calcd for [C19H27N5(Ir-HCl2)]
+ 518.1896 m/z, found: 
518.1893 m/z. Elemental analysis: Calcd for C19H28Cl2IrN5: C, 38.71%; H, 4.79%; N, 11.88%. 
Found: C, 38.60%; H, 4.79%; N, 11.50%. 
[(η5-CpXbiph)Ir(Metf)Cl]Cl (26). Complex 26 was synthesized following the method similar 
to complex 20, where [(η5-CpXbiph)IrCl2]2 (100 mg, 0.0933 mmol), metformin hydrochloride  
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(32 mg, 0.188 mmol) and triethylamine (53 µL, 0.376 mmol) were used. The crude product 
was purified by chromatography column (DCM/MeOH (10:1, v/v)), to obtain a red solid. Yield 
= 72 mg (58%). 1H NMR (300 MHz, MeOD-d4): δH 1.94 (s, 6H), 2.05 (s, 6H), 3.16 (s, 6H), 
7.38-7.43 (m, 1H), 7.49 (t, J = 8.1 Hz, 2H), 7.67 (q, J = 7.7 Hz, 15.0 Hz, 4H), 7.78 (d, J = 7.4 
Hz, 2H); 13C NMR (125.73 MHz, D2O): δc 8.8, 9.3, 37.2, 90.0, 91.1, 126.8, 127.33, 128.2, 
129.2, 130.9, 139.4, 141.2; HR-MS: Calcd for [C25H31N5(Ir-HCl2)]
+ 594.2209 m/z, found: 
594.2204 m/z. Elemental analysis: Calcd for C25H31ClIrN5(H2O)0.5: C, 47.05%; H, 5.05%; N, 
10.97%. Found: C, 46.88%; H, 4.86%; N, 10.63%. 
[(η5-CpXbiph)Ir(PhBig)]Cl (27). Complex 27 was synthesized following the method similar to 
complex 20, where [(η5-CpXbiph)IrCl2]2 (100 mg, 0.0933 mmol), 1-Phenylbiguanide 
hydrochloride  (41 mg, 0.188 mmol) and triethylamine (53 µL, 0.376 mmol) were used. The 
crude product was purified by chromatography column (DCM/MeOH (10:1, v/v)), to obtain a 
dark red solid. Yield = 57 mg (45%). 1H NMR (400 MHz, DMSO-d6): δH 1.90 (s, 6H), 1.98 (s, 
6H), 6.44 (s, 2H), 6.94 (t, J = 7.1 Hz, 1H), 7.24 (t, J = 7.8 Hz, 2H), 7.41 (t, J = 7.0 Hz, 1H), 
7.50 (t, J = 7.6 Hz, 2H), 7.56 (d, J = 8.1 Hz, 2H), 7.63 (d, J = 8.2 Hz, 2H), 7.72 (d, J = 7.6 Hz, 
2H), 7.77 (d, J = 8.1 Hz, 2H), 9.18 (s, 2H), 9.24 (s, 1H); 13C NMR (125.73 MHz, CDCl3): δc 
127.0, 127.9, 128.0, 129.0, 129.6, 130.5; HR-MS: Calcd for [C29H31N5(Ir-Cl)]
+ 642.2209 m/z, 
found: 642.2209 m/z. Elemental analysis: Calcd for C25H31ClIrN5(H2O)0.5: C, 50.75%; H, 
4.70%; N, 10.21%. Found: C, 50.78%; H, 4.54%; N, 10.10%. 
[(η5-CpXbiph)Ir(4-F-PhBig)]Cl (28). Complex 28 was synthesized following the method 
similar to complex 20, where [(η5-CpXbiph)IrCl2]2 (200 mg, 0.187 mmol), 1-(4-Fluoro 
phenyl)biguanide hydrochloride  (93 mg, 0.4 mmol) and triethylamine (112 µL, 0.8 mmol) 
were added. The crude product was purified by chromatography column (DCM/MeOH (10:1, 
v/v)), to obtain a dark red solid. Yield = 118 mg (43%). 1H NMR (400 MHz, MeOD-d4): δH 
1.96 (s, 6H), 2.06 (s, 6H), 7.05 (t, J = 8.6 Hz, 2H), 7.41 (t, J = 7.2 Hz, 1H), 7.47-7.51 (m, 4H), 
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7.64 (d, J = 8.2 Hz, 2H), 7. 96 (d, J = 7.4 Hz, 2H), 7.77 (d, J = 8.2 Hz, 2H); 13C NMR (125.73 
MHz, CDCl3): δc 127.0, 127.9, 128.0, 129.1, 130.6; 19F NMR (376.4 MHz, D2O): δF -121.8; 
HR-MS: Calcd for [C29H30FN5(Ir-HCl2)]
+ 660.2114 m/z, found: 660.2105 m/z. Elemental 
analysis: Calcd for C29H30ClFIrN5(H2O): C, 48.83%; H, 4.52%; N, 9.82%. Found: C, 48.97%; 
H, 4.19%; N, 9.77%. 
[(η5-CpXbiph)Ir(Phen)Cl]Cl (29). Complex 29 was synthesized following the method similar 
to complex 20, where [(η5-CpXbiph)IrCl2]2 (200 mg, 0.187 mmol), phenformin hydrochloride 
(92 mg, 0.38 mmol) and triethylamine (110 µL, 0.76 mmol) were added. The crude product 
was purified by chromatography column (DCM/MeOH (10:1, v/v)), giving a dark red solid. 
Yield = 183 mg (66%). 1H NMR (300 MHz, MeOD-d4): δH 1.93 (s, 6H), 2.02 (s, 6H), 2.82 (t, 
J = 7.1 Hz, 2H), 3.38-3.40 (m, 2H), 7.20-7.29 (m, 5H), 7.42 (d, J = 6.5 Hz, 1H), 7.47-7.52 (m, 
2H), 7.61 (d, J = 7.7 Hz, 2H), 7.68 (d, J = 7.6 Hz, 2H), 7.75 (d, J = 7.5 Hz, 2H); 13C NMR 
(125.73 MHz, MeOD-d4): δc 42.4, 126.6, 127.3, 127.6, 128.1, 128.5, 128.7, 130.9; HR-MS: 
Calcd for [C31H34N5(Ir-HCl2)]
+ 670.2522 m/z, found: 670.2519 m/z. Elemental analysis: Calcd 
for C31H36Cl2IrN5: C, 50.20%; H, 4.89%; N, 9.44%. Found: C, 50.74%; H, 4.88%; N, 9.38%. 
[(η5-CpXbiph)Ir(TolBig)Cl]Cl (30). Complex 30 was synthesized following the method similar 
to complex 20, where [(η5-CpXbiph)IrCl2]2 (200 mg, 0.187 mmol), 1-(o-Tolyl)biguanide  (73 
mg, 0.38 mmol) and triethylamine (110 µL, 0.76 mmol) were added. The crude product was 
purified by chromatography column (DCM/MeOH (10:1, v/v)), giving a dark red solid. Yield 
= 125 mg (46%). 1H NMR (300 MHz, MeOD-d4): δH 1.92 (s, 6H), 2.04 (s, 6H), 2.26 (s, 3H), 
7.11-7.16 (m, 1H), 7.21 (d, J = 7.7 MHz, 1H), 7.28 (d, J = 7.7 Hz, 1H), 7.38-7.44 (m, 2H), 
7.48-7.53 (m, 2H), 7.57 (d, J = 7.5 Hz, 2H), 7.71 (t, J = 8.6 Hz, 4H); 13C NMR (125.73 MHz, 
CDCl3): δc 126.8, 127.0, 127.3, 127.4, 127.9, 128.0, 129.1, 130.2, 131.7. HR-MS: Calcd for 
[C30H33N5(Ir-HCl2)]
+ 656.2365 m/z, found: 656.2362 m/z. Elemental analysis: Calcd for 
C30H34Cl2IrN5: C, 49.51%; H, 4.71%; N, 9.62%. Found: C, 49.49%; H, 4.46%; N, 9.69%. 
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[(η5-CpXbiph)Ir(TolBig)Br]Br (31). [(η5-CpXbiph)IrCl2]2 (100 mg, 0.093 mmol) in methanol (30 
mL) and sodium bromide (1.92 g, 18.7 mmol) in deionised water (10 mL) were mixed in a 
round bottom flask. The solution was heated to 343 K for 1 h. Then, a solution of 1-(o-
Tolyl)biguanide  (36.6 mg, 0.191 mmol) and triethylamine (54 µL, 0.383 mmol) were added, 
the reaction was heated at 343 K under nitrogen atmosphere for 12 h. After which the solvent 
was removed on a rotary evaporator giving a dark red solid. The solid was re-dissolved in 
chloroform and washed with brine (3 × 50 mL), and dried over MgSO4. The crude product was 
further purified by chromatography column (DCM/MeOH (20:1, v/v)). Yield = 100 mg (65%). 
1H NMR (400 MHz, MeOD-d4): δH 1.69 (s, 6H), 1.82 (s, 6H), 2.14 (s, 3H), 7.31 (t, J = 7.6 Hz, 
1H), 7.10 (t, J = 6.8 Hz, 1H), 7.17 (d, J = 7.3 Hz, 2H), 7.30 (t, J = 7.4 Hz, 1H), 7.39 (t, J = 7.2 
Hz, 4H), 7.56 (t, J = 7.4 Hz, 4H); 13C NMR (125.73 MHz, CDCl3): δc 16.6, 65.5, 126.6, 127.3, 
127.5, 128.7, 130.5, 140.0. HR-MS: Calcd for [C30H33N5(Ir-HBr2)]
+ 656.2365 m/z, found: 
656.2376 m/z. Elemental analysis: Calcd for C30H34Br2IrN5(Et2O)0.6: C, 45.19%; H, 4.68%; N, 
8.13%. Found: C, 45.24%; H, 4.32%; N, 8.33%. 
[(η5-CpXbiph)Ir(TolBig)I]I (32). [(η5-CpXbiph)IrCl2]2 (100 mg, 0.093 mmol) in methanol (30 
mL) and potassium iodide (3.1 g, 18.7 mmol) in deionised water (10 mL) were mixed in a 
round bottom flask. The solution was heated to 343 K for 1 h. Then, a solution of 1-(o-
Tolyl)biguanide  (36.6 mg, 0.191 mmol) and triethylamine (54 µL, 0.383 mmol) were added, 
the reaction was heated at 343 K under nitrogen atmosphere for 12 h and a scarlet precipitate 
was observed. After which the solvent was removed on a rotary evaporator giving a dark red 
solid. The solid was re-dissolved in chloroform and washed with brine (3 × 50 mL), and dried 
over MgSO4. The crude product was further purified by chromatography column (DCM/MeOH 
(20:1, v/v)), to get an orange solid. Yield = 102 mg (59%). 1H NMR (400 MHz, MeOD-d4): 
δH 1.76 (s, 6H), 1.90 (s, 6H), 2.23 (s, 3H), 7.11-7.18 (m, 3H), 7.26 (d, J = 7.4 Hz, 1H), 7.41 (d, 
J = 8.0 Hz, 3H), 7.50 (t, J = 7.4 Hz, 2H), 7.59 (d, J = 8.2 Hz, 2H), 7.66 (d, J = 7.2 Hz, 2H); 13C 
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NMR (125.73 MHz, CDCl3): δc 8.3, 9.0, 16.7, 126.6, 127.2, 127.5, 128.7, 130.4, 131.3, 140.0, 
141.2; HR-MS: Calcd for [C30H34IN5(Ir-I)]
+ 784.1488 m/z, found: 784.1488 m/z. Elemental 
analysis: Calcd for C30H34I2IrN5: C, 39.57%; H, 3.76%; N, 7.69%. Found: C, 39.96%; H, 
3.77%; N, 7.60%. 
[(η5-CpXbiph)Ir(TsTolBig)Cl] (33). Complex 33 was synthesized following the method similar 
to complex 20, where [(η5-CpXbiph)IrCl2]2 (130 mg, 0.121 mmol), 4-methyl-N-(N-(N-(o-
tolyl)carbamimidoyl)carbamimidoyl)benzenesulfonamide (93 mg, 0.269 mmol) and  
triethylamine (110 µL, 0.76 mmol) were added. The crude product was purified by 
chromatography column (DCM/MeOH (25:1, v/v)), giving a yellow solid. Yield = 139 mg 
(68%). 1H NMR (400 MHz, MeOD-d4): δH 1.53 (s, 6H), 1.72 (s, 6H), 2.17 (s, 3H), 2.30 (s, 
3H), 7.17-7.22 (m, 5H), 7.27 (d, J = 6.9 Hz, 1H), 7.36 (d, J = 8.2 Hz, 2H), 7.40 (d, J = 7.4 Hz, 
1H), 7.49 (t, J = 7.4 Hz, 2H), 7.57 (d, J = 8.2 Hz, 2H), 7.65-7.67 (m, 4); 13C NMR (125.73 
MHz, MeOD-d4): δc 8.7, 18.0, 21.4, 126.1, 127.0, 127.6, 127.6, 128.9, 129.2, 130.4, 131.5, 
133.8, 140.3, 140.8, 141.3, 141.4, 151.7, 152.9; HR-MS: Calcd for [C37H39N5O2S(Ir-Cl)]
+ 
810.2454 m/z, found: 810.2449 m/z. Elemental analysis: Calcd for C37H39ClIrN5O2S(H2O)0.4: 
C, 52.12%; H, 4.70%; N, 8.21%. Found: C, 52.16%, H, 4.62%, N, 8.07%. 
[(η5-CpXbiph)Ir(4-BrTolSulTolBig)Cl] (34). Complex 34 was synthesized following the 
method similar to complex 20, where [(η5-CpXbiph)IrCl2]2 (200 mg, 0.187 mmol), 4-
(bromomethyl)-N-(N-(N-(o-tolyl)carbamimidoyl)carbamimidoyl)benzenesulfonamide (173.6 
mg, 0.410 mmol) and triethylamine (116 µL, 0.83 mmol) were added. The crude product was 
purified by chromatography column (DCM/MeOH (25:1, v/v)), giving a yellow solid. Yield = 
131 mg (38%). 1H NMR (300 MHz, MeOD-d4): δH 1.56 (s, 6H), 1.75 (s, 6H), 2.18 (s, 3H), 
2.32 (s, 1H), 4.60 (s, 1H), 7.19-7.22 (m, 3H), 7.27 (d, J = 8.8 Hz, 1H), 7.37-7.52 (m, 5H), 7.57-
7.59 (m, 2H), 7.67 (d, J = 9.2 Hz, 3H), 7.79 (d, J = 10.4 Hz, 1H); 13C NMR (125.73 MHz, 
MeOD-d4): δc 7.6, 8.4, 16.5, 44.4, 91.2, 126.2, 126.6, 127.2, 127.2, 127.3, 127.5, 128.6, 128.7, 
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128.9, 129.1, 130.4, 131.3, 140.1. HR-MS: Calcd for [C37H38N5O2SBr(Ir-Cl)]
+ 888.1559 m/z, 
found: 888.1551 m/z. Elemental analysis: Calcd for C37H38ClBrIrN5O2S: C, 48.08%; H, 4.14%; 
N, 7.58%. Found: C, 48.09%; H, 4.14%; N, 7.45%. 
[(η5-CpXbiph)Ir(4-F-PhSulTolBig)Cl] (35). Complex 35 was synthesized following the 
method similar to complex 20, where [(η5-CpXbiph)IrCl2]2 (111 mg, 0.103 mmol), 4-
(bromomethyl)-N-(N-(N-(o-tolyl)carbamimidoyl)carbamimidoyl)benzenesulfonamide (86 
mg, 0.228 mmol) and triethylamine (64 µL, 0.455 mmol) were used. The crude product was 
purified by chromatography column (DCM/MeOH (25:1, v/v)), giving a yellow solid. Yield = 
84 mg (48%). 1H NMR (400 MHz, MeOD-d4): δH 1.58 (s, 6H), 1.75 (s, 6H), 2.18 (s, 3H), 7.18-
7.21 (m, 3H), 7.27 (d, J = 6.9 Hz, 1H), 7.37-7.41 (m, 3H), 7.49 (t, J = 7.4 Hz, 2H), 7.58 (d, J 
= 8.0 Hz, 2H), 7.65 (d, J = 7.7 Hz, 2H), 8.02 (d, J = 8.6 Hz, 2H), 8.25 (d, J = 8.3 Hz, 2H); 13C 
NMR (125.73 MHz, MeOD-d4): δc 7.5, 8.3, 16.4, 123.5, 126.6, 127.1, 127.2, 127.5, 128.7, 
130.4, 131.2, 140.0; HR-MS: Calc for [C36H36N6O4S(Ir-Cl)]
+ 841.2148 m/z, found: 841.2143 
m/z. Elemental analysis: Calcd for C36H36ClFIrN5O2S: C, 50.90%; H, 4.27%; N: 8.24%. 
Found: C, 50.56%; H, 4.26%; N, 8.20%. 
[(η5-CpXbiph)Ir(4-NO2-PhSulTolBig)Cl] (36). Complex 36 was synthesized following the 
method similar to complex 20, where [(η5-CpXbiph)IrCl2]2 (150 mg, 0.140 mmol), 4-fluoro-N-
(N-(N-(o-tolyl) carbamimidoyl)carbamimidoyl)benzenesulfonamide (103 mg, 0.294 mmol) 
and triethylamine (82 µL, 0.588 mmol) were added. The crude product was purified by 
chromatography column (DCM/MeOH (25:1, v/v)), and a yellow solid was obtained. Yield = 
162 mg (66%). 1H NMR (400 MHz, MeOD-d4): δH 1.58 (s, 6H), 1.75 (s, 6H), 2.18 (s, 3H), 
7.12-7.22 (m, 5H), 7.28 (d, J = 6.9 Hz, 1H), 7.38-7.41 (m, 3H), 7.49 (t, J = 7.4 Hz, 2H), 7.60 
(d, J = 8.1 Hz, 2H), 7.67 (d, J = 7.44 Hz, 2H), 7.82 (t, J = 7.5 Hz, 2H); 13C NMR (125.73 MHz, 
MeOD-d4): δc 7.4, 8.3, 16.4, 91.4, 115.2, 115.4, 126.6, 127.2, 127.2, 127.5, 127.8, 128.7, 130.4, 
131.3, 140.0, 141.4; 19F NMR (376.38 MHz, MeOD-d4): δF -109.97; HR-MS: Calcd for 
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[C36H36N5O2SF(Ir-Cl)]
+ 814.2203 m/z, found: 814.2200 m/z. Elemental analysis: Calcd for 
C36H36IrN6O4S: C, 49.33%; H, 4.14%; N, 9.59%. Found: C, 49.14%; H, 4.06%; N, 9.49%. 
[(η5-CpXbiph)Ir(DsTolBig)Cl] (37). Complex 37 was synthesized following the method similar 
to complex 20, where [(η5-CpXbiph)IrCl2]2 (120 mg, 0.112 mmol), 5-(dimethylamino)-N-(N-(N-
(o-tolyl)carbamimidoyl)carbamimidoyl)naphthalene-1-sulfonamide (100 mg, 0.236 mmol) 
and triethylamine (66 µL, 0.472 mmol) were added. The crude product was purified by 
chromatography column (DCM/MeOH (25:1, v/v)), giving a yellow solid. Yield = 91.2 mg 
(44%). 1H NMR (400 MHz, MeOD-d4): δH 1.45 (s, 6H), 1.68 (s, 6H), 2.06 (s, 3H), 2.76 (s, 
6H), 7.11 (s, 1H), 7.17-7.24 (m, 6H), 7.36-7.41 (m, 4H), 7.47-7.54 (m, 3H), 7.60 (d, J = 7.4 
Hz, 2H), 8.06 (d, J = 6.8 Hz, 1H), 8.40 (d, J = 8.5 Hz, 1H), 8.56 (d, J = 8.6 Hz, 1H); 13C NMR 
(125.73 MHz, MeOD-d4): δc 7.4, 8.2, 16.3, 44.3, 91.9, 114.7, 122.9, 126.6, 127.0, 127.1, 127.1, 
127.2, 127.5, 128.7, 129.9, 130.3, 131.3, 140.0, 151.4; HR-MS: Calcd for [C42H44N6O2S (Ir-
Cl)]+ 889.2876 m/z, found: 889.2883 m/z. Elemental analysis: Calcd for C42H44ClIrN6O2S: C, 
54.56%; H, 4.80%; N, 9.09%. Found: C, 54.23%; H, 4.77%; N, 8.75%. 
6.2.3 Preparation of Samples and Antibiotic Standards  
Antimicrobial screening against Gram-negative bacteria, fungi, and MRSA as well as the 
cytotoxicity determination against HEK-293 human kidney cells and blood cells was carried 
out by Community for Open Antimicrobial Drug Discovery (CO-ADD) of the University of 
Queensland, Australia. 
Colistin and vancomycin were used as positive bacterial inhibitor standards for Gram-negative 
and Gram-positive bacteria, respectively. Fluconazole was used as a positive fungal inhibitor 
standard for C. albicans and C. neoformans. The antibiotics were provided in 4 concentrations, 
with 2 above and 2 below its MIC value, and plated into the first 8 wells of column 23 of the 
384-well NBS plates. The quality control (QC) of the assays was determined by the 
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antimicrobial controls and the Z’-factor (using positive and negative controls). Each plate was 
deemed to fulfil the quality criteria (pass QC), if the Z’-factor was above 0.4, and the 
antimicrobial standards showed full range of activity, with full growth inhibition at their 
highest concentration, and no growth inhibition at their lowest concentration. 
6.2.4 Antibacterial Assay  
All bacteria were cultured in Cation-adjusted Mueller Hinton Broth (CAMHB) at 310 K 
overnight. A sample of each culture was then diluted 40-fold in fresh broth and incubated at 
310 K for 1.5-3 h. The resultant mid-log phase cultures were diluted (CFU/mL measured by 
OD600), then added to each well of the compound containing plates, giving a cell density of 5 
× 105 CFU/mL and a total volume of 50 μL. All the plates were covered and incubated at 310 
K for 18 h without shaking. Inhibition of bacterial growth was determined measuring 
absorbance at 600 nm (OD600), using a Tecan M1000 Pro monochromator plate reader. The 
percentage of growth inhibition was calculated for each well, using the negative control (media 
only) and positive control (bacteria without inhibitors) on the same plate as references. The 
significance of the inhibition values was determined by modified Z-scores, calculated using the 
median and MAD of the samples (no controls) on the same plate. Samples with inhibition value 
above 80% and Z-Score above 2.5 for either replicate (n = 2 on different plates) were classed 
as actives. Samples with inhibition values between 50-80% and Z-Score above 2.5 for either 
replicate (n = 2 on different plates) were classed as partial actives.  
6.2.5 Antifungal Assay 
Fungi strains were cultured for 3 days on Yeast Extract-Peptone Dextrose (YPD) agar at 303 
K. A yeast suspension of 1 × 106 to 5 × 106 CFU/mL (as determined by OD530) was prepared 
from five colonies. The suspension was subsequently diluted and added to each well of the 
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compound-containing plates giving a final cell density of fungi suspension of 2.5 × 103 
CFU/mL and a total volume of 50 μL. All plates were covered and incubated at 308 K for 24 
h without shaking. Growth inhibition of C. albicans was determined by measuring absorbance 
at 530 nm (OD530), while the growth inhibition of C. neoformans was determined measuring 
the difference in absorbance between 600 and 570 nm (OD600-570), after the addition of 
resazurin (0.001% final concentration) and incubation at 308 K for additional 2 h. The 
absorbance was measured using a Biotek Synergy HTX plate reader. The percentage of growth 
inhibition was calculated for each well, using the negative control (media only) and positive 
control (fungi without inhibitors) on the same plate. The significance of the inhibition values 
was determined by modified Z-scores, calculated using the median and MAD of the samples 
(no controls) on the same plate. Samples with inhibition value above 80% and Z-Score above 
2.5 for either replicate (n = 2 on different plates) were classed as actives. Samples with 
inhibition values between 50-80% and Z-Score above 2.5 for either replicate (n = 2 on different 
plates) were classed as partial actives. 
6.2.6 Cytotoxicity Determination  
Growth inhibitions of HEK-293 and RBC cells were determined measuring fluorescence at ex: 
530/10 nm and em: 590/10 nm (F560/590), after the addition of resazurin (25 µg/mL final 
concentration) and incubation at 310 K and 5% CO2, for additional 3 h. The fluorescence was 
measured using a Tecan M1000 Pro monochromator plate reader. The percentage of growth 
inhibition was calculated for each well, using the negative control (media only) and positive 
control (cell culture without inhibitors) on the same plate. 
CC50 values (concentration giving 50% cytotoxicity against HEK-293) were calculated by 
curve fitting the inhibition values vs. log (concentration) using a sigmoidal dose-response 
function, with variable values for bottom, top and slope. The curve fitting is implemented using 
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Pipeline Pilot's dose-response component (giving similar results to similar tools such as 
GraphPad's Prism and IDBS's XlFit). Any value with > indicates a sample with no activity (low 
DMax value) or samples with CC50 values above the maximum tested concentration (higher 
DMax value). 
HC10 (concentration producing 10% haemolytic activity, human red blood cells) were 
calculated by curve fitting the inhibition values vs. log (concentration) using Sigmoidal dose-
response function, with variable values for bottom, top and slope. The curve fitting is 
implemented using Pipeline Pilot's dose-response component (giving similar results to similar 
tools such as GraphPad's Prism and IDBS's XlFit). The curve fitting resulted in HC50 (50%) 
values, which are converted into HC10 by HC10 = HC50*(10/90)^(1/Slope);  Any value with > 
indicates a sample with no activity (low DMax value) or samples with HC10 values above the 
maximum. 
Cytopathic Effect. HaCaT keratinocyte cells were cultured in freshly prepared growth media 
(including 10 mL 10 × Minimal Essential Medium (MEM), 3 mL 7.5% sodium bicarbonate 
and 10 mL foetal bovine serum). 1 × 104 cells per well of HaCaT cells were incubated in 96-
well plates with concentration range of 0-256 μg mL-1 for complexes 27-30, 34, 35 and 37 in 
200 μL of growth medium at 310 K with 5% CO2. The cytopathic effect was checked every 
hour under microscopy. 
6.2.7 Antibacterial Assay for Gram-positive Bacteria  
Antibacterial screening against Gram-positive bacteria was carried out under the supervision 
of Mr. John Moat; and anti-biofilm study in Section 6.2.11 was performed with the help of Dr. 
Freya Harrison in School of Life Sciences at Warwick. 
The minimum inhibitory concentrations (MICs) against a variety of Gram-positive bacteria 
were determined by following the broth microdilution method in the CLSI guidelines.26 The 
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bacterial strains were cultured in Cation-adjusted Mueller Hinton Broth (CAMHB) and was 
diluted to give the concentration of 5 × 105 CFU/mL. The IrIII complexes in broth were serially 
diluted in the sterile 96-well plate to give the volume of 100 µL. The media solutions with 
bacteria were then dispensed to each well cell to make the final volume of 200 µL and the final 
concentration of IrIII complexes ranged from 0.125-256 µg/mL; all the plates were covered and 
incubated at 310 K for 18 h without shaking. Inhibition of bacterial growth was determined 
measuring absorbance at 600 nm (OD600), using a Tecan SPARK 10M plate reader. The 
negative control (media only) and positive control (bacteria without inhibitors) on the same 
plate were used as references to determine the growth inhibition of bacteria. Samples with 
inhibition value above 90% were classified as active agents. The minimum bactericidal 
concentrations (MBCs) were determined by treating the agar plate with 5 µL sample solutions 
from each well with no visible growth observed. The agar plates were placed in a 310 K oven 
for 18 h without shaking (S. pyogenes were incubated under a 5% CO2 atmosphere at 310 K). 
The ones with no colony formed at minimum concentrations were taken as MBCs. 
6.2.8 Generation of Resistance  
The standard bacterial strain S. aureus (ATCC 29213) was cultured in HB medium (1 mL) in 
the presence of 0.25 µg/mL (1/4 of MICs) of complexes 27, 28 and 30, and overnight 
incubation at 310 K was considered as the first passage. At the second day, 40 µL of bacterial 
medium was added to the prepared complex stockings (1 mL), and such a treatment was 
repeated for 24 times (count as 24 passages). The antibacterial activity of complexes 27, 28 
and 30 against the treated S. aureus was determined by culturing the microbe on agar plate 
containing IrIII complexes 27, 28 and 30 (at MIC concentrations) every 4 days.  
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6.2.9 Kinetics of Growth Inhibition  
Bacterial strain S. aureus (Bacterial strain: ATCC 29213) was cultured in CAMHB overnight 
at 310 K. Three bacterial suspensions of 1 × 105, 1 × 107 and 1 × 108 CFU/mL were prepared 
by culture dilution. Complex in broth was diluted to give the concentration 0.125× MIC to 8× 
MIC. The negative control (media only) and positive control (culture bacteria with DMSO 
(1%-10%)) were used as comparisons. The measurement of absorbance at OD600 was 
determined on a Tecan SPARK 10 M plate reader with shaking for 18 h at 310 K, the 
absorbance was detected every 5 min for the first one hour and every 30 min for the rest of 17 
h. No growth was observed for the negative control. 
6.2.10 Relative Hydrophobicity  
Relative hydrophobicity measurements were performed utilizing an Agilent 1200 HPLC 
system with a VWD and 50 µL loop. The column used was an Agilent Zorbax 300SB C18, 150 
× 4.6 mm with a 5 µm pore size. The mobile phase was H2O (50mM NaCl)/H2O/CH3CN 1:1 
(50 mM NaCl), with a flow of 1 mL min-1. The detection wavelength was set at 254 nm with 
the reference wavelength at 360 nm. All compounds were dissolved in 10% MeOH/90% H2O 
(v/v) in 50 mM NaCl to ensure that hydrolysis was prevented. Sample injections were the loop 
volume (50 μL) with needle washes of H2O and MeOH between injections. Reported retention 
times (tR) and standard deviations (SD) are from duplicates of triplicate measurements. The 
gradient used is shown in Figure 6.3. 
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Figure 6.3 Relative hydrophobicity measurements on HPLC using H2O 50 mM NaCl (Solvent 
A) and H2O/CH3CN 1:1 50 mM NaCl (solvent B).  
6.2.11 Biofilm Cultivation and Antibiotic Treatment 
Biofilm was prepared according to a reported literature with modifications.27 Generally, 
bacterial strain: S. aureus (ATCC 29213) were cultured in synthetic wound fluid (SWF, 
consisting of 50% fetal bovine serum and 50% autoclaved peptone water, v/v) at 310 K on an 
orbital shaker. To a sterile falcon tube, polymerized rat tail collagen matrix was prepared  and 
kept on ice bath, containing (for example 10 mL collagen matrix) 2 mL collagen stock solution 
(10 mg/mL), 6 mL SWF solution, 1 mL acetic acid (0.1%, v/v) and 1 mL NaOH solution (0.1 
M in deionized water).  After mixing, 400 μL of the collagen solution was added to separate 
well of 24-wells polystyrene microtiter plate without introducing bubbles and placed at 310 K 
for 1 h. Then 100 μL of diluted bacteria culture (OD600 at approximately 0.1 in SWF) was 
added to each collagen matrix, at least on well was left empty as negative control and collagen 
matrix with SWF as positive control (check for contamination). The plate was incubated at 310 
K without shaking for 24 h. 
On the second day, 200 μL of the tested complexes (complexes 27-32, in DMSO/H2O, 
5:95(v/v)) was added to the collagen matrix and placed at 310 K for further 24 h. Then 600 μL 
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of collagenase (0.5 mg/mL in PBS) was added to each wound, and incubated at 310 K for 1 h. 
Serial dilution of each wound was made in PBS using a sterile 96-well plate, and 10 μL of each 
dilution were dropped onto a LB agar plate for triplicate. The potency against biofilm of each 
complex was calculated based on the bacteria colonies on the LB plate. The Welch’s t-tests 
were carried out to determine the variations of the data. 
6.2.12 Live/Dead Cell Assessment by PI Staining 
1 × 108 CFU/mL of S. aureus cells were seeded in 50-mL Falcon tubes and exposed to two 
concentrations of complex 30 (equipotent MIC and 2 MIC) for 2 h without shaking. S. aureus 
cells without any antibiotics were used as negative comparison. After the indicated incubation 
time, cell suspensions were collected by centrifugation at 8000 rpm for 10 min and washed 
with PBS (0.01 M) 3 times. The cell pellets were then re-suspended in water in 2 mL Eppendorf 
tubes and treated with 3 μM PI for 30 min in the dark at room temperature. Excessive PI was 
removed by washing cells with PBS 3 times, and 20 μL of samples were placed on a glass slide 
with a glass coverslip. The fluorescence of each glass slide was detected on a confocal 
microscope (LSM 880, AxioObserver) at excitation and emission wavelengths of 514/642 nm. 
6.2.13 Transmission Electron Microscopy 
5 × 108 CFU/mL of S, aureus cells were cultured in 50-mL Falcon tubes and exposed to two 
concentrations of complex 30 (10 MBC and 50 MBC) at 310 K for 2 h without shaking. After 
incubation, the cell suspensions were harvested by centrifugation at 8000 rpm for 3 min and 
washed with PBS (0.01 M) 2 times at 277 K. The cells were fixed by 2.5% glutaraldehyde in 
PBS at 277 K for 1 h, washed with PBS (2 times)/water (1 time) and centrifuged. Then the 
bacterial pellet was re-suspended in 10% ethanol, and dehydrated with 20%-100% ethanol with 
20 min of each. Cells were left in 100% fresh ethanol for over 24 h. Then the cell pellets were 
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left in propylene oxide for 2 h, propylene/LV resin (1:1, v/v) for 5 h and 100% LV resin 
overnight. After which, cells were polymerised at 338 K for 24 h and cut on Ultracut E 
Microtome to 100 nm and stained with 4% uranyl acetate. Finally, TEM monitoring was carried 
out on a JEOL 2011 LaB6 instrument with Gatan Ultrascan 1000 camera. 
 
6.3 Results and Discussion 
6.3.1 Synthesis and Characterization 
Generally, RuII, OsII or IrIII dimers and biguanide ligands were dissolved in anhydrous 
methanol, to which trimethylamine was added, and the solution was allowed to heated at 318 
K under nitrogen for 18 h.28 Dark red solid was obtained after removal of solvent on a rotary 
evaporator, which was further purified by recrystallization (MeOH and diethyl ether) or by 
column chromatography (MeOH and DCM). Particularly, complexes 31 (Ir-Br) and 32 (Ir-I) 
were synthesized by adding a 100-fold excess of sodium bromide and potassium iodide for the 
halogen exchange (Scheme 6.1). 
Crystals of complexes 22 [(η6-p-cym)Os(Metf)Cl]Cl, 23 [(η6-biph)Os(Metf)Cl]Cl, 24 [(η5-
Cp*)Ir(Metf)Cl]Cl and 27 [(η5-CpXbiph)Ir(Metf)]Cl  suitable for x-ray diffraction were obtained 
by slow diffusion of diethyl ether into the saturated complex methanol solution at ambient 
temperature (Figure 6.4). The crystallographic data and selected bond lengths and angles are 
given in Table 6.1 and Table 6.2. The +1 charged complexes 22, 23 and 24 adopt pseudo-
octahedral structures with metal bound to the arene, neutral metformin and chloride to form a 
typical ‘piano-stool’ geometry, and chloride as counter anion to make the complex an 18 e 
species. Ir in complex 27 is coordinated to η5-CpXbiph ring and deprotonated N,N-bound 
phenylbiguanide forming a non-typical 16 e- species, with a chloride counter anion. The 
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asymmetric unit of complex 27 contains two crystallographically independent but chemically 
identical complexes, two chloride counter ions and a small amount of electron density modelled 
as a partially occupied methanol (40% occupancy). The M-N2 (M: Os or Ir) lengths of 
complexes 22, 23 and 24 are around 2.07-2.08 Å, slightly longer than for complex 27 (1.97(3) 
Å). The N-M-N angles for complexes 22, 23 and 24 (range 82.33°-83.21°) are smaller than that 
of complex 27 (85.25°). The compositions of complexes 22, 23, 24 and 27 suggest that these 
novel complexes can be fine-tuned by the chelated ligands to be 16-e or 18-e species.  
 
Figure 6.4 Structures of complexes 22, 23, 24 and 27, and with atom labelling. Thermal 
ellipsoids are drawn at 50% probability level. All hydrogen atoms and solvent molecule have 
been omitted for clarity. 
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Table 6.1 Selected Bond Length (Å) and Angles (˚) for Complexes 22, 23, 24 and 27. 
Bonds 
Bond Length (Å)/Angle (o) 
22 23 25 27 
M–Na 2.076(3) 2.080(4) 2.087(2) 1.975(3) 
M–Nb 2.075(3) 2.070(4) 2.074(2) 1.973(3) 
M–arene 
(centroid) 
1.663 1.647 1.777 1.775 
Ca–Na 1.299(4) 1.299(7) 1.301(4) 1.334 (5) 
Ca–Nc 1.376(4) 1.378(7) 1.369(3) 1.331(5) 
Cb–Nb 1.293(4) 1.298(7) 1.287(4) 1.348(4) 
Cb–Nc 1.377(4) 1.374(7) 1.390(4) 1.321(5) 
Na–M–Nb 82.33(11) 83.09(17) 81.97(9) 85.38(13) 
C1–Nc–C2 127.0(3) 125.5(4) 124.3(2) 122.2(3) 
Na corresponds to N3, N3, N5, N111; Nb: N5, N6, N3, N108. Nc: N4, N4, N4, N109 
Ca corresponds to C5, C3, C3, C110; Cb: C3, C5, C5, C108 
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Table 6.2 Crystallographic Data for Complexes 22, 23, 24 and 27. 
  22 23 24 27 
Formula C15H29Cl2N5OOs C17H25Cl2N5OOs C14H26Cl2IrN5 C29H32ClIrN5 
FW 556.53 576.52 527.50 683.64 
Temp (K) 150(2) 150(2) 150(2) 150(2) 
Crystal system monoclinic monoclinic monoclinic triclinic 
Space group P21/c P21/n P21/c P-1 
a (Å) 10.22801(15) 7.22327(18) 13.09904(18) 9.80400(17) 
b (Å) 11.96146(14) 31.0708(6) 7.96973(11) 15.8991(2) 
c (Å) 16.9490(3) 9.2514(2) 17.6195(2) 18.4457(3) 
α (º) 90 90 90 82.7271(13) 
β (º) 106.7580(16) 109.557(3) 92.2718(14) 86.7456(14) 
γ (º) 90 90 90 72.2390(14) 
Volume (Å3) 1985.51(5) 1956.54(8) 1837.95(4) 2715.64(8) 
Z 4 4 4 4 
Dcalc(mg/cm3) 1.862 1.957 1.906 1.672 
μ(mm-1) 6.704 14.964 7.559 5.043 
F(000) 1088.0 1120.0 1024.0 1350.0 
Crystal size 
(mm3) 
0.24 × 0.18 × 0.08 
yellow/olive block 
0.2 × 0.08 × 0.01 
yellow block 
0.35 × 0.35 × 
0.08 orange 
block 
0.5 × 0.13 × 
0.038 brown 
block 
Reflections 
measured 
31218 7696 29267 83915 
Indep reflection 6647 4051 6136 18356 
R1 [I>2σ(I)] 0.0238 0.0426 0.0258 0.0330 
wR2 (all data) 0.0810 0.1208 0.0903 0.0751 
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6.3.2 Relative Hydrophobicity 
The relative hydrophobicities of complexes 24-37 were determined by RP-HPLC using a 
reverse-phase C18 column. To ensure solubility of the Ir
III complexes, MeOH/H2O, 1:9 v/v was 
used with NaCl (50 mM) present to suppress the hydrolysis. The HPLC eluents were also 
prepared with 50 mM NaCl (The measurements were listed in Figure 6.2). The resulting 
retention times are shown in Table 6.5. Complex 24 [(η5-Cp*)Ir(Metf)Cl]Cl shows the shortest 
retention time (least hydrophobic) at 13.0 min. It is evident that complexes with more phenyl 
groups on the η5-CpX (complexes 25-26), have higher retention times, indicating higher 
hydrophobicity. Complexes 27-32 with more hydrophobic functional phenyls on the chelating 
biguanide ligands have retention times range within 20.9-25.3 min, and the introduction of 
sulfonyl groups with aromatic substituents on the chelated biguanide ligands significantly 
enhances the hydrophobicity with retention time various of 32-37 min with the exception of 
complex 33 (toluene sulfonyl, 21.44 min) which was much less hydrophobic. 
6.3.3 Antimicrobial Activity  
The minimum inhibitory concentrations (MIC) of complexes 20-37 were determined against 
Gram-negative bacterial strains: FDA-controlled Escherichia coli, multi-drug resistant 
Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, and Gram-
positive bacteria strains: Bacillus subtilis, Streptococcus pyogenes, Enterococcus faecalis, 
Staphylococcus epidermidis and Staphylococcus aureus (including methicillin resistant strain 
type MRSA). Antifungal activity against Candida albicans and Cryptococcus neoformans was 
also studied. 
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First, the antimicrobial activity of the biguanide chelating ligands alone was determined against 
Gram-positive, Gram-negative bacteria and fungii. None of these ligands showed any 
antimicrobial activity or cytotoxicity, with MICs > 32 µg/mL, Table 6.3. 
Table 6.3 Antimicrobial Activity and Cytotoxicity Determination of Biguanide Ligands 
Screened by CO-ADD (µg/mL). 
Ligand MRSA E. c K. p A. b C. a C. n HEK-293 RBC 
Met >32 >32 >32 >32 >32 >32 >32 >32 
PB >32 >32 >32 >32 >32 >32 >32 >32 
4-F-PB >32 >32 >32 >32 >32 >32 >32 >32 
Phen >32 >32 >32 >32 >32 >32 >32 >32 
TolB >32 >32 >32 >32 >32 >32 >32 >32 
TsTolB >32 >32 >32 >32 >32 >32 >32 >32 
DsTolB >32 >32 >32 >32 >32 >32 >32 >32 
 
Initially, the antibacterial activity against S. aureus and B. subtilis of metformin RuII and OsII 
complexes 20-23 was determined in comparison with metformin IrIII complexes 24-26. 
Complexes 20-23 are probably more hydrophilic and have shown low antimicrobial activity 
with MIC values > 128 μg/mL. By contrast, complex 24 with the lowest hydrophobicity gives 
a similar MIC value, however, antibacterial activity of complexes 24-26 increased with 
increase in hydrophobicity (longer HPLC retention times, Table 6.4), probably due to the 
increased uptake of the complexes within the membranes of the bacteria.29 This trend is also 
apparent from the antibacterial activity of complexes 24-27 against MRSA (Figure 6.5). 
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Table 6.4 Antibacterial Activity of Metformin Complexes 20-26 against S. aureus and B. 
subtilis (μg/mL, in brackets µM)a. 
Complex M Arene/Cp* S. a B. s 
20 Ru p-cymene >128 (>294) >128 (>294) 
21 Ru biphenyl 128 (281) 128 (281) 
22 Os p-cymene >128 (244) >128 (244) 
23 Os biphenyl 128 (235) 64 (117) 
24 Ir Cp* >128 (>243) >128 (>243) 
25 Ir CpXPh 64 (109) 64 (109) 
26 Ir CpXbiph 8 (12) 4 (6) 
a Bacterial strains: S. aureus R 34, B. subtilis DSM 10.  
 
 
Figure 6.5 Correlation of MIC (μM) values for complexes 24-27 against MRSA with HPLC 
retention times (hydrophobicity). 
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Next antimicrobial activity of complexes 24-37 against a broader spectrum of nosocomial 
pathogens was screened by CO-ADD.  
Complexes 27-30 exhibit the highest potency (MICs, 4 μg/mL (5.4-5.8 μM)) against A. 
baumannii, an important nosocomial Gram-negative non-motile aerobic bacterial pathogen;30 
and show potent activity (MICs 4-8 μg/mL (5.4-11.2 μM)) towards E. coli (FDA controlled). 
However, all IrIII biguanide complexes had little activity towards P. aeruginosa, probably due 
to the poor membrane permeability, only about 8% of that of E. coli; also, P. aeruginosa has 
very effective efflux system, which has made this type of strain intrinsically antibiotic 
resistant.31 Complexes 27-30 have moderate potency of (MICs 16-32 μg/mL (21.6-44 μM)) 
towards K. pneumoniae, a Gram-negative nosocomial bacterium that is known to cause a range 
of infections, e. g. urinary tract, pneumoniae, and intra-abdominal infections.32  
In order to study the effect of the halide ligand on the antimicrobial activity, the Cl in complex 
30 was substituted by Br and I to obtain complexes 31 [(η5-CpXbiph)Ir(TolBig)Br]Br and 32 
[(η5-CpXbiph)Ir(TolBig)I]I, respectively. To increase the hydrophobicity and potentially 
enhance uptake of the complexes, a sulfonyl group with an aromatic substituent was introduced 
onto the terminal nitrogen of the 1-(o-tolyl)biguanide ligand, complexes 33-37 (Scheme 6.1).  
Interestingly, complexes bromido 31 and iodido 32 showed higher antibacterial activity against 
K. pneumoniae compared to chloride complex 30, but were less potent towards E. coli and A. 
baumannii. By introducing the sulfonyl substituents, the potency of complexes 33-37 
decreased dramatically, with MICs all above 32 μg/mL. This suggests that the terminal NH2 
on biguanide ligands may play an important role in activity (Table 6.5).  
The antifungal activity of complexes 24-37 was screened towards, C. albicans, a very common 
fungus in humans which can cause superficial mycoses, invasive mucosal infections, and 
disseminated systemic disease,33 and C. neoformans, an opportunistic yeast that can cause 
meningitis).34 The clinical antifungal agent Fluconazole was used as a reference compound 
217 
 
(Table 6.5). Interestingly, complexes 27-32 exhibited excellent antifungal activity against 
these fungii (MICs = 0.25-1 μg/mL (0.34-1.45 μM)), ca. 76-fold more active than Fluconazole 
(8 μg/mL (26.1 μM)). The monodentate halido ligand had little effect on the antifungal activity. 
The introduction of sulfonyl functional groups lowered the activity slightly (MICs of 
complexes 33-37 of 1-2 μg/mL (1.1-2.4 μM)).  
Complexes 27-37 showed higher antibacterial activity against Gram-positive bacteria MRSA, 
compared to Gram-negative bacteria, with MICs of 1 μg/mL (1.1-1.4 μM), as good as the 
benchmark compound Vancomycin, a broad-spectrum clinical drug against Gram-positive 
pathogens.  
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Table 6.5 Antimicrobial Activity of IrIII Complexes 24-37 (MICs, µg/mL (μM))a, compared 
with colistin, vancomycin and fluconazole. 
Complex MRSAb E. c K. p P. a A. b C. a C. n R-T (min)d 
24 
32 
(59.7) 
>32 
(>59.7) 
>32 
(>59.7) 
>32 
(>59.7) 
>32 
(>59.7) 
>32 
(>59.7) 
>32 
(>59.7) 
13.0±1.4 
25 
16 
(27.2) 
>32 
(>54.3) 
>32 
(>54.3) 
>32 
(>54.3) 
>32 
(>54.3) 
>32 
(>54.3) 
>32 
(>54.3) 
14.4±0.6 
26 
4 
(6.3) 
16 
(25) 
>32 
(>50) 
>32 
(>50) 
32 
(>50) 
4 
(6.3) 
4 
(6.3) 
17.8±0.3 
27 
1 
(1.5) 
4 
(5.8) 
32 
(46.6) 
32 
(46.6) 
4 
(5.8) 
1 
(1.5) 
0.25 
(0.36) 
25.2±1.1 
28 
1 
(1.4) 
8 
(11.2) 
>32 
(>44.8) 
>32 
(>44.8) 
4 
(5.6) 
1 
(1.4) 
0.25 
(0.35) 
23.4±0.3 
29 
1 
(1.3) 
4 
(5.4) 
16 
(21.6) 
32 
(43.2) 
4 
(5.4) 
1 
(1.3) 
0.25 
(0.34) 
22.6±0.3 
30 
1 
(1.4) 
4 
(5.5) 
32 
(44) 
>32 
(>44) 
4 
(5.5) 
1 
(1.4) 
0.5 
(0.7) 
22.5±0.3 
31 
1 
(1.2) 
8 
(9.3) 
8 
(9.3) 
>32 
(>37.2) 
4 
(4.7) 
1 
(1.2) 
0.5 
(0.6) 
20.93±0.02 
32 
1 
(1.1) 
8 
(8.8) 
16 
(17.6) 
>32 
(>35) 
16 
(17.6) 
1 
(1.1) 
0.5 
(0.55) 
20.95±0.02 
33 
1 
(1.2) 
>32 
(>38) 
>32 
(>38) 
>32 
(>38) 
>32 
(>38) 
2 
(2.4) 
1 
(1.2) 
21.44±0.07 
34 
1 
(1.1) 
>32 
(>35) 
>32 
(>35) 
>32 
(>35) 
>32 
(>35) 
2 
(2.2) 
2 
(2.2) 
32.2±0.1 
35 
1 
(1.2) 
>32 
(>38) 
>32 
(>38) 
>32 
(>38) 
>32 
(>38) 
2 
(2.4) 
2 
(2.4) 
36.93±0.08 
36 
1 
(1.2) 
>32 
(>38) 
>32 
(>38) 
>32 
(>38) 
>32 
(>38) 
2 
(2.4) 
1 
(1.2) 
34.89±0.02 
37 
1 
(1.1) 
>32 
(>35) 
>32 
(>35) 
>32 
(>35) 
>32 
(>35) 
2 
(2.2) 
1 
(1.1) 
32.42±0.01 
Colis.c 
>32 
(>27.7) 
0.125 
(0.11) 
0.125 
(0.11) 
0.25 
(0.22) 
0.25 
(0.22) 
>32 
(>27.7) 
32 
(27.7) 
n. d. 
Vanc. 
1 
(0.7) 
>32 
(>22) 
>32 
(>22) 
>32 
(>22) 
>32 
(>22) 
>32 
(>22) 
>32 
(>22) 
n. d. 
Flucon. 
>32 
(>104) 
>32 
(>104) 
>32 
(>104) 
>32 
(>104) 
>32 
(>104) 
0.125 
(0.41) 
8 
(26) 
n. d. 
aMIC: the minimal concentration at which no visible bacterial growth is found (μg/mL). bBacterial 
strains: MRSA: Methicillin-resistant S. aureus, ATCC 43300; E. c: E. coli (FDA control), ATCC 
25922; K. p: MDR K. pneumoniae, ATCC 700603; P. a: P. aeruginosa, ATCC 27853; A. b: A. 
baumannii, ATCC 19606. Fungus strains: C. a: C. albicans, ATCC 90028; C. n: C. neoformans, ATCC 
208821. cModel antibiotics: Colistin (Colis.) and Vancomycin (Vanc.) as antibacterial agents; 
Fluconazole (Flucon.) as antifungal agent; dR-T: retention time on RP-HPLC. 
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The minimum bactericidal concentrations (MBCs) of complexes 27-37 were also determined. 
Generally, as can be seen from Table 6.6, complexes 27-37 show higher antibacterial activity 
against Gram-positive bacteria strains when compared to the benchmark compound 
Vancomycin, with MICs within the range 0.125-32 μg/mL (0.17-38 μM). In particular, 
complexes 27-37 exhibit excellent inhibitory and bactericidal activity towards S. pyogenes and 
S. epidermidis. S. pyogenes is a pathogenic strain also known as Group A Streptococcus (GAS), 
among the top 10 pathogens, and responsible for ca. 517000 deaths annually.35 S. pyogenes can 
cause invasive diseases, e. g. necrotizing fasciitis, rheumatic fever and rheumatic heart 
disease.36 S. epidermidis is an opportunistic microorganism which exists in human skin and 
mucosa.37 Nosocomial genotypes of S. epidermidis are the main cause of catheter-related 
bloodstream infections and frequently cause joint and biomedical device-related infections.38  
Complexes 27-32 show potent antibacterial activity against E. faecalis (MICs, 0.5-1 μg/mL 
(0.58-1.45 μM)), about 4× more potent than vancomycin (2.8 μM). The MBCs of complexes 
27-32 range from 4-32 μg/mL (5.5-43 μM), are also lower than that of Vancomycin (> 64 
μg/mL (> 44 μM)). E. faecalis is part of the intestinal flora, causes about 90% of enterococcal 
infections by inhibiting alimentary canals of man which can induce lethal diseases, E. faecalis 
can survive in nosocomial (hospital infection) environments due to intrinsic resistance to 
several antibiotics.39 
Complexes 33-37 exhibited significant inhibitory activity against S. aureus, B. subtilis, S. 
pyogenes and S. epidermidis, with MICs all below 1 μg/mL (0.3-1.2 μM). However, 
bactericidal activity against these pathogens decreased dramatically, with MBCs against S. 
aureus and S. epidermidis of >32 μg/mL (>38 µM). Hence it is again apparent that introduction 
of sulfonyl functional groups which block the NH2 of the biguanide ligand diminishes the 
antibacterial activity against Gram-positive bacteria as well as Gram-negative bacteria and 
fungii, suggesting an important role of this NH2 in target recognition. 
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Table 6.6 Antibacterial Activity (MIC/MBCa), Cytotoxicity and Haemolytic Activity of 
Complexes 27-37 (µg/mL (μM)). 
Comp
lex 
S. a B. s S. p S. e E. f HEK-293 RBC HaCaT 
Gram-positive bacteriab Mammalianc 
27 
2/2 
(2.9) 
0.5/0.5 
(0.7) 
0.25/1 
(0.4/2.9) 
0.25/0.5 
(0.4/0.7) 
1/8 
(2.9/11.7) 
>32 
(>47) 
1.40 
(2.0) 
64 
(94) 
28 
2/2 
(2.8) 
0.5/0.5 
(0.7) 
0.25/0.25 
(0.4) 
0.5/0.5 
(0.7) 
1/8 
(1.4/11.2) 
>32 
(>45) 
1.26 
(1.8) 
128 
(179) 
29 
2/2 
(2.7) 
1/2 
(1.3/2.7) 
0.125/0.5 
(0.17/0.7) 
0.25/0.25 
(0.3) 
1/32 
(1.3/43.1) 
17.2 
(23.2) 
0.89 
(1.2) 
128 
(173) 
30 
1/2 
(1.4/2.8) 
0.25/0.5 
(0.3/0.7) 
0.125/0.125 
(0.17) 
0.5/0.5 
(0.7) 
1/4 
(1.4/5.6) 
>32 
(>44) 
2.40 
(3.3) 
128 
(176) 
31 
0.5/1 
(0.6/1.2) 
0.5/1 
(0.6/1.2) 
0.25/0.25 
(0.3) 
0.5/1 
(0.6/1.2) 
0.5/32 
(0.6/37) 
23.72 
(27.6) 
1.03 
(1.2) 
n. d. 
32 
0.5/4 
(0.5/4.4) 
0.25/1 
(0.3/1.1) 
0.25/0.25 
(0.3) 
0.5/0.5 
(0.5) 
1/16 
(1.1/17.6) 
16.99 
(18.6) 
1.29 
(1.4) 
n. d. 
33 
0.5/>32 
(0.6/>38) 
0.5/16 
(0.6/19) 
0.25/0.25 
(0.3) 
0.25/>32 
(0.3/>38) 
>32/>32 
(>38) 
>32 
(>38) 
14.6 
(17) 
n. d. 
34 
0.5/>32 
(0.5/>35) 
0.5/16 
(0.5/17) 
1/2 
(1.1/2.2) 
0.5/>32 
(0.5/>35) 
>32/>32 
(>35) 
>32 
(>35) 
>32 
(>35) 
128 
(139) 
35 
0.5/>32 
(0.6/>38) 
1/32 
(1.2/38) 
1/8 
(1.2/9.4) 
0.25/>32 
(0.3/>38) 
>32/>32 
(>38) 
>32 
(>38) 
>32 
(>38) 
128 
(151) 
36 
0.5/>32 
(0.6/>38) 
0.5/16 
(0.6/19) 
0.5/8 
(0.6/9.5) 
0.25/>32 
(0.3/>38) 
>32/>32 
(>38) 
>32 
(>38) 
8.53 
(10.1) 
n. d. 
37 
0.5/>32 
(0.5>35) 
0.5/32 
(0.5/35) 
1/4 
(1.1/4.4) 
0.25/>32 
(0.3/>35) 
>32/>32 
(>35) 
>32 
(>35) 
>32 
(>35) 
32 
(35) 
Vanc
. 
2/>64 
(1.4/>44) 
0.25/0.25 
(0.2) 
1/1 
(0.7) 
4/4 
(2.8) 
4/>64 
(2.8/>44) 
n. d. n. d. n. d. 
aMBC: the minimum bactericidal concentration (μg/mL). bBacterial strains: S. a: S. aureus, ATCC 
29213; B. s: B. subtilis, DSM 10; S. p: S. pyogenes, ATCC 151112; S. e: S. epidermidis, ATCC 12228; 
E. f: E. faecalis, ATCC 29212. cMammalian cells: HEK-293 human embryonic kidney cells ATCC 
CRL-1573, RBC human red blood cells, HaCaT human keratinocytes. 
Superoxide dismutase (SOD) is an important enzyme in mammalian cells and microorganisms 
which quenches high levels of superoxide.40 Next, the minimum inhibitory concentrations of 
complexes 27-33 under anaerobic conditions were determined against bacterial strains: S. 
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aureus (ATCC 29213, SOD sufficient) and S. pyogenes (ATCC 151112, SOD deficient). The 
anaerobic atmosphere was generated with Oxoid AnaeroGen 2.5L Sachets (from Thermo 
Scientific) in a plastic container. As can be seen from Table 6.7, no significant change of MICs 
of complexes 27-33 was discerned against those organisms when compared to MICs under 
aerobic conditions, which indicates that these complexes are less likely to induce ROS in 
bacteria, and may have a new mechanism of action. 
Table 6.7 Antibacterial Activity (MICs, µg/mL) of Complexes 27-33 against S. aureus and S. 
pyogenes under Anaerobic Conditions. 
Complex 
MIC (µg/mL) 
S. aureus S. pyogenes 
27 2 0.5 
28 2 0.5 
29 2 0.5 
30 2 0.5 
31 2 1 
32 2 1 
33 2 1 
 
6.3.4 Cytotoxicity (CC50), Haemolytic Activity (HC10) and Cytopathic Effects  
To investigate the selectivity of the complexes for microorganisms versus mammalian cells, 
the concentrations giving 50% cytotoxicity towards human embryonic kidney cells (HEK-293) 
and 10% haemolytic activity towards human red blood cells for active IrIII complexes 27-37 
were determined (Table 6.6). As shown in Table 6.6, IrIII complexes with high potency against 
Gram-positive bacteria, exhibited high CC50 values (>32 µg/mL, except complexes 29, 31 and 
32), indicating a high tolerance towards human mammalian cells.  
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Complexes 27-32 show high haemolytic activity, with HC10 values within the range of 0.89-
2.40 μg/mL (1.2-3.3 μM). However, complexes 33-35 and 37 have relatively high HC50 values 
(i.e. a low level of haemolysis of human red blood cells), and ca. 20× higher than the respective 
antibacterial MIC values.  
Subtle changes on the organometallic complex structures often have a significant effect on the 
biological properties.41 Complexes 31 and 32, with monodentate Br and I, respectively, as 
halido ligand show higher cytotoxicity towards HEK-293 cells, decreasing in the order: 30 > 
31 > 32, and haemolytic activity in blood cells. This is probably because complexes 31 and 32 
are more inert and less likely to hydrolysis in aqua media, and may have different targets.42 
The cytopathic effect of a representative set of Ir complexes 27-30, 34, 35 and 37 on HaCaT 
keratinocyte cells (a immortalized, non-tumorigenic cell line) was also determined.43 A 4 h-
exposure of keratinocyte cells to these selected antimicrobial agents induced morphological 
changes in keratinocytes cells at concentrations of 128 µg/mL (139-179 μM) for 28-30 and 34-
35, and of 64 µg/mL (94 μM) and 32 µg/mL (35 μM) for complexes 27 and 37, respectively.  
These concentrations are ca. 64× higher than the corresponding MIC values against Gram-
positive bacteria, suggesting sensitivity of human keratinocyte to these IrIII complexes against 
human keratinocyte cells and excellent selectivity between pathogens and human mammalian 
cells.  
6.3.5 Long-term Antibacterial Activity 
The stability of complexes 27-33 by using S. aureus as model bacterium was investigated by 
determining their MICs after various time intervals (1-21 days). The complexes were dissolved 
in Cation-adjusted Mueller Hinton Broth at the concentration of 128 μg/mL and stored at three 
different temperatures: 255 K, 291 K and 315 K. Antibacterial testing was performed on days 
1, 4, 8 and 21 (Table 6.8). Little change in MICs of complexes 27-30 was observed after 21 
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days at 315 K (in the range of 2-4 µg/mL), indicative of high stability. However, MICs of 
complexes 31-33 increased gradually from day 8 to day 21 at 315 K, with MICs rising from 1 
μg/mL to 16, 8 and 32 μg/mL, respectively, indicative of some degradation of these complexes 
at this temperature (315 K). 
Table 6.8 Stability Testing of Active Complexes 27-33 as Indicated by MICs (μg/mL). 
Complex 
Day 1 Day 4 Day 8 Day 21 
255 K 291 K 315 K 255 K 291 K 315 K 315 K 315 K 
27 2 2 2 2 1 2 2 4 
28 2 2 2 2 1 4 1 4 
29 2 2 2 2 1 4 8 4 
30 2 2 1 2 2 2 2 4 
31 4 2 1 1 4 2 4 16 
32 2 2 1 2 1 1 2 8 
33 2 1 1 2 2 4 8 32 
 
6.3.6 Resistance Generation 
To investigate the rate of generation of bacterial resistance towards these novel IrIII biguanide 
complexes, the mutation rate of standard strain S. aureus exposed to complexes 27 [(η5-
CpXbiph)Ir(PhBig)]Cl, 28 [(η5-CpXbiph)Ir(4-F-PhBig)]Cl and 30 [(η5-CpXbiph)Ir(TolBig)Cl]Cl at 
concentrations of 0.25× MIC, for sustained passages was determined. MICs were determined 
after every 4 passages. After a total of 24 passages, MIC values for complexes 27, 28 and 30 
against S. aureus remained unchanged, suggesting that Gram-positive bacteria are unlikely to 
become resistant to these IrIII biguanide complexes.    
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6.3.7 Kinetics of Growth Inhibition 
The kinetics of growth inhibition by complex 30 [(η5-CpXbiph)Ir(TolBig)Cl]Cl was studied in 
three different S. aureus cultures of density 105, 107 and 108 CFU/mL (Figure 6.6a-c), and the 
effect of DMSO concentration (1%, 5% and 10% DMSO in medium, v/v) in the broth medium 
on the cell growth (at bacterial intensity of 105 CFU/mL, Figure 6.6d). It is evident that high 
DMSO concentrations can greatly inhibit the bacterial growth (slower growth in 10% 
DMSO/90% medium).  Concentrations of complex 30 in three ranges in bacterial culture 
medium were studied: 0.125 MIC to 2 MIC (cell density of 1 × 105 CFU/mL), 0.25× MIC to 
4× MIC (1 × 107 CFU/mL) and 0.5× MIC to 8× MIC (1 × 108 CFU/mL). As can be seen in the 
Figure 6.6, bacterial growth was well inhibited at MIC concentration when the cell culture 
density was 1 × 105 CFU/mL; at higher cell culture densities (1 × 107 and 1 × 108 CFU/mL), 
the total bacterial growth inhibition concentration of complex 30 increased to 2× MIC, but the 
complex inhibited the growth of S. aureus for ca. 500 min at MIC concentration when the cell 
culture density was 1 × 107 CFU/mL. Complex 30 exhibits a density-dependent antibacterial 
activity against S. aureus, consistent with MIC values. The growth of S. aureus was effectively 
hindered at sub-MIC and MIC concentrations of complex 30 at different culture cell densities, 
which indicates that these IrIII complexes may be sequestered inside bacteria and exhibit a 
constant bactericidal activity towards Gram-positive bacteria such as S. aureus. 
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Figure 6.6 Kinetics of growth inhibition study for complex 30 against S. aureus, a) bacterial 
suspension of 1 × 105 CFU/mL with complex concentrations range with 0.125× MIC to 2× 
MIC; b) bacterial suspension of 1 × 107 CFU/mL with complex concentrations range with 
0.25× MIC to 4× MIC; c) bacterial suspension of 1 × 108 CFU/mL with complex concentrations 
range with 0.5× MIC to 8× MIC; d) DMSO effect on the growth of bacteria. 
6.3.8 Synergistic Effects 
The emergence in pathogens of intrinsic and acquired resistance towards antibiotics has 
become a major problem.44 Some newer antibiotics have little effect on highly resistant 
microorganisms, and the problem of antibiotic resistance has diminished the odds of new 
antimicrobial drugs being approved.45 Co-administration of new antibiotics with different 
mechanisms of action with existing clinical drugs (to which pathogens have developed 
resistance) may re-activate their antimicrobial activity. Here the synergistic activity of organo-
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iridium complexes 27[(η5-CpXbiph)Ir(PhBig)]Cl, 30 [(η5-CpXbiph)Ir(TolBig)Cl]Cl,   and 33 [(η5-
CpXbiph)Ir(TsTolBig)Cl]Cl and the clinical drugs Cefoxitin and Vancomycin towards two 
highly resistant nosocomial pathogens: Vancomycin-resistant Enterococci (VRE), Methicillin-
resistant Staphylococcus aureus (MRSA), has been investigated.  
Table 6.9 Antibacterial Activity of IrIII Complexes 27, 30 and 33 and Clinical Drugs against 
MRSA and VRE (μg/mL). 
Strains 
Compound 
27 30 33 vancomycin cefoxitin 
MRSA 2 0.5 0.5 n. d. 32 
VRE 4 2 4 64 n. d. 
Initially MICs of IrIII complexes and clinical drugs towards VRE and MRSA according to CLSI 
guidelines were examined with concentrations within the range 0.007-512 μg/mL (MIC values 
listed in Table 6.9). The IrIII complexes themselves exhibit high antibacterial activity against 
VRE and MRSA with MICs of 0.5-4 μg/mL. MICs of Cefoxitin against MRSA and 
Vancomycin against VRE are 32 μg/mL and 64 μg/mL, respectively.  As can be seen from 
Table 6.10, no synergistic effect of Cefoxitin against MRSA was observed when co-
administered with IrIII complexes 27, 30 and 33 (at equipotent of 0.5× MIC concentrations over 
the range 0.007-256 μg/mL). Interestingly, the combination of complexes 27, 30 and 33 with 
vancomycin towards VRE showed very high synergy, significantly decreasing the MIC values 
to 0.25, 4 and 2 μg/mL, respectively.  
Table 6.10 Synergy Study of Complexes 27, 30 and 33 with cefoxitin and vancomycin. 
Strain 
27 30 33 
27+Cef. 27+Vanc. 30+Cef. 30+Vanc. 33+Cef. 33+Vanc. 
MRSA 32 n. d. 32 n. d. 32 n. d. 
VRE n. d. 0.25 n. d. 4 n. d. 2 
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In further experiments, the reverse synergistic effect by co-incubation of vancomycin (at the 
MIC concentrations of 0.25, 4 and 2 μg/mL) with complexes 27, 30 and 33 (in the concentration 
scope of 8-0.007 μg/mL) against VRE was examined. However, no growth inhibitory towards 
VRE below 0.5 MIC complex concentrations was observed after 24 h, at 310 K.  
6.3.9 Anti-biofilm Action 
Biofilms are integrations of microorganism communities with extracellular polymeric 
substances which consist mainly of a variety of bio-polymers.46 The slow growth rate or low 
metabolism of organisms in biofilms makes the bacteria difficult to eradicate, and thus 
generates antibiotic resistance.46,47 Biguanide derivatives, both polymers48 and low weight 
molecules14a are reported as biofilm disruptors. The efficacy of complexes 27-32 (at 100, 50, 
30, 20, 10, 5 and 2 μg/mL) in biofilm disruption in a S. aureus model was studied. The 
logarithm of the numbers of bacterial colonies is listed in Table 6.11.  
Table 6.11 Disruption Biofilms of S. aureus (log) by Various Concentration of Complexes 27-
32 (2-100 μg/mL). 
Complex 
Logarithm of Number of S. aureus  
Complex Concentration (μg/mL) Negative 
Control 100 50 30 20 10 5 2 
27 3.33±0.35 3.73±0.05 7.40±0.02 8.10±0.19 8.84±0.06 8.92±0.08 9.07±0.11 
9.13±0.11 
28 3.40±0.17 3.97±0.07 7.35±0.04 7.99±0.08 8.59±0.11 8.81±0.29 8.86±0.09 
29 3.91±0.12 4.09±0.09 7.44±0.03 8.16±0.11 8.89±0.11 8.88±0.03 8.96±0.10 
30 3.61±0.39 4.05±0.02 7.12±0.07 8.03±0.12 8.78±0.15 8.77±0.21 8.80±0.04 
31 3.89±0.21 4.98±0.09 7.42±0.11 8.14±0.14 8.76±0.15 9.17±0.11 8.93±0.08 
32 3.85±0.14 6.11±0.07 7.86±0.09 8.22±0.09 8.74±0.24 8.99±0.09 8.90±0.05 
 
228 
 
It is evident from Figure 6.7, that after treatment of mature biofilms with IrIII biguanide 
complexes, at the concentrations of 100 and 50 μg/mL, at least a 3-log difference from the 
negative control is observed, suggesting that at such complex concentrations, over 99.9% of S. 
aureus are killed. Anti-biofilm efficacy at complex concentrations of 30 and 20 μg/mL 
decreased significantly, but there was still a reduction of 1.5 and 1 log, respectively, compared 
to the negative control, which indicates that IrIII biguanide complexes can eradicate over 90% 
biofilm cells at equipotent 10× to 15× MIC concentrations. No significant decrease of cell 
viability was observed at lower complex concentrations (10, 5 and 2 μg/mL). 
 
Figure 6.7 Effect of complexes 27-32 on disruption of S. aureus biofilms at a variety of 
complex concentrations, determined as the logarithm transformation from bacteria density; t-
tests with unequal variances, Welch’s tests, were calculated, comparing to negative control 
(bacteria culture without treating any antibiotics), p< 0.001 for ***, p < 0.01 for **, p < 0.05 
for * and p > 0.05 for a. 
229 
 
6.3.10 Induced Permeability Change in Bacterial Cell Walls 
In order to provide insight into the mode of action for the potent bactericidal activity of IrIII 
biguanide complexes against Gram-positive bacteria, the permeability change of bacterial cells 
were measured based on a fluorescence DEAD/LIVE assay by exposure of S. aureus to 
complex 30 [(η5-CpXbiph)Ir(TolBig)Cl]Cl at equipotent 4× MBC and 8× MBC concentrations, 
without adding any antibiotic as negative control. The bacterial viability was checked before 
staining. Propidium iodide (PI) is an effective dye which can bind uniquely to DNA or RNA 
nucleobase. PI itself cannot cross the membranes of viable cells, while dead cells with broken 
cell membranes are readily recognized by PI for intracellular staining.49,50 It is evident from 
the images in Figure 6.8a-c, that little PI fluorescence was observed in the negative control, 
the percentage of PI stained cells is ca. 7% when treated with complex 30 at equipotent 4× 
MBC concentration. Interestingly, the percentage increased significantly up to ca. 28% at 8× 
MBC concentration of 30. However, either at 4× MBC or 8× MBC concentration of complex 
7, no obvious diffused fluorescence clusters were found, which implies that the bacterial cell 
membranes are intact with no leakage of nucleobases. 
Next, the change of cell wall morphology was examined by transmission electron microscopy 
(TEM). It is apparent from Figure 6.8d, that complex 30 did not break the cell wall at 
equipotent concentrations of 10× MBC and 50× MBC. This is highly consistent with the 
confocal microscopy observations, which indicates that these biguanide Ir complexes are not 
likely to target bacterial cell walls. 
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Figure 6.8 Monitoring of complex 30 induced permeability change of cell membranes of S. 
aureus (ATCC 29213) via PI staining by confocal microscopy and morphological change by 
TEM; a-c) complex 30 at concentrations of 0, 4× MBC and 8× MBC, respectively; the left 
images show the contrast mode of both stained and unstained cells and the right images the PI 
fluorescent cells; d) TEM image, complex 30 at concentrations of 10× MBC (left) and 50× 
MBC (right). 
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6.4 Conclusions 
In summary, a library of novel RuII, OsII and IrIII biguanide complexes [(arene)M(Big)Z]Z 
(where arene = η5-Cp*, η5-CpXPh, η5-CpXBiph, η6-p-cymene or η6-biphenyl, M = Ru, Os or Ir,  
Big = biguanide ligands and functional sulfonyl substituted biguanide ligands,  Z = Cl, Br or I) 
has been synthesized. The X-ray crystal structures of complexes 22 [(η6-p-cym)Os(Metf)Cl]Cl, 
23 [(η6-biph)Os(Metf)Cl]Cl, 24 [(η5-Cp*)Ir(Metf)Cl]Cl and 27 [(η5-CpXbiph)Ir(PhBig)]Cl  
show that they can form both 16-e and 18-e species. Most of the IrIII biguanide complexes 
displayed high antimicrobial potency against Gram-positive bacteria and fungii, with MICs as 
low as 0.125 and 0.25 μg/mL, respectively; and moderate-to-good antibacterial activity 
towards Gram-negative bacteria. The potency of these complexes towards microbes and human 
mammalian cells can be tuned effectively by modifying the chelated biguanide ligands or the 
monodentate halides; the more hydrophilic Metformin complexes (either Ru, Os or Ir) show 
less potency against microorganisms, Ir (CpXbiph) complexes with more hydrophobic ligands 
(as indicated by reverse phase HPLC retention times), e.g. Phenylbiguanide (PhBig), 4-F-
PhBig and Phenformin, display excellent antimicrobial activity; and the unsubstituted NH2 of 
biguanide ligands is very important for both inhibition and bactericidal activity. Probably the 
more cationic terminal NH2 can mimic peptides which is be identified by negatively charged 
cell membranes,51 and the higher hydrophobicity facilitates cellular uptake and lead to protein 
binding on entering bacteria.  
The stability and mutation study against S. aureus suggest that these novel complexes are 
highly stable in broth medium and less likely to generate mutations. These complexes also have 
a significant synergy with vancomycin against VRE, with MIC of Vancomycin dramatically 
decreasing from 64 μg/mL to 0.25 μg/mL when complex 27 was used. Reactivation of 
vancomycin makes these IrIII biguanide complexes promising potentiators and may provide an 
alternative strategy to treat multidrug resistance. Such IrIII complexes also display anti-biofilm 
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activity in the biofilm model of S. aureus. However, biguanide IrIII complexes do not appear to 
target cell walls of Gram-positive bacteria, and may have a different mode of action in killing 
bacteria. The excellent properties make those novel biguanide complexes promising 
antimicrobial drug candidates and may provide an alternative strategy for treating multidrug 
resistance. 
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Chapter 7 
 
Conclusions and Future Work 
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The aims of the PhD project are mainly divided into two sections:  
i) Design and synthesis of more efficient and stable RuII ethylenediamine complexes for the 
catalytic TH reduction of cell coenzyme nicotinamide adenine nucleotide (NAD+) using 
sodium formate as hydride source, and use of Ru catalysed TH reduction of NAD+ to NADH 
in antiproliferative study against various cancer cell lines.  
ii) Synthesis and characterization of novel organo IrIII complexes using biguanide molecules as 
bidentate ligands, and determination of their antimicrobial activity against Gram-positive and 
Gram-negative bacteria, including some nosocomial pathogens, e.g. S. aureus and P. 
aeruginosa; and fungii.   
7.1 The Role of Substituents on Ethylenediamine in Catalytic 
Efficiency of TH Reduction of NAD+ (Chapter 3) 
Initially, [(η6-arene)Ru(en)Cl]+ complexes (Figure 7.1) were synthesized as potent anticancer 
agents,1 however, RuII-en complexes are poor TH catalysts in TH reduction of NAD+ to NADH 
(TOF, 0.1 h-1).2 Given the success of Noyori type complexes and their potent catalytic activity 
in TH reduction of aromatic ketones, Soldevila-Barreda et al. introduced sulfonyl substituents 
in the ethylenediamine ligand to achieve to achiral RuII complexes [(η6-arene)Ru(TsEn)Cl] 
(Figure 7.1).3 As expected, these complexes are more potent than RuII-en complexes in TH 
catalysis of NAD+ to NADH with formate as hydride source; the TOF increased up to 2.8 h-1.3  
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Figure 7.1 Chemical structures of complexes [(η6-p-cym)Ru(en)Cl]+, [(η6-p-cym)Ru(TsEn) 
Cl] and substituted [(η6-p-cym)Ru(TsEn(R1,R2))Cl]. 
In Chapter 3, to improve the efficiency of TH reduction of NAD+ to NADH, RuII-TsEn 
complexes were modified to obtain a series of new RuII toluenesulfonyl ethylenediamine 
complexes 1-6 of the type [(η6-p-cym)Ru(TsEn(R1,R2))Cl], where R1,R2 are aliphatic or 
aromatic substituents on a terminal N of ethylenediamine (Figure 7.1). Interestingly, with the 
enhancement of bulkiness of substituents, the catalytic activity of TH reduction of NAD+ to 
NADH significantly increased, giving TOFs up to 7.4 h-1 for complex 4 (R1 is benzyl). 
Meanwhile, complex 4 was also shown to have the best antiproliferative activity towards 
A2780 human ovarian cancer cells among these new complexes, with IC50 as low as 1.0 μM 
(comparable to clinical used drug cisplatin, IC50, 1.2 μM). Co-incubation of RuII complexes 1-
6 (Chart 3.1 in Chapter 3 for structure details) with cell-tolerable amounts of sodium formate 
can improve the antiproliferative activity by up to 36% (complex 6, R1 is napthyl, R2 is H in 
Figure 7.1) against A2780 cancer cells. Also, complex 4 can bind rapidly to 9-ethylguanine in 
aqueous solution; however, DNA is unlikely to be the target of those complexes, as no 
significant binding to either calf thymus or plasmid DNA was observed. DFT calculations 
revealed that the hydride transfer and release of carbon dioxide are costly in energy, perhaps 
the rate-limiting steps in the transfer hydrogenation cycle. 
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7.2 High Affinity of RuII Sulfonyl Ethylenediamine Complexes with 
Glutathione (Chapter 4) 
RuII complex [(η6-p-cym)Ru(TsEnBz)Cl] (complex 4, Chart 3.1 in Chapetr 3) achieved both 
high catalytic activity in TH reduction of NAD+ to NADH and high potency in anticancer 
activity against A2780 human ovarian cancer cells. As an extension of complex 4, to improve 
the catalytic efficiency, a series of RuII (OsII, complex 10) sulfonyl ethylenediamine complexes 
7-15 [(η6-arene)Ru(BzEnR)Cl], where arene is p-cymene, biph or HO(CH2)2OPh, R is 
phenylsulfonyl (PhSul), 4-F-PhSul, or 4-NO2-PhSul, were synthesized in Chapter 4 (Table 4.1 
for details), those complexes also exhibited potent catalytic activity in TH reaction of NAD+ to 
NADH using sodium formate as hydride donor, with TOFs in the range of 2.5-12.9 h-1. The 
interaction of complex 8 [(η6-biph)Ru(TsEnBz)Cl] with thiol-containing molecules, 
glutathione (GSH) and N-acetyl-L-cysteine (NAC) was studied via NMR, HPLC and LC-MS. 
The adducts were identified as [(η6-biph)2Ru2(GS)3]2+ and [(η6-biph)2Ru2(NAC)3]+ dimers. 
Such reactions can liberate free ethylenediamine ligands which can retrigger the fluorescence 
of complex 15 which has dansyl substituent. The catalytic activity of complex 8 for TH reaction 
of NAD+ to NADH is hampered in the presence of GSH.  
These new complexes have variable antiproliferative activity against A2780 human ovarian 
and A549 human lung cancer cells, and the levels of reactive oxygen species and anticancer 
activity decreased with increase of GSH concentration. The rapid reaction of Ru sulfonyl 
ethylenediamine complexes with thiol-containing molecules may appears to introduce a 
potential metabolic pathway for complexes entering cancer cells. 
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7.3 Tethered RuII Sulfonyl Ethylenediamine Complexes in 
Anticancer Research (Chapter 5) 
Four achiral tethered RuII sulfonyl ethylenediamine complexes [Ru(η6-Ph(CH2)3-
ethylenediamine-N-R)Cl], where R is Ms, Ts, Tf and Nb (complexes 16-19, respectively, in 
Scheme 5.1) were synthesized and their structures confirmed by X-ray crystallography in 
Chapter 5. Tethered RuII complex 17 [Ru(η6-Ph(CH2)3-ethylenediamine-N-Ts)Cl] can react 
rapidly with GSH to form 17-SG adduct, however, the 17-SG adduct degraded slowly to release 
free ligand [η6-Ph(CH2)3-ethylenediamine-N(H)-Ts] after 24 h at 310 K. Such interaction of 17 
with GSH can block the catalytic TH reaction of NAD+ to NADH with TOF decreasing from 
4.7 h-1 (no GSH) to 4.27 h-1 (0.5 mol equiv of GSH), until the complete inhibition of the TH 
reaction (with 1 mol equiv of GSH).  
These complexes exhibited moderate to good anticancer activity towards A2780 human 
ovarian, A2780 cisplatin resistant human ovarian, A549 human lung, MCF7 human breast and 
HEPG2 human liver cancer cell lines, with IC50 values as low as 7.3 μM. Complex 17 [Ru(η6-
Ph(CH2)3-ethylenediamine-N-Ts)Cl] showed better selectivity than cisplatin against A2780 
cancer cells and MRC 5 human fibroblast normal cells. Also, complex 17 is less likely to be 
cross resistant with cisplatin against A2780 cancer cells. Co-incubation of these tethered RuII 
complexes with non-toxic amounts of sodium formate gave up to 22% of enhancement 
(complex 16) in antiproliferative activity against A2780 cancer cells. The good 
antiproliferative activity of 17 against A2780 cancer cells probably arises from to the high 
intracellular ROS levels induced, which may provide a basis for killing cancer cells. 
Complex 17 can induce G1 cell cycle arrest at IC50 concentration in A2780 cancer cells. 
However, no obvious binding was observed to calf thymus (ct) DNA, bacterial plasmid DNA 
and short single- or double-stranded oligonucleotides, suggesting that these complexes do not 
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target DNA in cells. Together with a DNA study of complex 4 [(p-cym)Ru(TsEnBz)Cl], the 
conclusion can be drawn that RuII ethylenediamine complexes with sulfonyl substituents are 
unlikely to target DNA or RNA in cells.  
7.4 Novel IrIII Biguanide Complexes with Potent Antimicrobial 
Activity and Bio-compatibility (Chapter 6) 
In Chapter 6, a library of RuII, OsII or IrIII biguanide complexes [(arene/CpX)M(Big)X]Y 
(complexes 20-37, where arene = η5-Cp*, η6-p-cymene or η6-biph, M = Ru, Os or Ir,  X, Y = 
halides, Big = biguanide ligands or functional sulfonyl substituted biguanide ligands) was 
synthesized (Chart 6.1 for details). The structures of metformin and phenylbiguanide 
complexes 22 (Os(cym)Metf), 23 (Os(biph)Metf), 24 (Ir(Cp*)Metf) and 27 (Ir(CpXbiph)PhBig) 
were confirmed by X-ray crystallographic analysis. Complexes 20-24 with high hydrophilic 
property exhibited poor antibacterial activity, while complexes 27-35 display moderate to good 
antibacterial activity towards Gram-negative bacteria (including multidrug resistant pathogens, 
with MICs as low as 4 μg/mL, shown in Table 6.5), and excellent antimicrobial activity against 
Gram-positive bacteria (MICs as low as 0.125 μg/mL) and fungii (MICs as low as 0.5 μg/mL); 
but low toxicity towards human mammalian cells (embryonic kidney cells, keratinocytes and 
red blood cells, shown in Table 6.6).   
Interestingly, the potency of biguanide IrIII complexes towards both microorganisms and 
human mammalian cells can be tuned by modifying the chelated bidentate biguanide ligands 
and the monodentate halido ligands. These complexes are highly stable in culture medium and 
mutation studies of selected active complexes 27 [(CpXbiph)Ir(PhBig)]Cl, 28 [(CpXbiph)Ir(4-F-
PhBig)]Cl and 30 [(CpXbiph)Ir(TolBig)Cl]Cl  against S. aureus suggested that these novel 
complexes are less likely to generate any mutation (over 24 passages).  
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Also these complexes (e.g. complex 27 [(CpXbiph)Ir(PhBig)]Cl) exhibit a synergistic effect with 
the clinical drug vancomycin against vancomycin-resistant Enterococci, with MIC decreasing 
significantly from 64 μg/mL to 0.25 μg/mL. Reactivation of vancomycin makes these IrIII 
biguanide complexes promising potentiators and may provide an alternative strategy to treat 
multidrug resistance. Such IrIII complexes also can effectively disrupt biofilms in the model of 
S. aureus at 10× MIC concentration. The primary mode of action study by DEAD/LIVE 
staining and TEM reveals that those novel complexes are less likely to target cell walls, but 
may interfere in the intracellular metabolism of bacteria cells. 
 
 
 
7.5 Future Work 
7.5.1 Design and Synthesis of Novel Half-sandwich RuII Complexes  
The interesting reaction of complex 8 [(η6-biph)Ru(TsEnBz)Cl] with thiol-containing 
molecules to form Ru-S bridged dimers in Chapter 4 may open the possibility for enhancement 
of antiproliferative activity, upon modification of arene or bidentate ligands with biologically 
active anticancer drugs or scaffolds in Ru ethylenediamine complexes in future research. 
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Figure 7.2 Structures of Chlorambucil, a new ligand and RuII ethylenediamine complexes. 
Chlorambucil is a chemotherapeutic agent initially synthesized and reported by Everett et al. 
in 1950s (Figure 7.2),4 in combination with other drugs for the treatment of lymphocytic 
leukemia.5,6 Ru-en complex [(η6-p-cym)Ru(en)Cl]+ (Figure 7.1) preferentially binds to 
nucleobase versus GSH;7 however, complex [(η6-p-cym)Ru(TsEnBz)Cl] becomes more 
thiophilic when the electron distribution in ethylenediamine changes (introduction of electron 
withdrawing sulfonyl functional groups). Given the labile property of RuII complex [(η6-
arene)Ru(TsEnBz)Cl] in the presence of cell-abundant GSH, the novel Ru complex [(η6-
arene)Ru(BzEnChlo)Cl] (Figure 7.2) could be synthesized and characterized, the interaction 
of these novel complexes with GSH can be fully investigated (new complex may decompose 
in the presence of GSH similar to sulfonyl substituted complexes); the amide bond may 
hydrolyse in the acidic envirvoment in cancer cells to release the biologically active anticancer 
drug Chlorambucil and [(η6-arene)Ru(REn)Cl], which may work synergistically in cancer 
cells. 
7.5.2 Mode of Action Study of Potent Antimicrobial Ir Biguanide Agents 
Based on a wealth of preliminary screening for antimicrobial study. The mode of action for the 
IrIII biguanide complexes (Chapter 6) in Gram-positive bacteria can be determined.  
246 
 
Initially, the time- and dose-dependence of accumulation of metalloantibiotcs in bacteria 
(uptake/efflux)) can be determined by cell fractionation and ICP-MS to determine metal 
(iridium) concentrations. 
The localisation of the complexes (Ir) in bacteria can be investigated by nanofocussed 
synchrotron X-ray fluorescence (at Diamond and ESRF synchrotrons).8 
The metalation of proteins in bacteria (initially S. aureus) can be studied using continuous flow 
gel electrophoresis combined with ICP-MS and MS/MS for metal detection and protein 
identification.9 The changes in proteins in bacteria before and after metalloantibiotic treatment 
can be studied by using ultra high resolution mass spectrometry (FTICR-MS).10 
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Appendix 
NAD+ Model Compounds 
In order to study the mechanism of TH reduction of NAD+ to NADH, a series of NAD+ model 
compounds were synthesized, and the purity was confirmed by their 1H NMR spectra (Figure 
A1). 
 
Figure A1 Structures of synthesized NAD+ model compounds with various substituents. 
The TH reduction was initially monitored by UV-vis spectroscopy using complex 4 [(η6-p-
cym)Ru(TsEnBz)Cl] as catalyst and formate as hydride source (Figure A2). Complex 4 (84 
µM) was dissolved in MeOH/H2O (1:4 v/v) in a glass vial. Solutions of NAD
+ models (510 
µM) and sodium formate (102 mM) were made in H2O. An aliquot of 330 μL from each 
solution was added to a 1 mL cuvette bringing the total volume to 1 mL and complex 4, NAD+ 
models and formate in molar ratio of 1:6:1200 (final concentrations: 4 28 µM; NAD+ models 
170 µM; formate 34 mM;). The pH was adjusted to 7.2 before the sample was introduced and 
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UV spectra were recorded every 5 min until completion of the reaction. The spectrum was 
monitored by following the absorbance in the range of 350-450 nm. 
 
Figure A2 Monitoring of TH reduction of NAD+ model compounds by UV-vis spectroscopy 
using complex 4 as catalyst and formate as hydride donor. Complex 4, NAD+ models and 
formate were in the ratio of 1: 6: 1200. The pH was adjusted to 7.1 ± 0.1, 310 K. 
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Next, the catalytic rate of TH reduction of NAD+ model compounds by complex 4 was 
determined by 600 MHz NMR using formate as hydride donor (Table A1). Solutions of 
complex 4 (1.4 mM, MeOD-d4/D2O 1:4 v/v), sodium formate (35 mM, D2O) and NAD
+ models 
(5.6 mM, D2O) were prepared. An aliquot of 200 μL from each solution was added into a 5 
mm NMR tube, to give the final volume to 0.64 mL (4 0.44 mM; NAD+ models 1.75 mM; 
NaHCO2 10.94 mM; in molar ratio of 1:4:25). The pH
* was adjusted to 7.2 ± 0.1. The 1H NMR 
spectrum were recorded at 310 K every 162 s until the completion of the reaction. The TOFs 
were calculated following the precedures decribed in Section 3.2.4 in Chapter 3, giving values 
in the range of 2.3-7.2 h-1. 
Table A1 Catalytic Activity of Complex 4 as Catalyst in the TH Reduction of NAD+ Model 
Compounds Monitored on NMR (600 MHz) Using Formate as Hydride Source.  
 
R1 R2 TOF 
-CONH2 H 5.45±0.25 
-COOCH3 H 7.16±0.15 
-COCH3 H 7.0±0.1 
-CN H 2.17±0.12 
-COOH H 2.36±0.32 
-NO2 H 7.2±0.2 
-CHO H 5.54±0.08 
-CONH2 F 4.87±0.12 
F H No Reaction 
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Discussion 
It is evident from Table A1, that substitutions on the C4 position of pyridine influence the TH 
activity more significantly than that on the pyridine nitrogen. The reaction rate for hydride 
transfer is greatly affected by electronic effects form the substituents. Strong electron 
withdrawing groups, e.g. ester and nitro groups (TOFs ca. 7.2 h-1), facilitate hydride transfer. 
No TH reaction was observed with F as the R1 substituent on the pyridine ring (structure in 
Figure A1), which is highly consistent with the observations of Fish et al. (Angew. Chem. Int. 
Ed. 1999, 38, 1429-1432), indicating that the electronic properties of substituents on C4 of the 
pyridine ring are very important for the formation of the metal-NAD+ six-membered 
intermediate (proposed mechanisms and structures are shown in Figure 1.18 in Chapter 1) 
which is essential for hydride transfer. 
 
